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         PART I 
INTRODUCTION
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Chapter 1.   The intestinal microbiota                                 
The  term “microbiota”  defines  the  microbial  flora  harboured  by  normal,  healthy 
individuals. 
The autochthonous microbiota (or indigenous microbiota, or  normal microbiota) is a 
population of different microorganisms in a dinamic equilibrium. This population is 
formed  by resident  microrganisms  present  in  all  communities  of  different  animal 
species.  They  are  always  present  in  the  gastrointestinal  (GI)  tract  of  healthy 
individuals, they can colonize particular niches in GI and can grow without oxygen in 
this ecosystem (Berg, 1996; Klaenhammer, 2001). The allochthonous microbiota is a 
group of microrganisms acquired temporarily and that therefore is unable to colonize 
a particular habitat, except under abnormal conditions (Berg, 1996). True pathogens 
are microorganisms acquired accidentally and therefore not normally present in all 
members of a community of an animal species (Berg, 1996). If persistent, they cause 
infections and diseases.
According to the Oxford English Dictionary, to colonize is “to establish a settlement 
in  a  new  country”  This  is  precisely  what  microbes  do  when  they  colonize  the 
intestine. Although in most cases the term colonization implies a long-term presence 
in the intestine, actually this is not always true. The presence of any of the microbes 
at one particularl time in a particular niche does not necessarily mean that this has 
been colonized.
At genus level, the intestinal microbiota of an adult appears to be particularly stable, 
and even at species level, variations in the composition of the microbiota appear to be 
minor. At strain level, however, a considerable variation in the composition of the 
faecal  microbiota  has  been  observed.  Thus,  some  subjects  may  be  continuosly 
colonized with new microbes (Isolauri et al.,  2004). In a stable GI ecosystem, all 
available  habitats  or  niches  are  occupied  by  indigenous  microorganisms.  Any 
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transient species derived from food, water or others (even derived from another part 
of the GI system or from the skin), often will not adhere  and will pass trough the GI 
tract. 
Before  birth,  the  fetus,  including  its  intestine,  is  sterile.  Birth  brings  about  an 
immediate  end to this sterility: microbial  colonization begins after  birth. The first 
microbial population the newborn comes into contact with are the maternal intestinal 
and vaginal microflora. Successively, the newborn will be exposed to the microbes 
from the environment.  The microbial population of the newborn changes from the 
weaning time to the adulthood, also in relation to other factors like diet (breast versus 
formula feeding) and country (Berg, 1996; Guarnier and Malagelada, 2003).
The  intestinal microbiota of humans and animals is a specific ecosystem made of a 
complex  collection  of  microorganisms  (~  1014 –  1015)  which  forms  an  individual 
microbiota  typical  for  each  being .  In  particular,  the  human intestinal  microbiota 
consists of more than 400 different species. In 1994, Hagiage divided the intestinal 
microbiota into two groups: a dominant group and a subdominant group. 
- The “dominant microbiota” in human colon is constituted by Gram negative or not 
sporulating microrganisms principally belonging to the genus Bacteroides (Hagiage, 
1994) and by Gram positive bacteria from the genera Eubacterium, Bifidobacterium, 
Peptostreptococcus,  Ruminococcus,  Veillonella,  Clostridium.  The  concentration 
levels are 109-1011 ufc per faecal gram with inter-individual modifications (Hagiage, 
1994).
 The  “subdominant  group”  is  constituted  by  anaerobes  and  aerobes  bacteria, 
principally belonging to the genera  Enterobacter, Streptococcus and Lactobacillus. 
The concentration of this group is lower than that of the dominant group, since it 
ranges between 106 and 108 ufc per gram or mL of intestinal content (Hagiage, 1994).
The  allochthonous  microbiota,  consisting  of  variable  microbiota  among  resident 
microbes, has a concentration of 105-106 ufc/gr and it includes the following genera: 
Citrobacter,  Klebsiella,  Proteus,  Enterobacter,  Pseudomonas and  Staphylococcus 
and some yeasts like Candida albicans.
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The indigenous bacteria are not randomly distributed throughout the GI tract but are 
found at characteristic levels in particular regions of the tract (Berg, 1996). The oral 
cavity harbours a complex microbiota of about 200 species, consisting of both strict 
and facultative anaerobes, like streptococci, lactobacilli, bifidobacteria,  Bacteroides 
and yeast, like Candida albicans. 
Most oral bacteria are destroyed by gastric acid leaving only a few surviving species, 
so that  the gastric  concentration usually  is  less  than 103 colony forming units/ml 
(cfu/ml). The small quantity of microbes in this area results also from the peristaltic 
movement from the stomach through the small bowel (Berg, 1996). The microflora of 
the stomach is gram-positive and aerobic and the most commonly isolated species are 
acid-tolerant lactobacilli and streptococci, staphylococci, various fungi, which, unlike 
the majority of the microorganisms found in food, survive the passage through the 
stomach. 
The  small  intestine  can  be  considered  a  zone  of  transition  between  the  sparsely 
populated  stomach  and  the  luxuriant  bacterial  flora  of  the  colon.  Under  normal 
conditions the microflora of the proximal small bowel (duodenum and jejunum) is 
similar  to  that  of  the  stomach.  The  bacterial  concentration  is  103-105 cfu/ml  of 
gastrointestinal  contents  and  the  predominant  species  include  streptococci, 
staphylococci and lactobacilli. Veillonellae and  Actinomyces sp. are also frequently 
isolated  whereas  coliforms  and  other  anaerobic  bacteria  are  found  in  lower 
concentrations. 
Also  the  distal  small  intestine  (ileum)  is  considered  a  “transition  zone”.  The 
microrganism content ranges from the relatively rare microbiota of upper bowel to 
the rich and diverse microbiota of the large intestine (Berg, 1996). In the distal ileum 
gram-negative bacteria start  to outnumber gram-positive organisms.  Coliforms are 
consistently  present,  and anaerobic  bacteria  such as  Bacteroides,  Bifidobacterium, 
Fusobacterium and Clostridium are found in substantial concentrations. The ability of 
the distal ileum to support an anaerobic bacterial flora can be seen in  its oxidation-
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reduction potential  (Eh) of -150mV, similar to but not as reduced as the -200mV 
potential found in the cecum.
Distal to the ileocecal sphincter bacterial concentrations increase sharply. Within the 
colon  the  bacterial  concentration  is  1011 to  1012 ucf/gr  of  intestinal  contents, 
consequently the colon is the primary site of microbial colonization in humans and 
animals, because of its very low oxidation-reduction potential and the slow intestinal 
motility. Anaerobic bacteria outnumber aerobes by 1000-fold. The predominant ones 
are  Bacteroides,  Bifidobacterium and  Eubacterium. Anaerobic gram-positive cocci, 
Clostridia, enterococci and various species of  Enterobacteriaceae are also common 
(Fig. 1).
Fig. 1.  Composition of human colonic microflora 
There are approximately 400-500 species present as indigenous GI bacteria. About 
40% of those species have not been cultured in laboratory (Berg, 1996). Researches 
using  molecular  procedures  have  show that  many  DNA sequences  correspond  to 
undescribed microorganisms. 
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Due to regulatory factors,  the colonic microbiota appears stable with a lower cell 
division  due  to  high  mortality,  a  competition  for  substrates  and  the  existence  of 
inhibitory factors associated with the release of antimicrobial substances (Hagiage, 
1994). The vast majority of human colonic microrganisms are anaerobes. However, 
they show varying degrees of tolerance toward oxygen, ranging from the relatively 
oxygen  tolerant  bifidobacteria  and  bacteroides  to  very  strictly  anaerobic 
mathanogenic Archeae. These latter outnumber aerobic species by a ratio between 
100 and 1000, and the  Bacteroides fragilis group, bifidobacteria, eubacteria, and a 
variety of anaerobic Gram positive cocci have proven prevalent. While superficially 
similar to the faecal microflora in the other animal species,  the human microbiota 
differs  in  many  respects,  e.g..  the  relatively  high  numbers  of  clostridia  and 
enterobacteria. 
Only  generic  information  is  available  about  the metabolic  relationships  that  exist 
between individual  bacterial  communities  in  the  colon,  or  about  the  ecology and 
multicellular organisation of the microbiota. A variety of host, microbiological and 
environmental factors affects colonisation of the large bowel (Table 1). The diversity 
of  bacterial  species  largely  derives  from the  multiplicity  of  different  carbon  and 
energy sources available for fermentation in the colon, and the principal host factors 
regulating the microbiota are substrate availability and colonic transit time. Various 
types  of  ecological  interaction  take  place  between  intestinal  microrganisms,  i.e. 
commensalism, in which one species is stimulated by another, which in its turn is not 
influenced  by  the  growth  and  activities  of  the  first;  neutralism,  with  co-existing 
bacterial communities which however do not have a significant metabolic effect on 
one another; antagonism, in which the growth of one population is hindered by the 
inhibitory substances produced by another, and symbiosis, where two species have a 
necessary dependence on each other.  However,  the ability to compete  for  limited 
nutrients and, in some circumstances, adhesion sites on food particles, colonic mucus 
or the mucosa, is considered the most important microbiological factor determining 
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the composition of the microbiota, with unsuccessful species being rapidly eliminated 
from the ecosystem.
Table 1.  Factors affecting bacterial colonisation in the large intestine
  
Environmental                                           
Amounts and types of substrate available  
pH of intestinal contents
Redox potential        
Geographical residence/cultural factors associated with host
Host
Diet
Colonic transit time, epithelial cell turnover rates
Disease,  drugs,  antibiotic  therapy,  rates  of  mucus  production  and  its  chemical  composition, 
pancreatic and other secretions, lysozyme at mucosa
IgA production and defensin secretion at mucosal surface.
Microbiological
Competition for limited nutrients and adhesion sites on food particles, mucus and intestinal mucosa. 
Cooperative interactions between microorganisms
Generic and species composition of microbiota
Inhibition  of  allochthounous  species  by  fermentation  products  including  HS+,  SCFA,  phenolic 
compounds,  deconjugated  bile  salts  etc.  Bacterial  secretion  of  antagonistic  substances  such  as 
bacteriocins
Synergistic  effects  of  bacterial  antagonism and local  immunity  in  the  mucus  layer  and on  the 
colonic mucosa
Functions of the microbiota
A common method to analyse the interaction between host and GI microbiota is the 
germ-free  animal  model  which  provides  a  “living  test  tube”  (Berg,  1996).  It  is 
possible to keep experimental  animals  in germ-free conditions by delivering pups 
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through sterile caesarean section and rearing them aseptically. The animals are bred 
in an isolator which is ventilated with filtered sterile air. These gnotobiotc (germ-
free) animals can be colonized with one or more bacteria species. In this way it is 
possible to study their interaction with the host in a simplified system (Berg, 1996). 
However,  germ free animals  colonized with certain microorganisms can never be 
considered “true conventional animals”, as they lack the influence (immunological, 
physiological, etc.) of an indigenous GI. Nonetheless these gnotobiotc models offer a 
good comparison between conventional and germ free animals, revealing the effects 
asserted on its host (Berg, 1996). The data obtained from these studies suggest that 
the microbiota has an important and specific role in metabolic, trophic and protective 
functions. 
Before describing these functions, it is necessary to give a definition of colonisation 
resistance. The community that the GI microbiota develops at each site will consist of 
microbes able to adhere to the existing substrates and utilise the available nutrients 
and will be in a state of dynamic equilibrium. Any exogenous microbe attempting to 
colonise  such  a  site  will,  therefore,  be  faced  with  a  very  difficult  task,  and  the 
microbiota of that site is said to exhibit “colonisation resistance” as a consequence of 
its  members  having  occupied  all  of  the  available  physical,  physiological,  and 
metabolic niches (Wilson, 2004). The term is also used to refer to the capacity of a 
microbiota  to  control  the number  of  potentially  pathogenic  members  that  may be 
present in that community. Colonisation resistance by the indigenous microbiota of a 
site  involves  a  number  of  mechanisms,  including:  occupation  of  adhesion  sites, 
alteration of the physicochemical environment, production of antagonistic substances 
and utilisation of all available nutrients within a site.
Colonization  is  the  first  type  of  interaction  between  host  and  external  partners. 
Intestinal  mucosa  is  coated with a  layer  of  protective mucus  that  is  continuously 
produced by epithelial cells. In the intestines two types of mucus are present:
1) an insoluble gel strongly attached to cells;
2) a viscous layer soluble in water that covers the gel.
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The constituents of mucus are mucins (i.e. glycoproteins) whose structure is formed 
by gel and by polysaccharide components  containing five types of carbohydrates: 
galactose, fucose, N-acetylglucosamine, N-acetilgalactosamine and sialic acid. These 
carbohydrates are combined in order to form different structures showing a multiple 
repertoire of linking sites for bacteria. Moreover this structure plays an important role 
in the cell to cell recognition process.
Bacteria  come  into  contact  with  intestine  through adhesion  sites  that  are  surface 
structures called adhesins. The nature of the adhesion site is genetically controlled by 
the  host.  Thus  the  genome  of  the  host  determines  bacterial  adhesion  via  mucin 
interaction. Various experiments have shown that normal microbiota always remains 
on the surface of the mucus, at the entrance of villi but never inside crypts. Initially in 
newborns  the  repertoire  of  adhesion  sites  is  genetically  coded.  During  this  time, 
structures  undergo  a  partial  or  total  deterioration  since  mucus  glycoproteins  are 
degraded by  the  resident  microbiota  (Peptostreptococcus  micros and  members  of 
genera Ruminococcus and Bifidobacteria produce a variety of glycoside hydrolases) 
(Falk et al., 1998). The first bacteria to colonize the newborn’s gastrointestinal tract 
depend on an innate repertoire which varies according to the the individual genome. 
The adhesion sites evolve enabling new species to bind. This is the reason why every 
person has a peculiar intestinal microbiota.
The mucosal barrier function depends on the integrity of the physical mucosa and on 
the reactivity of the defensive factors i.e. mucosal blood flow, mucosal secretions and 
epithelial cells functionality (tight junctions, cell turnover, recognition and process of 
foreign compounds). This “barrier effect” is  only one of the numerous functions that 
the intestinal microbiota perform.
Other functions are those related to host nutrition, detoxification, host development.
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Functions related to host nutrition
The  microbiota  of  the  colon  makes  a  significant  contribution  to  the  nutritional 
requirements  of  its  host,  and  this  microbial  community  may  be  considered  an 
important digestive “organ”. In the colon bacteria have access to nutrients, i.e. all of 
the food chemicals eaten by the host not yet absorbed (such as fibres and indigestible 
sugars), materials derived from the  host (mucus, death cells) and various metabolites 
resulting from bacterial enzyme activities. Quantitatively, the most important dietary 
constituent  to  escape  digestion  in  the  upper  regions  of  the  GI  is  starch:  some 
experimental  evidence has  shown that  in  individuals  with a  typical  Western diet, 
approximately 10% of dietary starch reaches the colon, but the proportion can be 
much higher in countries where starchy foods constitute a larger proportion of the 
diet.
The other  main  group of  undigested  polysaccharides  reaching the colon are  non-
starch  polysaccharides  which  constitute  the  “dietary  fibre”  (plant  cell  wall 
components, storage polymers and exudates).
A number of low-molecular mass carbohydrates also reach the colon, like lactose, 
galacto-oligosaccharides and fructo-oligosaccharides. 
Finally, host macromolecules – such as mucins, glycosphingolipids, hyaluronic acid 
and chondroitin  sulphate-  are  also important  sources of  carbohydrates  for  colonic 
microbes. 
Of the five principal genera present in adult human colon (Bacteroides, Eubacterium, 
Bifidobacterium,  Peptostreptococcus,  and  Fusobacterium),  only  Fusobacterium 
contains species that usually don’t utilize sugars (Falk et al., 1998). In addition, the 
ability  to  degrade  complex  carbohydrates  is  not  common  among  all  strains. 
Intracellular and secreted enzymes transform simple carbohydrates into pyruvic acid 
via fermentation processes. The metabolic endpoint is the generation of short-chain 
fatty acids (SCFA as butyric acid, acetic acid, propionic acid, lactic acid). Acetic acid 
is the dominant substrate and butyric acid is the main source of energy (assessed on 
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70%)  for  colonic  cells  and  it  is  a  decisive  factor  for  cellular  differentiation  (it 
stabilizes  mitosis,  promotes  cellular  repair  and  increases  DNA  levels)  (Hagiage, 
1994).  In  particular  SCFAs  and  lactic  acid  are  absorbed  and  serve  as  energy 
substrates  for  colonocytes  (butyric  acid),  liver  cells  (propionate  and lactate),  and 
peripheral tissues. In addition to short chain fatty acids, the other major waste product 
of  glucose  fermentation  are  gases,  principally  hydrogen,  carbon  dioxide,  and 
methane. Volatile fatty acids are absorbed by intestinal cells and their concentration 
regulates  the  intestinal  pH,  which  influences  the  activation  of  different  bacterial 
enzymes.  Their action is correlated with the modification of intraluminal  contents 
that may reduce the production of carcinogenic metabolites (Hagiage, 1994).
In  addition  to  carbohydrates,  the  colon  also  receives  proteins  and  peptides  from 
several sources (the diet, the exfoliated epithelial cells, and pancreatic enzymes); they 
are  rapidly  degraded  by  a  variety  of  microbial  proteases  and  peptidases.  Many 
colonic  microbes  can  ferment  these  aminoacids  to  generate  a  range  of  products, 
including SCFAs. These important acids are also used as a precursor for the synthesis 
of mucosal lipids.
A number of vitamins are present in the colon,too and derive both from the diet and 
from the colonic microbiota – particularly  Bifidobacterium spp.,  Clostridium spp., 
amd enterobacteria. Vitamins produced by colonic bacteria include biotin, vitamin K, 
nicotinic acid, folate, riboflavin, pyridoxine, vitamin B12, and thiamine.
In  conclusion,  the  results  of   this  complex  nutrition  activity  of  the  host  are:  the 
recovery of metabolic energy and absorbable substrates for the host; the supply of 
energy  and  the  production  of  nutrition  necessary  for  the  bacterial  growth  and 
proliferation.
Functions related to detoxification  
It  has  been  shown  that  the  metabolic  capabilities  of  the  colonic  microbiota  can 
produce detoxification of potentially harmful dietary constituents. In fact, it has been 
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demonstrated  that  many  microbial  inhabitants  of  the  human  colon  can  affect  the 
mutagenicity  of  the  heterocyclic  aromatic  amines  by  binding  to  them and/or  by 
somehow  modifying  their  structure  (Kassie  et  al.,  2001).  On  the  whole,  Gram-
positive species (e.g. Lactobacillus spp., Clostridium spp. and Bifidobacterium spp.) 
have a stronger effect in reducing the mutagenicity of these compounds. In humans 
the consumption  of  L.  casei or  L.  acidophilus has  proven successful  in  reducing 
greatly the urinary and fecal mutagenicity linked to the ingestion of meat. 
Plant glycosides are non-toxic, low-molecular mass compounds widely distributed in 
fruits, vegetables, tea and wine. In the colon, the sugar moieties of these compounds 
are removed by  β-glicosidases,  yielding aglycones. Many of these compounds are 
toxic, mutagenic, or carcinogenic. However, the flavonoids liberated from flavonoid 
glycosides  in  the  colon  also  have  protective  effects  against  other  mutagens  and 
carcinogens. Such compounds include quercetin, rutin, myricetin, and morin.     
Functions related to host development
There are several examples in the animal and plant kingdoms of indigenous microbes 
affecting the development of host tissues. Most informations regarding the role of 
microbes  in  mammalian  development  has  been  obtained  by  comparative  studies 
involving  germ-free  animals.  The  lack  of  an  indigenous  microbiota  can  produce 
serious consequences on the anatomy and the physiology of an animal. 
One of the major roles the intestinal microbiota plays is in stimulating the growth and 
differentiation of epithelial cells. In addition, gut microbes also appear to have a role 
in the maturation of the gut that occurs during weaning in mice. During this period, 
the levels of ileal ephitelial lactase decrease, and this coincides with colonisation of 
the gut by B. thetaiotaomicron. 
It  is  well  established  that  the  indigenous  microbiota  plays  a  key  role  in  the 
development  of  a  competent  immune  system.  Since  the  gut-associated  lymphoid 
tissue (GALT) contains the largest collection of immunocompetent cells in the human 
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body, most studies have included the GI tract and its microbiota. Several structural 
and functional abnormalities are present in the immune system of germ-free animals: 
including  low  density  of  lymphoid  cells  in  the  gut  mucosa,  low  circulating 
concentrations of antibodies,  small specialised follicle structures etc. However, the 
exposure of the gut mucosa to the indigenous microbiota has a dramatic effect on 
GALT. Consequently, the number of intra-epithelial lymphocytes expands greatly; 
germinal centres with antibody- producing cells appear in follicles and in the lamina 
propria; the levels of circulating antibodies increase; and increased quantities of IgA 
are secreted into the gut lumen.
As  described  before,  a  healthy  intestinal  epithelium,  in  association  with  an 
established  and  stable  intestinal  microbial  population,  represents  a  vital  barrier 
against the invasion or the uptake of pathogenic microrganisms, antigens and harmful 
compounds  from  the  gut  lumen. Specific  immune  responses  are  evoked  by  the 
specialized  antigen  transport  mechanisms  in  the  villus  ephitelium  and  Peyer’s 
patches.  In  the  past  the  positive  function  of  gut  microrganisms  in  human  health 
wasn’t properly considered and most attention was drawn to the enteric pathogens 
and factors leading to gastrointestinal disorders or “dysbiosis”. Now it is generally 
believed that a stable barrier, typical of healty individuals, can ensure the protection 
of the host and serve as support for the normal intestinal function and immunological 
resistance. Researchers consider GALT as the largest “immune organ” in the human 
body, and this “barrier” serves for the intrinsic protection against infective agents. 
Around 80% (1010)  of all  immunoglobulin-producing cells are found in the small 
bowel  and  the  gut  microbial  population  is  essential  for  the  mucosal  immune 
stimulation  and  the  amplification  of  immunocompetent  cells.  Numerous 
physiological functions have been ascribed to the “normal” gut microbial population; 
the following are some of the most relevant: 
• Maintenance and restoration of barrier function
• Stimulation of the immune system
• Maintenance of mucosa nutrition and circulation
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• Improvement of bioavailability of nutrients
• Stimulation of bowel motility and reduction of constipation
Inflammatory bowel diseases
Inflammatory bowel diseases (IBDs) are chronic, relapsing inflammatory disorders of 
the intestine. The ulcerative colitis affects the colon, while the Crohn’s Disease most 
commonly affects the distal small intestine and proximal large intestine. Diarrhoea 
and abdominal  pains are among the most frequent clinical features of IBD. It has 
been observed that while some IBD patients enjoy good health and long periods of 
remission,  others  suffer  from chronic  poor  health  and  a  significant  disruption  of 
lifestyle. The reasons for IBDs incidence are still to be fully understood, but current 
evidence suggests that IBD may result from the interaction between genetic factors 
and occurrence of intestinal inflammation early in life. The resulting dysregulation of 
the immune system produces the chronic, relapsing conditions. Observations from 
human cases and experimental animal studies suggest that the intestinal microflora, 
or  their  metabolic  products,  could  play  a  fundamental role  either  as  targets  for 
immune cells,  or  facilitators  or  amplifiers  of  inflammations,  although the specific 
aetiological agents are, as yet, unknown.
At present investigations about the use of probiotics and prebiotics in the treatment of 
IBDs  have  shown  promising  perspectives.  As  a  matter  of  fact,  the  efficacy  of 
probiotic feeding in animal models of IBD and other non-pathogenic strains of  E. 
coli is comparable to the performance of antibiotics. 
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Chapter 2.   Genus Lactobacillus and Bifidobacterium
Genus Lactobacillus 
The genus Lactobacillus belongs to the lactic acid bacteria (LAB), a group of Gram-
positive, catalase-negative bacterial species which are able to produce lactic acid as 
the main end-product of the carbohydrate fermentation. 
Fig.2.  Lactobacillus brevis, image from SEM
Lactobacillus is a well-characterized genus belonging to the phylum Firmicutes, class 
Bacilli, order Lactobacillales, and family Lactobacillaceae.
They are  gram-positive  non-sporeforming rods  that  are  catalase  negative,  usually 
nonmotile, or motile by peritrichous flagella. 
Their growth temperature ranges from 20 to 53°C, the optimum being between 30 
and 40°C and their pH ranges from 5.5 to 6.2. They are aerotolerant anaerobes, and 
the microaerophilic atmosphere with 5 to 10% CO2. enhance their growth. Glucose is 
used  either  homofermentatively  or  heterofermentatively,  and  they  have  complex 
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nutritional  requirements  for  amino  acids,  carbohydrates,  peptides,  nucleic  acid 
derivatives, vitamins, salts, fatty acids, or fatty acid esters.
Lactobacillus includes 113 recognized species and 16 subspecies and the type species 
is  Lactobacillus  delbrueckii Leichmann  1896  (Beijerinck,  1901).  The  genus 
Lactobacillus is very heterogeneous, encompassing species with a large variety of 
phenotypic,  biochemical,  and  physiological  properties.  This  heterogeneity  can  be 
seen in the range of moles percentage G+C of the genomic DNA of species included 
in the genus, which ranges range being 32 to 54%.
Metabolism and nutritional requirements
Lactobacilli  possess  efficient  carbohydrate  fermentation  pathways  coupled  to 
substrate level phosphorylation. A second substrate level phosphorylation site is the 
conversion of carbamyl phosphate to CO2 and NH3.
Two main  sugar  fermentation  pathways  can  be  identified  among lactobacilli:  the 
Embden-Meyerhof pathway which results almost exclusively in lactic acid as an end 
product (homolactic fermentation) and the 6-phosphogluconate pathway producing 
significant amounts of other end products such as ethanol, CO2, acetate, formate, or 
succinate, in addition to lactic acid (heterolactic fermentation). Each species has its 
own exact nutritional requirements which are often strain specific. In general, they 
require carbohydrates as energy and carbon sources as well  as nucleotides, amino 
acids,  and  vitamins.  Thiamine  is  necessary  only  for  the  growth  of  the 
heterofermentative lactobacilli, while pantothenic acid and nicotinic acid are required 
by all species. The requirements for riboflavin, pyridoxal phosphate, folic acid and p-
aminobenzoic acid vary widely among the various species, riboflavin being the most 
frequently  required,  whereas biotin and vitamin B12 are  requested by only a few 
strains.
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Habitat of Lactobacilli
Lactobacilli  are widely distributed in  nature and have been isolated from various 
sources.  They are almost ubiquitous: we can find Lactobacilli also in environments 
where  carbohydrates  are  available,  such  as  dairy  products,  fermented  meat,  sour 
doughs, vegetables, fruits and beverages.
They are part of the indigenous microbiota of the oral cavity, the gastrointestinal tract 
and the vagina in humans and animals, are isolated from plants, and are essential in 
the production of fermented foods such as dairy products,  cured meats, marinated 
fish, wines, and silages (Morishita et al., 1981).
They  constitute  some  of  the  most  common  gram-positive  bacteria  in  the  human 
microbiota. Lactobacilli are scattered throughout the entire gastrointestinal tract; from 
the upper part of small bowel, where they survive thanks to their acid resistance, to 
the large bowel (colon), where they reach a concentration of 106-108 bacteria per 
gram of intestinal contents.
In  the  oral  cavity  L.  casei,  L.  acidophilus,  and  L.  fermentum  are  present.  In  the 
gastrointestinal  tract,  lactobacilli  can  be  found  at  different  levels;  qualitative  and 
quantitative variations exist among individuals in relation to individual, ethnic, and 
nutritional  factors  (Barbés,  2001).  The  most  frequent  lactobacilli  in  the 
gastrointestinal  tract  belong  to  the  following  species:  L.  acidophilus and  L. 
fermentum in the stomach;  L.  acidophilus,  L. fermentum,  and L.  salivarius in the 
ileum; and  L. fermentum and  L. salivarius  in the large intestine. Other strains have 
been isolated in smaller numbers:  L. casei,  L. plantarum,  L.brevis,  L. buchneri,  L. 
crispatus, and L. reuteri.
Lactobacillus spp. include the dominant members of the vaginal microbiota, at 107 to 
108 CFU/g of vaginal fluid in healthy premenopausal women, constituting 61.5 % of 
all microorganisms isolated; L. crispatus, L. gasseri, L. jensenii, and L. Iners are the 
species most frequently found (Jin et al., 2007). 
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Lactobacilli have been found also on the skin, in nasal and conjunctival secretions, in 
the ear, in breast milk, and in sperm. Lactobacillus spp. are present in the intestines of 
pigs,  chicken,  dog,  mice,  rats,  and hamsters  (Mitsuoka,  1992).  In  addiction,  it  is 
possible to find lactobacilli in sewage and in plant material. 
Recently some species have been isolated from infections, above all there are several 
reports about L. rhamnosus.
Taxonomy, probiotic action and application
According to Euzéby (2007), the genus  Lactobacillus is composed of 113 species. 
The reclassification of a number of strains and the descriptions of several new species 
have  been  published  recently  in  the  International  Journal  of  Systematic  and 
Evolutionary Microbiology (Euzéby, 2007).
Lactobacillus spp.  are  among  the  most  frequent  and  better  characterised 
microorganisms  used  as  a  probiotic.  Important  considerations  in  the  choice  of  a 
probiotic include safety, functional aspects and technological aspects (Donohue et al. 
1998). The genus Lactobacillus has a long history of safe use, and most strains are 
considered commensal microorganisms with no pathogenic potential.
Most probiotic formulation usually contains one or several selected strains of bacteria 
generally  recognised  as  safe  (GRAS).  The   Lactobacillus genus  has  received the 
recognition  of  ‘Long-standing  Presumption  of  Safety’  status  (Bernardeau  et  al., 
2008). 
Food and industrial applications
With regard to  Lactobacillus spp., the following strains are used commercially:  L. 
acidophilus,  L.  plantarum,  L.  casei,  L.  fermentum,  L.  johnsonii,  L.  paracasei,  L.  
reuteri, L. rhamnosus and L. salivarius (Sanders and Veld, 1999; Senok et al., 2005). 
Each strain could be used more specifically for a particular illness or disorder, that is 
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why the future of probiotics will depend on the ability of choosing suitable strains for 
a given person, to treat specific disorders.
   
Fig. 3.  Lactobacillus acidophilus isolated from food.
Fig. 4.  Lactobacillus casei
Some commercially probiotic products containing lactobacilli.  Some examples are 
indicated in table below:
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Table 2. Lactobacillus species in intestines of humans and animals.
  
Lactobacillus species included                                 Type of product
in probiotic preparation                                          
L. acidophilus NCFM                          Fermented products, dietary supplement and toddler formula
L. acidophilus R0052                           Pharmaceutical preparation for microbiota replacement
L. acidophilus LB                                Pharmaceutical preparation for microbiota replacement
L. casei DN114001                              Dairy fermentations
L. casei Shirota                                    Dairy fermentations
L. fermentum VRI003                          Pharmaceutical preparation for microbiota replacement
L. johnsonii Lj-1 (La-1)                       Pharmaceutical preparation for microbiota replacement
L. paracasei CRL 431                         Dairy fermentations
L. paracasei F19                                  Pharmaceutical preparations for microbiota replacement
L. plantarum 299 V                              Fruit juice, dairy fermentations, pharmaceutical preparation 
L. reuteri RC 14                                   Pharmaceutical preparation for microbiota replacement
L. reuteri SD2112                                 Pharmaceutical preparation for microbiota replacement
L. rhamnosus GR-1                              Pharmaceutical preparation for microbiota replacement
L. rhamnosus R0011                            Pharmaceutical preparation for microbiota replacement
L. rhamnosus 271                                 Dairy fermentations
L. rhamnosus GG                                 Pharmaceutical preparation for microbiota replacement
L. rhamnosus LB21                             Dairy fermentations and fruit juice
L. rhamnosus HN001 (DR 20)            Dairy fermentations and pharmaceutical preparation 
L. salivarius UCC118                          Dairy fermentations 
Many Lactobacilli have been used in food fermentation processes, in functional foods 
as  probiotic  microorganisms  and  in  pharmaceutical  preparations  for  microbiota 
replacement.
An application of  Lactobacillus spp. in industry is as a food preservative because 
bacteriocins,  organic  acids  and  other  additional  metabolites  produced  during  the 
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fermentation of foods can inhibit growth of pathogenic organisms, thus extending the 
shelf life of fermented foods.
Lactobacillus spp. also produce heteroplysaccharides; microbial exopolysaccharides 
are biothickeners that can be added to a variety of food products, where they serve as 
viscosifying,  stabilizing,  emulsifying  and  gelling  agents.  Dextrans,  a  microbial 
exopolysaccharides can be used in the pharmaceutical and medical industries.
In  addition,  commercial  strains  can  be  genetically  modified  to  improve  inherent 
properties, to introduce desirable characteristics or to remove the unwanted ones. 
Medical applications
Lactobacilli  are  useful  in  the  treatment  of  gastrointestinal  diseases  (antibiotic 
associated diarrhea, traveler’s and infectious diarrhea, ulcers related to Helicobacter 
pylori,  lactose  malabsorption  symptoms,  gastroenteritis  and  inflammatory  bowel 
disease) and genitourinary infections. They have also other clinical applications (they 
reduce the recurrence of early atopic disease in curing or  preventing atopic eczema 
in  infants,  they  have  moderate  hypocholesterolemic  properties  and  they  cause  a 
significant reduction in the severity of pneumonia in children).
Lactobacilli in animals 
In contrast to humans, the proximal portions of the digestive tracts of pig, mouse and 
rat harbour large populations of bacteria (about 108 bacteria per gram of content). The 
stomach  of  pigs,  mice  and  rats  is  lined  partly  with  a  non-glandular,  squamous 
stratified epithelium,  unlike the stomach of  men,  which is  lined with a glandular 
mucosa. These regions of rats are colonized by lactobacilli adhering directly to the 
epithelium. Lactobacilli from this layer continuously inoculate the digesta, so they 
can be found in large numbers throughout the gastrointestinal tract. 
28
The cell counts for lactobacilli in the rodent forestomach, colon and cecum can be 
higher  than  108 bacteria  per  gram  of  content  with  slightly  lower  counts  in  the 
duodenum (106–107), jejunum and the ileum (107–108).
In ilea and large intestines of pigs  L. amylovorus,  L. johnsonii  and  L. reuteri are 
numerically  dominant;  a  new species,  L.  pantheris,  was  detected  in  the  feces  of 
jaguars. L. salivarius is the predominant organism in the crop of birds.
In addition,  L. aviarius  with the subspecies  aviarius  and  araffinosus  were isolated 
from  the feces  and  alimentary  tract  of  chickens  and  ducks.  Other  adhering 
microorganisms were isolated from the nonsecreting area of the horse stomach:  L. 
salivarius, L. crispatus, L. reuteri and L. agilis. 
Lactobacillus equi was not recovered at that time but occurred in the feces of horses. 
The Lactobacillus strains that adhere to epithelial cells show specificity for an animal 
host, even if some exceptions occur. 
Relatively little is still known about the  Lactobacillus  population of the ruminants 
and especially  of  the  rumen  of  adult  animals.  The numbers  of  lactobacilli  vary 
according to the age and diet of the animal. In adult sheep and cattle, LAB constitute 
usually only a minor component of the microbial flora of the rumen.
Many (but not all) LAB are sensitive to animal feed antibiotics.
Although insects may play a role as vectors for the dissemination of lactobacilli, little 
is known about the lactobacilli in these animals.
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The Bifidobacteria
Fig. 5.  Scanning electron micrographs of Bifidobacterium spp.
In 1900, Tissier observed and isolated in the feces of breast-fed infants a bacterium 
with a strange and characteristic Y shape and called him "Bacillus bifidus" (Tissier, 
1899). This bacterium was anaerobic, Gram-positive and did not produce gas during 
its growth (Tissier, 1899). He proposed its inclusion in the family Lactobacillaceae. 
For a long time, bifidobacteria were included in the genus  Lactobacillus.  In the 8th 
edition  of  Bergey’s  Manual  of  Determinative  Bacteriology  bifidobacteria  were 
classified for the first time in the genus Bifidobacterium and comprised eight species. 
Nowadays,  according  to  Taxonomic  Outline  of  the  Prokaryotes,  the  genus 
Bifidobacterium belongs  to  the phylum  Actinobacteria,  class  Actinobacteria,  sub-
class Actinobacteridae, order Bifidobacteriales, family Bifidobacteriaceae. The other 
genera  belonging  to  this  family  are:  Aeriscardovia,  Falcivibrio,  Gardnerella, 
Parascardovia and Scardovia. 
At present the species included in the genus Bifidobacterium are:
Bifidobacterium adolescentis,  Bifidobacterium angulatum,  Bifidobacterium animalis 
(with  two  subspecies  B.  animalis  subsp.  animalis  and  B.  animalis  subsp.  lactis), 
Bifidobacterium asteroids,  Bifidobacterium bifidum (type species),  Bifidobacterium 
boum,  Bifidobacterium  breve,  Bifidobacterium  catenulatum,  Bifidobacterium 
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choerinum, Bifidobacterium coryneforme, Bifidobacterium cuniculi, Bifidobacterium 
dentium,  Bifidobacterium  gallicum,  Bifidobacterium  gallinarum,  Bifidobacterium 
indicum,  Bifidobacterium  longum,  Bifidobacterium  magnum,  Bifidobacterium 
merycicum,  Bifidobacterium  minimum,  Bifidobacterium  pseudocatenulatum, 
Bifidobacterium pseudolongum (with  the  two  subspecies  B.  pseudolongum subsp.  
pseudolongum  and  B.  pseudolongum  subsp.  globosum),  Bifidobacterium 
psychraerophilum,  Bifidobacterium  pullorum,  Bifidobacterium  ruminantium, 
Bifidobacterium  saeculare,  Bifidobacterium  scardovii,  Bifidobacterium  subtile, 
Bifidobacterium thermacidophilum (with  the  two  subspecies  B.  thermacidophilum 
subsp.  thermacidophilum  and  B.  thermacidophilum  subsp.  porcinum),  and 
Bifidobacterium thermophilum.
Bifidobacterium longum is the most common species in the human gut and has been 
isolated  both  in  infants  and  adults  (Biavati  et  al.,  2000).  Scardovi  et  al.  (1979) 
outlined the strong genetic link between B. longum and B. infantis with DNA-DNA 
homologies values in the 65%-80% range. Moreover a group of strains isolated in 
calves  with  a  75%-80%  homology,  with  both  B.  longum and  B.  infantis,  was 
described. Researchers concluded that  B. infantis and B.  longum can form a single 
species, a “continuum”, the middle position of which is taken by the strains isolated 
in  calves.  Recently  (Mattarelli  et  al.  2008),  with  the  aid  of  different  genotypic 
techniques mattarelli and collaborators proposed a new classification of 3 biotypes of 
B. longum in 3 subspecies:   B. longum subsp. longum subsp. nov., B. longum subsp. 
infantis comb. nov. and B. longum subsp. suis comb. nov.
 
Physiology and metabolism
Bifidobacteria  are  Gram-positive polymorphic  branched rods that  occur singly,  in 
chains or in clumps. They are non-spore forming, non-motile and non-filamentous. 
They are anaerobic : their sensitivity to oxygen changes in relation to the species and 
the different strains of each species. Bifidobacteria are chemoorganotrophs, having a 
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fermentative type of metabolism. They produce acid but not gas from a variety of 
carbohydrates. They are catalase negative (with some exceptions). Their genome GC 
content varies from 42 mol% to 62 mol% (Biavati and Mattarelli, 2001).
The optimum temperature for growth is 37-41 °C, while no growth occurs below 20 
°C and above 46 °C. Growth at 45 °C seems to discriminate between animal and 
human strains. Bifidobacteria are acid-tolerant microorganisms. 
The optimum pH is between 6.5 and 7.0 and no growth is recorded below pH 4.5. 
Bifidobacteria are in fact acid tolerant but they are not acidophilic microorganisms.
Bifidobacterium produces lactic and acetic acid from glucose. 
The global equation is:
2 glucose + 5 ADP + 5 P → 3 acetate + 2 lactate + 5 ATP
This peculiar metabolic pathway is called “fructose-6-phosphate shunt” or “bifidus 
shunt”. The key enzyme of this pathway is fructose-6-phosphate-phosphoketolase, 
which was considered a taxonomic character for the identification on the genus level 
(Biavati and Mattarelli, 2001). Different species produce variable amounts of acetate, 
lactate ethanol and formate under the same conditions. Bifidobacteria utilize a great 
variety of mono- and disaccharides as carbon sources and are able to metabolize also 
complex carbohydrates  that  are  normally  not  digested in the small  intestine.  This 
feature  should  give  an  ecological  advantage  to  colonizers  of  the  intestinal 
environment where complex carbohydrates, such as mucin, are present either because 
they  are  produced  by  the  epithelium of  the  host  or  because  they  are  introduced 
through diet. 
Habitat
The presence of bifidobacteria in the alimentary tracts of human adults and infants 
has stimulated much interest among bacteriologists and nutritionists. The number and 
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the composition of the microbial populations in different regions of the GI tract are 
controlled  by  many  factors.  In  the  intestinal  tract  of  animals  and  humans, 
bifidobacteria coexist  with a large variety of bacteria,  most  of which are obligate 
anaerobes; the components of this microflora are different in the different areas of the 
tract.
Studies on the ecology of bifidobacteria performed at the Institute of Agricultural 
Microbiology at Bologna University, Italy, have led to the isolation of a large number 
of strains (at present more than 7,000) from many different habitats.
Studies  on  the  distribution  of  bifidobacteria  have  pointed  out  that  the  most 
represented species in the faeces of newborns are:  B. breve and B. infantis, whereas 
in the faeces of  adults B. adolescentis, B. angulatum, B. dentium and B. gallicum are 
prevalent;  Bifidobacterium spp.  are  found  in  both  newborns  and  adults,  like  B. 
bifidum,  B.longum (the  two  most  representative),  B.  catenulatum and  B. 
pseudocatenulatum.  B. breve,  B. dentium and  B. longum are normally colonizers of 
human vagina. In "pathological conditions" such as in dental caries it is possible to 
find  B. denticolens,  B. dentium and  B. inopinatum,  and these  same species,  with 
B.infantis and B. longum, are also present in case of hypochlorhydria. 
Furthermore, bifidobacteria have been isolated from many animals, and among the 
insects, from honeybees. In general,  Bifidobacterium species are specific either for 
humans or for animals; with the only exception of the same Bifidobacterium species 
found in the intestinal  microflora  of suckling calves and breast-fed infants. Some 
species, 12 out of 16, are host-specific, and they are typical of a given animal habitat 
(Fig. 6).
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Fig. 6. Bifidobacterium species found in the animals. 
Eleven species of  Bifidobacterium have been found in sewage:  B. adolescentis,  B. 
angulatum,  B.breve,  B.  longum,  B.  pseudocatenulatum  are  from  humans,  B. 
animalis,  B.  choerinum,  B.  pseudolongum subsp.  globosum,  thermophilum  from 
animals and B. minimum and B. subtile are found only in sewage. 
Bifidobacteria in animals
Studies  on  the  intestinal  microflora,  carried  out   mostly  on  domestic  animals, 
revealed  a  complex  microflora:  Bacteroides,  eubacteria,  anaerobic  lactobacilli, 
anaerobic  Gram-positive  cocci,  spirillaceae  and  often  bifidobacteria.  Almost  all 
chickens, dogs, pigs, rats and hamsters presented bifidobacteria, although in a smaller 
quantity than lactobacilli.  Mice, rabbits and horses rarely displayed bifidobacteria, 
and  cats  and  minks  never  had  them.  Many  factors  influence  the  composition  of 
bifidobacteria microflora in animals: the age, the species and the diet of the host.
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Some species apparently are host-specific: B. magnum and B. cuniculi have only been 
found in rabbit faecal samples, B. pullorum and B. gallinarum only in the intestine of 
chickens and B. suis only in piglet faeces (Matteuzzi et al., 1971; Fig. 6). 
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Chapter 3. Probiotics 
History of Probiotics
The term probiotic, meaning “for life,” is derived from the Greek language and it is 
currently used to name bacteria associated with beneficial  effects  for humans and 
animals.  The  original  observation  of  the  positive  role  played  by  some  selected 
bacteria is  attributed to  Eli  Metchnikoff,  the  Russian  Nobel  Prize working at  the 
Pasteur  Institute  at  the  beginning of  the last  century;  Metschnikoff  (1908)  in  his 
bestseller  The  Prolongation  of  Life was  probably  the  first  to  advocate,  or  rather 
postulate, the health benefits of LAB associated with fermented milk products. He 
hinted that the longevity of the Caucasians could be related to the high intake of 
fermented milk products and that  the intake of yogurt containing lactobacilli might 
result in a reduction of toxin-producing bacteria in the gut and that this could increase 
the  longevity  of  the  host.  Tissier,  a  French  paediatrician,  recommended  the 
administration  of  bifidobacteria  to  infants  suffering  from  diarrhea,  claiming  that 
bifidobacteria supersede the putrefactive bacteria that cause the disease (Doderlein, 
1892).  The  expression  “probiotic”  was probably  first  defined by Kollath in  1953 
(Kollath, 1953), when he proposed the term to identify all organic and inorganic food 
complexes as “probiotics,” in contrast to harmful antibiotics in order to upgrade such 
food complexes as supplements.  In his publication “Anti- und Probiotika," Vergio 
(1954)  compared  the  detrimental  effects  of  antibiotics  and  other  antimicrobial 
substances with favorable factors (“Probiotika”) on the gut microbiology.
The word "probiotic" was coined in 1965 by Lilly and Stillwell (1965) to describe 
“substances secreted by one microorganism which stimulates the growth of another” 
and thus was contrasted with the term antibiotic. It may be because of this positive 
and general claim of the definition that the term probiotic was subsequently applied 
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to other substances and gained a more general meaning. In 1971 Sperti (Sperti, 1971) 
applied the term to tissue extracts that stimulate microbial growth. Parker (1974) was 
the first  to  use  the  term  probiotic  in  the  sense  that  it  is  used  today.  He defined 
probiotics  as  “organisms  and  substances  which  contribute  to  intestinal  microbial 
balance.” The use of the word substances in Parker’s definition of probiotics resulted 
in a wide connotation that included antibiotics. Although numerous definitions have 
been proposed since then, none has proved completely satisfactory because of the 
need for additional explanations, e.g., with regard to statements such as “beneficial 
balance,”  “normal  population,”  or  “stabilization  of  the  gut  flora.”  In  1989 Fuller 
(Fuller,  1989)  attempted  to  improve  Parker’s  definition  of  probiotic  with  the 
following distinction: “A live microbial feed supplement which beneficially affects 
the host animal by improving its intestinal microbial balance.” This revised definition 
emphasized the requirement of viability for probiotics and introduced the feature of a 
beneficial effect on the host, which was, according to his definition, an animal.  A 
similar definition was proposed by Havenaar and Huis in 't Veld (1992) “…mono- or 
mixed  cultures  of  live  microorganisms  which,  when  applied  to  animal  or  man, 
beneficially affect the host by improving the properties of the indigenous microflora.” 
Probiotics are best known by the average consumer in relation to food where they are 
defined  by  the  EU  Expert  Group  on  Functional  Foods  in  Europe  (FUFOSE)  as 
“viable preparations in foods or dietary supplements to improve the health of humans 
and animals”.  Salminen (1996) and Schaafsma (1996) broadened the definition of 
probiotics even further by no longer limiting the proposed health effects to influences 
on the indigenous microflora. According to Salminen, a probiotic is “a live microbial 
culture  or  cultured  dairy  product  which  beneficially  influences  the  health  and 
nutrition  of  the  host.”  According  to  Schaafsma,  “Oral  probiotics  are  living 
microorganisms which upon ingestion in certain numbers, exert health effects beyond 
inherent basic nutrition.” , In 2001, Schrezenmeir and Michael de Vrese proposed the 
following  definition:  “A  preparation  of  or  a  product  containing  viable,  defined 
microorganisms in sufficient numbers, which alter the microflora (by implantation or 
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colonization) in a compartment of the host and by that exert beneficial health effects 
in this host”. In 2002, FAO/WHO has adopted the definition of probiotics as “Live 
microorganisms  which  when  administered  in  adequate  amounts  confer  a  health 
benefit on the host” (FAO/ WHO, 2002). 
In the past decades studies in the area of probiotics have progressed considerably and 
significant advances have been made in the selection and characterisation of specific 
probiotic cultures and in the identification of the positive effects they have on the 
health. Members of the genera  Lactobacillus  and  Bifidobacterium  are now mostly 
employed, but not exclusively, as probiotic microorganisms and a larger variety of 
probiotic foods are now available to the consumer.
The original  assumption  of  Metchnikoff  was that  the dietary manipulation  of  gut 
microflora  performed  in  order  to  increase  the  relative  numbers  of  "beneficial 
bacteria" could contribute to the well being of the host. However he also stated that 
systematic  investigations  should  be  made  on  the  relation  of  gut  microbes  to 
precocious old age, and on the influence of diets which prevent intestinal putrefaction 
in prolonging life and maintaining the forces of the body." 
It is necessary to assess the efficacy and safety of probiotics and this constitutes an 
important  part  of  their  characterization for  human use.  The  probiotic  potential  of 
different bacterial strains, even within the same species, differs; different strains of 
the same species are always unique, and may have differing areas of adherence (site-
specific), specific immunological effects, and actions on a healthy versus an inflamed 
mucosal milieu may be distinct from each other. Present studies are being carried out 
in  order  to  characterize  the  healthy  normal  gut  microbiota  in  each  individual, 
analysing the species composition and the concentrations of different bacteria in each 
part  of  the intestine.  They are aimed at  fully  understanding the interactions host-
microbe within the gut, the microbe–microbe interactions within the microbiota and 
the combined health effects of these interactions in order to define the microbiota 
both as a tool for nutritional management of specific gut-related diseases and as a 
source of new microbes for future probiotic bacteriotherapy applications. 
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Microbes from many different  genera are being used as probiotics (Table 3). The 
most commonly used strains are members of the heterogeneous group of lactic acid 
bacteria; lactobacilli, enterococci and bifidobacteria. 
Table 3.  Microrganisms used as probiotics.
  
Species and example strains                          Health benefit and references                        
L. acidophilus La 5                     Reduced antibiotic-associated diarrhea (Black et al. 1991)
L. casei Shirota                           Shortening of rotavirus diarrhoea, reduced recurrence of superficial
                                                    bladder cancer, immune modulation (Nagao et al., 2000).
L. johnsonii La1                          Improved oral vaccination reduced colonisation by H.pylori 
                                                    (Felley et al. 2001)                                                      
L. plantarum 299v                      Relief of irritable bowel syndrome , reduction of  LDL-cholesterol
                                                    (Niedzielin et al., 2001)
L. reuteri SD2112                       Shortening of rotavirus diarrhoea (Shornikova et al., 1997)
L. rhamnosus GG                        Shortening of rotavirus diarrhoea, immune modulation, relief of   
                                                     inflammatory bowel disease, treatment and prevention of allergy 
                                                     (Kalliomäki et al. 2001)
Bifidobacterium lactis Bb12       Treatment of allergy, shortening of rotavirus diarrhoea, reduced incidence
                                                     of travellers diarrhoea Improved oral vaccination (Isolauri et al., 2001)
Effects of probiotics
The mechanism of probiotic action is still unknown but different approaches could be 
developed.  According  to  Fuller  (1989)  and  Huis  in’t  Veld  and  Havenaar  (1993) 
probiotic effect of lactic acid bacteria and bifidobacteria may be expressed by three 
main mechanisms of action:
1. Suppression of pathogenic microorganisms in the intestinal tract by:
a) production of antibacterial substances including primary metabolites, such as lactic 
acid,  acetic  acid,  carbon  dioxide,  diacetyl,  acetaldehyde,  hydrogen  peroxide  and 
39
bacteriocins; they are proteinaceous compounds with antimicrobial activities against 
other closely related bacteria;
b) competition for nutrients. In a paper about the large intestine Freter  et al.  (1983) 
claimed  that  the  competition  for  limited  nutrients  (specific  carbohydrates)  is  the 
determining factor withthe greatest scientific support;
c) competition for  adhesion receptors on the gut epithelium. Probiotic strains can 
adhere  specifically  or  non-specifically.  Specific  adhesion  takes  place  when  an 
adhesion  on  the  bacterial  cell  binds  to  a  receptor  on  the  epithelial  cell;  this  is 
commonly  defined  as  a  lock  and  key  function.  Non-specific  adhesion  is  a  more 
general phenomenon mediated by hydrophobic or electrostatic interaction. Although 
it may not have any partcular relevance in the colonisation of epithelia in vivo,  it may 
possibly  be important  in  the  colonisation  of  luminal  contents.  For  example,  non-
specific  adhesion may  enhance the substrate  uptake  and consequently  the growth 
(Jonsson, 1992).
2. Alteration of microbial metabolism in intestinal tract:
a) increasing the activity of useful enzymes,  e.g. -galactosidase in the alleviation of 
lactose maldigestion;
b)  decreasing  the  activity  of  some  colonic  enzymes  such  as  nitroreductase  and 
azoreductase known to have carcinogenic effects.
3. Stimulation of immunity:
Recent reports have shown that orally administered lactobacilli can improve immune 
status by increasing the circulating and local antibody levels, the gamma interferon 
concentration, the macrophage activity and the number of natural killer cells. The 
inclusion of lactic acid bacteria as members of physiological indigenous microflora 
into the mucosa and the subsequent translocation to other organs is currently regarded 
as a crucial step for the development of the normal mucosal and systemic immunity. 
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Mechanism of competitive exclusion
The resident microflora exists in a symbiotic relationship with the host and receives a 
rich and continuous nutrient supply. It improves nutrient bioavailability to the host 
and augments disease resistance mechanisms of the host. The ability of lactic acid 
bacteria  to  reduce  the  gastrointestinal  invasion  of  pathogenic  bacteria  has  been 
described in several works (Bernet et al., 1994; Bernet et al., 1993). The protection 
afforded  by  the  indigenous  flora  is  thought  to  be  related  also  by  competitive 
exclusion and interference with the attachment to mucosal surface. Many indigenous 
and pathogenic bacteria specifically adhere to complex oligosaccharides associated 
with  proteins  and/or  lipids  of  intestinal  membranes.  The  inter-  and  intra-species 
diversity  of  intestinal  glycosylation  patterns/carbohydrate  epitopes  is  well 
established.  Furthermore,  it  is  possible  that  the  ability  of  lactic  acid  bacteria  to 
compete  with pathogens for  adhesion to  the intestinal  wall  is  influenced by their 
membrane fluidity. This possibility was suggested by studies which claimed that the 
type and quantities of polyunsaturated fatty acids in the extracellular milieu influence 
the adhesive properties of lactic acid bacteria to the epithelium (Kankaanpaa et al., 
2004).
The  interaction  of  bacteria  with  binding  sites  may  evolve  direct  recognition  or 
recognition  of  cryptic  receptors  following  the  action  of  secreted  exoglycosidase 
enzymes. A Lactobacillus strain was shown to competitively inhibit the adhesion of 
enteropathogenic E. coli to pig ileum and interfered with bacterial attachment to the 
mucosal layer of ileal conducts (Loones, 1989). Although L. acidophilus inhibits the 
adhesion  of  several  enteric  pathogens  to  human  intestinal  cells  in  culture,  when 
pathogen  attachment  preceeded  the  treatment  with  L.  acidophilus,  no  inhibitory 
interference occurred indicating that steric hindrance of site occupation is important 
in the inhibition of adhesion. Thus, the therapeutic use is limited to the preventive 
application and not to a curative goal once binding of the pathogen has occurred. In 
addition, a dose-dependent inhibition against cell adhesion of several pathogens has 
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been demonstrated  only  for  one strain  of  L.  acidophilus (LA1)  (Beshkova et  al., 
1998).
A number of health effects are associated with the use of probiotics. These include:
Nutrient synthesis and bioavailability
It  has  been  shown  that  the  action  of  micro-organisms  during  the  preparation  of 
cultured foods or  in the digestive tract  can improve the quantity,  availability  and 
digestibility  of  some  dietary  nutrients.  The  fermentation  of  food  with  lactic  acid 
bacteria  increases  the  folic  acid  presence  in  yogurt,  kefir  and  bifidus  milk  (Alm 
1982). Similarly, niacin and riboflavin levels in yogurt rise with fermentation (Alm 
1982). The lactic acid bacteria are known to release various enzymes and vitamins 
into the intestinal  lumen.  This has synergistic effects  on the digestion,  alleviating 
symptoms of intestinal malabsorption, and producing lactic acid, which lowers the 
pH of the intestinal content and prevents the development of invasive pathogens such 
as Salmonella spp. or strains of  E. coli (Mallett et al. 1989; Mack et al. 1999). The 
bacterial  enzymatic  hydrolysis  may enhance the bioavailability  of  protein  and fat 
(Fernandes et al. 1987) and increase the production of free amino acids and short 
chain fatty acids (SCFA). When absorbed these SCFAs contribute to the available 
energy pool of the host (Rombeau et al. 1990; Rolfe 2000) and may protect against 
pathological changes in the colonic mucosa (Leavitt et al. 1978; Leopold and Eileler 
2000). SCFA concentration helps to maintain an appropriate pH in the colonic lumen, 
which  is  critical  in  the  expression  of  many  bacterial  enzymes  and  in  unfamiliar 
compounds and carcinogen metabolism in the gut (Mallett et al. 1989).
In addition to the nutrient synthesis, the action of microorganisms either during the 
preparation of cultured foods or in the digestive tract can, to a limited extent, improve 
the digestibility of some dietary nutrients. Several lines of evidence show that the 
appropriate  strain  of  lactic  acid  bacteria  (i.e.  Streptococcus  thermophilus, 
Lactobacillus bulgaricus and other lactobacilli used in fermented milk products) in 
adequate  amounts,  can  alleviate  symptoms  of  lactose  intolerance  by  delivering 
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enough bacterial lactase to the intestine and stomach where lactose is degraded to 
prevent  symptoms in  lactase  non persistent  individuls.  (Kilara  and Shahani 1975; 
Martini et al. 1991). Figure 7 is the representation of various functions and health 
benefits of probiotics.  
Fig 7. Various health benefits from probiotics consumption
Reduction of lactose intolerance
There  is  good  scientific  evidence  about  the  alleviation  of  lactose  intolerance 
symptoms by a specific probiotic lactic acid bacteria: several studies have reported 
that  lactose-intolerant  individuals  suffers  fewer  symptoms  if  milk  in  the  diet  is 
replaced  with  fermented  dairy  products.  The  bacterial  enzyme,  B-galactosidase, 
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which can be detected in duodenum and terminal ileum after consumption of viable 
yogurt, is the factor that improves digestibility by the hydrolysis of lactose.
Diarrhoea treatment
Numerous studies have been carried out in this field and  Lactobacillus rhamnosus 
GG has proved to be  effective in the treatment of rotavirus diarrhoea, since it reduces 
the duration of diarrhoea to about half in children with rotavirus diarrhoea. When 
different lactic acid bacteria were compared for their effects on the immune response 
to rotavirus in children with acute rotavirus gastroenteritis differences between strains 
were  observed.  Lactobacillus GG  was  found  to  be  more  effective  than  other 
preparations  (Streptococcus  thermophilus and a  L.  bulgaricus,  or  a  L.  rhamnosus 
strain or a preparation containing L. rhamnosus). During convalescence  the treatment 
with Lactobacillus GG was associated with an enhancement of IgA sASC to rotavirus 
and serum IgA antibody level. It was therefore believed that certain strains of lactic 
acid bacteria could promote systemic and local immune response to rotavirus. This 
may be of importance for protective immunity against reinfections.
Immune modulation by probiotics
As already evidenced in  the previous  chapter,  the  gut  microflora  is  an important 
constituent  in  the  intestines  defence  barrier.  The  gut  microflora  affects  the 
development  of  gut-associated  lymphoid  tissue  at  an  early  age  and  consequently 
directs  the  regulation  of  systemic  and  local  immune  responsiveness,  including 
hyporesponsiveness to antigens from micro-organisms and food.  The success of a 
probiotic  therapy  can  be  seen  in  the   normalisation  of  the  increased  intestinal 
permeability  and  the  altered  gut  microecology,  the  improvement  of  the  intestine 
immunological barrier functions and the  alleviation of the intestinal inflammatory 
response.  The  targets  for  probiotic  therapy  are  identified  as  clinical  conditions 
involving impaired mucosal barrier function, particularly infectious and inflammatory 
diseases (Isolauri 2001).
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Food allergy reduction
It is widely recognized that human beings are exposed to numerous environmental 
antigens  through  food.  The  intestinal  mucosa  can  efficiently  assimilate  antigens 
encountered by the enteric route, but a high-level antigen exposure during the first 
few months  of  life  may predispose  individuals  to  allergic  sensitization.  Intestinal 
inflammation seems to be a predisposing factor in the increased sensitization of a 
subject. In the absence of intestinal microflora, antigen transport is increased. Studies 
have  shown  that  intact  cow’s  milk  proteins  can  stimulate  peripheral  blood 
mononuclear cells to release pro-inflammatory cytokines in patients with cow’s milk 
allergy  (Heyman  et  al.,  1995).  However,  it  has  been  shown that  the  cow’s  milk 
proteins  degraded  by  Lactobacilli,  but  not  by  trypsin  or  pepsin,  may  generate 
tolerogenic peptides from the native protein. These findings tend to substantiate the 
hypothesis  that  specific  strains  of  intestinal  microflora  may  contribute  to  the 
protection  of  the  host  against  allergic  sensitization  (Hatakka  et  al.,  2001).  The 
management of food allergy is at present aiming at completely avoiding foods proven 
to cause symptoms as in the treatrment of infants with cow’s milk allergy in which 
extensively hydrolyzed formulas are used to eliminate cow’s milk antigens from the 
diet. 
Inflammatory diseases and irritable bowel syndromes
Pouchitis and the Crohn’s disease, as well as the irritable bowel syndrome (IBS) may 
be caused or aggravated by alterations in the gut flora including infection (Shanahan, 
2000).  Some  studies  support  the  potential  role  of  probiotics  in  the  therapy  and 
prophylaxis and illustrate that combinations of strains may have a role in remediation 
(Gupta et al., 2000). The intestinal microflora is likely to play a critical role in the 
inflammatory conditions in the gut, and probiotics could remediate such conditions 
through modulation of the microflora.
Indeed selected probiotics have been observed to reduce the number of relapses and 
to prolong the period of remission. Interestingly, not only the lactic acid bacteria, L. 
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salivarius  UCC118 and  L. rhamnosus  GG, but also  S. cerevisiae  (boulardii) and a 
strain of  E. coli  (Nissle) have proved effective in alleviating the symptoms of IBD 
(Gupta et al. 2000; Hamilton-Miller 2001). Clinical trials showed that in the IBS, L. 
plantarum 299v and DSM 9843 strains reduced abdominal pain, bloating, flatulence, 
and constipation (Steidler et al. 2000; MacFarlane and Cummings 2002). 
Colorectal cancer
There is a diverse aetiology of colorectal cancer in which diet is clearly involved 
(Greenwald et al. 2001). Diets which are high in meat and fat or low in fibre can 
cause changes in the composition of the intestinal microflora, with increasing levels 
of Bacteroides and Clostridium and decreased levels of Bifidobacterium (Benno et al. 
1991). This modification in the microflora composition is associated with an increase 
in faecal enzyme activity, β-glucuronidase, azoreductase, urease, nitroreductase and 
glycocholic acid reductase. These enzymes turn procarcinogens into carcinogens and 
may  thus increase  the risk  for  colorectal  cancer. It  has  been  observed  that  the 
consumption of selected lactobacilli reduces this faecal enzyme activity. Although it 
is still to be proven whether this also reduces the actual risk for colorectal cancer, 
most,  but not all,  epidemiological  studies suggest  that the regular consumption of 
fermented  dairy  products  is  related to  a  lower  risk  for  certain  types  of  cancer 
(Hirayama & Rafter 2000). Some positive effects of the probiotic lactic acid bacteria 
on the risk for colorectal cancer can therefore be anticipated although definite proof is 
still to be obtained.
Activity against Helicobacter pylori 
Specific strains of lactic acid bacteria have been reported to inhibit many intestinal 
pathogens including  Helicobacter pylori.  The lactic acid bacteria are often able to 
survive the acidic gastric conditions and therefore it has been proposed that they may 
have a beneficial influence during the eradication of H. pylori, which is involved in 
the  development  of  gastric  ulcer.  It  has  been  reported  that  both  the  inhibitory 
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substances and the specific strains may influence the survival of H. pylori and studies 
have been conducted especially with a  L. johnsonii strain. It has been shown that 
there is a good in vitro inhibition and that fermented milk containing the strain hase a 
positive effect when consumed during Helicobacter eradication therapy (Mitchetti et 
al., 1999). 
Hepatic disease
The  hepatic  encephalopathy  (HE)  is  a  liver  disease  and  its  effects  can  be  life 
threatening. The exact pathogenesis of HE still remains unknown. The probiotics S. 
thermophilus, Bifidobacteria,  L. acidophilus,  L. plantarum,  L. casei,  L. delbrueckii  
bulgaricus, and  E. faecium, which show a definite therapeutic effect, have multiple 
mechanisms of action that could disrupt the pathogenesis of HE and lower portal 
pressure with a reduction in the risk of bleeding, which may make them preferable  to 
conventional  treatment  (Cunningham-Rundles  et  al.  2000;  De  Santis  et  al.  2000; 
Gorbach 2000; Guslandi et al. 2000; Shanahan 2001; Solga 2003).
Hypertension
About 50-60 million people in United States are estimated to have hypertension, or 
elevated blood pressure. Antihypertensive effects have been documented in animal 
models  and in  mildly  hypertensive  adults  for  three  compounds  derived from the 
growth of certain lactobacilli: i) fermented milk containing two tripeptides derived 
from the  proteolytic action of  L. helveticus on casein in milk; ii) bacterial cell wall 
components  from cell  extracts  of  lactobacilli;  and  iii)  fermented  milk  containing 
fermentation-derived gamma amino butyric acid. Systolic blood pressure decreased 
by 10-20 mm Hg. These results suggest that consumption of certain lactobacilli, or 
products  derived  from  them,  may  reduce  blood  pressure  in  mildly  hypertensive 
people.  The  viability  of  Lactobacillus is  not  required  for  the  effect.  Several 
fermentation-derived, but nonprobiotic, products have been developed. 
Vaginosis 
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The vagina and its microbiota form a finely balanced ecosystem. Disruption of this 
ecosystem  can  lead  to  a  microbiological  imbalance  and  symptoms  of  vaginosis. 
Vaginosis used to be considered a mere annoyance, but it is now being studied for a 
role in serious conditions including pelvic inflammatory disease, pregnancy-related 
complications (low birth weight babies, etc.), and increased susceptibility to AIDS 
infection. Vaginosis can be caused by several different organisms, and in many cases, 
the  causative  agent  may  not  be  identified.  What  is  known  is  that  lactobacilli 
predominate  in  the  healthy  vagina,  and  a  lack  of  lactobacilli  (especially  those 
producing  hydrogen  peroxide)  is  a  risk  factor  for  vaginosis.  The  lactobacilli  are 
thought  to  maintain  a  favorable  vaginal  pH  in  the  acidic  range  and  to  inhibit 
pathogens,  possibly  through  the  production  of  hydrogen  peroxide  and  other 
antimicrobial  factors.  Intravaginal applications of lactobacilli  have been somewhat 
effective in treating bacterial vaginosis. 
Conditions of the genitourinary tract
The colon might  thus  be considered both  a  source  of  beneficial  and of  harmful 
bacteria for the urinary and genital tracts. It has been shown that both oral probiotics 
and vaginal suppositories of probiotics can reduce the incidence of recurrent urinary 
tract infection (McLean and Rosenstein 2000). One study suggests the possibility of 
vaginal contamination with faecal flora as the possible rationale for the effectiveness 
of this therapy (Cadieux et al. 2002).
Elevated blood cholesterol
Cholesterol is essential for many functions in the human body. It acts as a precursor 
to certain hormones and vitamins and it is a component of cell membranes and nerve 
cells. However, elevated levels of total blood cholesterol or other blood lipids are 
considered  risk  factors  for  developing  coronary  heart  disease.  Although  humans 
synthesize cholesterol to maintain minimum levels for biological functioning, diet is 
also known to play a role in serum cholesterol levels. The extent of influence varies 
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significantly from person to person. Probiotic cultures have been evaluated for their 
effect  on  serum  cholesterol  levels.  Clinical  studies  on  the  effect  of  lowering 
cholesterol  or  low-density  lipid  levels  in  humans  have  been  inconclusive.  Some 
studies  on  humans  suggest  that  elevated  blood cholesterol  levels  can  be  reduced 
consuming probiotic-containing dairy foods, but the evidence is not overwhelming. 
Benefits for healthy subjects
Determining the potential health effects of probiotics for healthy subjects is difficult 
although this is of major importance since probiotics are mainly marketed for healthy 
subjects. The effects of probiotics on healthy subjects are likely to be limited only to 
the reduction of possible risks. The consumption of fermented dairy products maybe 
linked to a reduced risk for colorectal cancer. However, the evidence for this is rather 
circumstantial.  Long  term consumption  of  probiotics  in  non-fermented  milk  may 
reduce the risk for infections, the absence from day care due to illness and the use of 
antibiotics, at least for children (Hatakka et al. 2001). This study indeed suggests that 
probiotics  can  also  be  of  benefit  to  the  healthy  consumer.  Probiotics  are  often 
marketed as ‘boosting the immune system’. For healthy individuals this may not be 
the case, since the immune system is likely to be working optimally (Spanhaak et al. 
1998). However, in combination with oral vaccination, improved antibody titres have 
been observed with probiotics (Link-Amster et al. 1994).
Prebiotics and Synbiotics
The term prebiotic was introduced by Gibson and Roberfroid (1995) who exchanged 
“pro” for “pre,” which means “before” or “for.” They defined prebiotics as “a non-
digestible  food  ingredients  which  beneficially  affect  the  host  by  selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in the 
colon.”  The  major  prebiotics  are  resistant  dietary  carbohydrates,  but 
noncarbohydrates  are not excluded from this definition.  Prebiotics  are believed to 
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stimulate  selectively  bacterial  groups  such  as  bifidobacteria,  lactobacilli,  and 
eubacteria resident in the colon which are considered particularly beneficial for the 
human host. Resistant short-chain carbohydrates (SCCs) are also called nondigestible 
oligosaccharides or low-digestible carbohydrates (LDCs). These SCC or LDCs offer 
interesting  possibilities  for  inclusion  into  conventional  food  products  for  their 
“bifidogenic”  effects.  Several  of  such  “candidate  prebiotics”  are  currently  under 
consideration  by  the  industry  for  human  consumption.  Inulin  and  fructo-
oligosaccharides  (FOSs)  are  considered  as  typical  “bifidogenic  factors”  and  are 
probably the most commonly used prebiotics on the market. 
Other  promising  prebiotic  oligosaccharides  under  consideration  are  galacto-
oligosaccharides, isomalto-oligosaccharides, soybean oligosaccharides, lactosucrose, 
and xylooligosaccharides. 
It  is  generally  agreed  that  there  are  a  number  of  beneficial  effects  of  prebiotics, 
particularly related to the favorable influence on the small bowel by improved sugar 
digestion and absorption, glucose and lipid metabolism, and protection against known 
risk factors of cardiovascular disease. In the colon, the fermentative production of 
SCFAs is to be considered a fundamental  beneficial  feature linked to the primary 
prevention of colorectal cancer. Other confirmed effects from prebiotics are related to 
the low energy value (<9 kJ/g) resulting from their nondigestibility, to an increase in 
stool  volume,  to  the  modulation  of  the  colonic  flora  by  stimulation  of  beneficial 
bacteria  and the  inhibition  of  “undesirable”  bacteria.  Some of  these  effects  ,  not 
confirmed yet,  concern the prevention of colorectal  cancer,  the modulation of the 
immune response, the prevention of intestinal infections and the  reduction of the 
serum cholesterol levelas well as an improved bioavailability. 
By  definition,  the word synbiotic  refers  to  a  product  in  which  a  probiotic  and a 
prebiotic  are  combined.  The  growth of  a  probiotic  strain  that  is  able  to  utilize  a 
prebiotic  will  be  selectively  stimulated  in  the  gut.  This  combination  of  pre  and 
probiotics in a single product has been shown to offer  more benefits  than  either 
substance  on its own. 
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Chapter 4.   Applications of probiotics 
Industry stakeholders for probiotics include businesses involved in conventional and 
speciality  foods  and  beverage,  dietary  supplements,  consumers’  health  care, 
biopharmaceuticals, veterinary health care, and agriculture. 
Probiotics in food industry
Functional foods as a marketing term appeared in Japan in the late 1980s and it was 
used to describe foods fortified with ingredients capable of producing health benefits. 
Nowadays,  the consumer pays a lot of attention to the relation between food and 
health. As a consequence, the market for functional foods has shown a remarkable 
growth over the past few years.  Probiotic products represent a remarkable growth 
area within the functional food group and intense research efforts are under way to 
develop  dairy  products  into  which  probiotic  organisms  are  incorporated.  The 
consumer market for probiotic food is about 1.4 billion in Western Europe (Saxelin, 
2008). The biggest sector is represented by yogurts and desserts, with sales of about 1 
billion euros, and the rest of the market is primarily about probiotic milks. The food 
supplement business is estimated at 10% of the total market for probiotics. Probiotics 
are added to both fresh and fermented dairy products (i.e. milk, fermented milk, and 
yogurt). The most popular format of probiotic, however, is the “daily-dose” drink, 
which  was  introduced  to  Europe  in  1994 by  the  Japanese  company  Yakult.  The 
differences  between  the  US  and  European  markets  for  probiotics  may  be  easily 
explained  by  the  annual  per-capita  consumption  of  fermented  milk  products 
(including yogurt)  in  Europe  (35-45 L/person/year),  which is  considerably  higher 
than in North America (4-5 L/person/year) (Saxelin, 2008). 
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In probiotic foods, probiotics can be added simultaneously with the standard cultures 
in the fermentation tank, or combined to form the final product, after fermentation 
has taken place.
The use of food additives is  regarded as  unnatural  and unsafe.  Yet,  additives are 
needed to  preserve  food products  from spoilage  and to  improve  the  organoleptic 
properties. The demand for a reduced use of additives and processing has put the food 
industry under pressure to look for alternatives. In food fermentation, one of the key 
points for intervention seems to be at the level of the starter culture. Probiotics, that 
are able to produce antimicrobial substances, represent a way of replacing chemical 
additives by natural compounds, proving at the same time the consumer with new, 
attractive food products.
A starter culture can be defined as a microbial preparation of a large number of cells 
of at least one strain to be added to a raw material to produce a fermented food by 
accelerating and steering its fermentation process. The group of lactic acid bacteria 
play a essential role in this process, through the production of organic acids (which 
cause  rapid  acidification  of  the  raw  material),  ethanol,  aroma  compounds, 
bacteriocins, exopolysaccharides, and several enzymes. In this way they enhance the 
shelf life and microbial safety, improve the texture, and contribute to the pleasant 
sensory profile of the end product.
Nonfermented probiotic milks also exist in Europe, although they do not have a long 
history of traditional use; many of them are available only at regional level and they 
have a moderate success on the market. Probiotics can also be included in juices and 
berry soups, ice cream, cheese, candy and chewing gum, although these do not play a 
major role in the marketplace. Sometimes, probiotics are combined with soy and oat 
and then they are added to cow milk-based probiotic products. Alternatively, entirely 
oat- or soy-based material is fermented with probiotics and other cultures. A new and 
promising product category includes breast-milk substitutes, milks for older babies 
(i.e. “follow-on” milks), and special infant formulas. The legislation for this kind of 
products is extremely strict and the strains used must be well documented.
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In  table  4  and  5 the  most  common  species  used  in  probiotic  foods  and  food 
supplements are listed. 
Table 4.  The most common species used in probiotic foods 
Lactobacillus acidophilus                                                  Lactobacillus johnsonii/gasseri
Lactobacillus casei                                                            Lactobacillus paracasei
Lactobacillus rhamnosus                                                   Lactobacillus plantarum
Lactobacillus reuteri                                                         Bifidobacteriumj animalis/lactis
Bifidobacterium bifidum                                                   Bifidobacterium breve
Bifidobacterium longum                                                   Bifidobacterium adolescentis
Table 5.  The most common species used in probiotic food supplements
Lactobacillus acidophilus/johnsonii/gasseri
Lactobacillus casei
Lactobacillus paracasei
Lactobacillus rhamnosus
Lactobacillus plantarum
Lactobacillus reuteri
Bifidobacteriumj animalis/lactis
Bifidobacterium bifidum
Bifidobacterium breve
Bifidobacterium longum
Bifidobacterium adolescentis
Streptococcus thermophilus
Lactobacillus delbrueckii subsp. bulgaricus
Enterococcus faecalis
Enterococcus faecium
Bacillus subtilis
Bacillus clausii
Escherichia coli strain Nissle
Saccharomyces boulardii and other yeasts
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A  wide  variety  of  probiotic  strains  is  used,  either  singly  or  in  combination,  as 
supplements  in  several  product  formulations:  hard  gelatin  or  vegetable  capsules, 
tablets with or without enterocoating, chewable tablets, and sachets (Saxelin, 2008). 
Some industrial applications of probiotics are listed below.
1. Food preservation and safety
Lactic acid bacteria strains represent an alternative to the use of chemical additives 
(such as nitrite, sulphite, propionic acid, sorbic acid and benzoic acid) used in food 
preservation, because of the production of several natural antimicrobials, including 
organic  acids,  carbon  dioxide,  hydrogen  peroxide,  diacetyl,  ethanol,  bacteriocins, 
reuterin and reutericyclin, which help to contrast microbial contamination. 
The  in  situ  production  of  bacteriocins  may  increase  the  competitiveness  of  the 
producer strain in the food matrix and contribute to the prevention of food spoilage. 
For instance, bacteriocin-producing LAB can be used as an alternative to potassium 
nitrate to prevent  the contamination of cheese by clostridia (Thomas et al.,  2000). 
Another example is the suppression of flavour-disturbing contaminating microbes, 
e.g., certain strains of L. lactis which produce off-flavours in dairy products (Stanley, 
1998). In addition, many bacteriocins are active towards foodborne pathogens such as 
Clostridium botulinum, Staphylococcus aureus, and Listeria monocytogenes. Several 
studies have indicated that LAB starter strains are able to produce their bacteriocins 
in food matrices and consequently show an inhibitory activity towards sensitive food 
spoilage or pathogenic bacterial strains. 
 The  reuterin  (β-hydroxypropionaldehyde)  produced  by  Lactobacillus  reuteri is 
active towards a wide spectrum of bacteria, moulds and yeasts, but it is not formed in 
sufficient amounts in the presence of sugars. Reutericyclin, a tetramic acid antibiotic 
with broad antimicrobial activity produced by L. reuteri, is believed to be responsible 
for the stability of certain German sourdoughs (Messens and De Vuyst, 2002).
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2. Probiotics for a more appealing product
Improvement of texture
In order to give a desired texture and mouthfeel to yoghurt, skim-milk powder, whey, 
gelatine (e.g., starch, pectin, guar gum, and alginate) and microbial polysaccharides 
(e.g., xanthan and gellan) are frequently added to the milk and this represents an extra 
cost for the producer. Polysaccharides increase the viscosity and firmness, improve 
the texture, reduce the susceptibility to syneresis, and contribute to the mouthfeel of 
low-fat products. LAB are able to product natural texture-improving sugar polymers 
(exopolysaccharides)  for  the  manufacturing  of  yoghurts,  sour  cream and whipped 
toppings, ice cream, and of low-fat Mozzarella (Leroy and De Vuyst, 2004) through 
the in situ use of functional starter cultures. Another application can be found in the 
bakery industry for a beneficial effect on bread volume and staling (Tieking et al., 
2003).  The  biodiversity  of  exopolysaccharides  produced  by  LAB  from  artisan 
yoghurts, fermented milks, vegetables, and cerealsis being investigated together with 
the conditions for an  optimal production, and their technological implementation in 
the industrial production of fermented foods. 
Another example of texture improvement of foods through functional starter cultures 
is the use of amylase-producing LAB. LAB producing thermostable amylases can 
help cereal fermentations, in particular in the sourdough technology for the natural 
inhibition of staling in bread.
Production of aroma and flavour
LAB contribute  to  the  aroma and flavour  of  fermented  products.  Their  action of 
acidification on the  food often produces  a tangy lactic acid taste and  frequently 
exerts proteolytic and lipolytic activities and produces aromatic compounds from, for 
instance, amino acids upon further bioconversion. The control over the activities of 
peptidases from LAB is a key target of the cheese ripening technology. For instance, 
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Italian ewe milk cheeses are characterised by a very heterogeneous non-starter lactic 
acid bacterial  flora which is influenced by geographical and technological factors, 
and which could be responsible for cheese diversity (De Angelis et al., 2001). Such 
strains offer an important base for product innovation, consequently research is going 
on  to  study  their  application  in  the  food  fermentation  industry.  The  addition  of 
NSLAB as adjunct  cultures for cheese manufacturing increases.  The level  of free 
amino acids, peptides, and free fatty acids is increased   adding NSLAB as adjunct 
cultures for cheese manufactoring; this often leads   to the intensification of  flavour 
and accelerated cheese ripening and they help to reproduce the flavour of raw milk 
cheeses when pasteurised milk is used (De Angelis et al., 2001).
Homofermentative  LAB  convert  the  available  energy  source  (sugar)  almost 
completely  into lactic  acid via  pyruvate  to  produce energy and to  equilibrate  the 
redox  balance.  However,  pyruvate  can  lead  to  the  generation  of  many  other 
metabolites such as acetate, ethanol, diacetyl, and acetaldehyde. In this way, LAB 
produce volatile substances that contribute to the typical flavour of certain fermented 
products,  such  as  sourdough  (determined  by  the  lactate/acetate  ratio),  kefir  and 
koumiss (ethanol), butter and buttermilk (diacetyl), and yoghurt (acetaldehyde). The 
control of optimal fermentation leads to the  improved production of some of these 
volatiles whereas  the metabolic engineering focuses on the steering of the metabolic 
flux in  a  well-defined direction.  Strategies  aiming  at  a  direct  modification  of  the 
redox balance have led to overproduction of the desired metabolites mentioned above 
(Leroy  and  De  Vuyst,  2004).  Alternatively,  the  introduction  of  novel  enzymatic 
activities into LAB may result in the formation of cells which produce interesting 
metabolites  from  the  supplemented  sugar.  The  overproduction  of  alanine 
dehydrogenase in suitable L. lactis cells has led to a homofermentative, stereospecific 
production of L-alanine from pyruvate (Hols et al.,  1999). L-Alanine is used as a 
sweetener in the food industry and its in situ production can lead to dairy products 
with an intrinsic sweetness.
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3. Functional starters for the acceleration of the maturation process of cheese
Several aromatic compounds are generated during the maturation of cheese due to the 
action of endogenous milk enzymes and to the proteolytic and lipolytic activities of 
LAB present in the cheese. The maturation stage is time- and space-consuming so 
accelerated maturation techniques are under study. Besides the  rational selection of 
the LAB starter and co-cultures and the application of process conditions for optimal 
activity of the endogenous enzymes, the addition of exogenous enzymes (enzyme-
modified  cheese)  as  well  as  the increased  in  situ  autolysis  of  the  LAB represent 
alternative solutions. The autolysis of the starter cells is followed by the release of 
intracellular peptidases in the curd. Bacteriocins may cause bacteriolysis, for example 
by  inducing  autolysins  or  by  deregulating  the  enzyme  action  due  to  energetic 
deficiency, which will result in the degradation of the cell wall and the consequent 
cell lysis. 
4. Functional starters with a health advantage: production of nutraceuticals and 
reduction of toxic or antinutritive factors
Nutraceuticals are food components that can contribute to the health of the consumer 
through a specific physiologiacl action.. Several nutraceuticals from bacterial origin 
have been added to food products.  The activity of LAB can be modified to increase 
the content of nutraceuticals in fermented foods such as fermented dairy products by 
selecting the strain and optimising the process.. As an example, fermented milks can 
be produced with LAB starter strains which produce high amounts  of low-calorie 
polyols so as to reduce the sugar content (Wisselink et al., 2002). Similarly, the use of 
oligosaccharide-producing  LAB  that  produce  sugar  polymers  with  a  controlled 
structure and chain length (and consequently molecular mass) may yield fermented 
products  with health  applications.  The health  effects  of  such oligosaccharides  are 
ascribed to their low-calorie character, their fibre-like nature, and their bifidogenic 
effect. In addition, certain LAB, such as the yoghurt bacteria Lb. delbrueckii subsp. 
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bulgaricus and  S.  thermophilus,  are  able  to  produce  vitamins  such  as  folate.  A 
controlled  use  of  these  bacteria  may  lead to  dairy  products  with increased  folate 
content. The fermentative action of specific LAB stains may lead to the removal of 
toxic or antinutritive factors, such as lactose and galactose from fermented milks to 
prevent  lactose  intolerance  and the  accumulation  of  galactose,  or  the  removal  of 
raffinose,  stachyose,  and verbascose  from soy to prevent  flatulence  and intestinal 
cramps,  of proteinase inhibitors from legumes and cereals to prevent maldigestion, 
of  phytic  acid  and  tannins  from  cereals  and  legumes  to  increase  mineral 
bioavailability, and of  natural toxins such as cyanogenic glucosides from cassava as 
well as of biogenic amines from traditional fermented foods (Holzapfel, 2002).
Probiotics for farm animals          
In  the early years of last century a number of human studies were carried out, but 
only in 1960s probiotics started to be used in the farm industry. In particular, the 
Swann Committee in 1969 suggested the limitation of the use of antibiotics in animal 
feeds: their use must be restricted to those antibiotics not used therapeutically. This 
fact stimulated the research on probiotic bacteria. Today, the probiotic research is 
applied to pets, horses and other farm animals, while the majority of research is done 
in chickens and pigs (Musa et al., 2009).
In  the animal  gut  there  is  a  very  complex  population  of  micro  organisms  which 
interact  with  each  other  and with  the  host  animal.  Estimates  rate  the  number  of 
different types of micro organisms in the gut at 400 and the total number of bacterial 
cells at 1014. Although the composition of the gut microflora is fairly constant and 
characteristic for each host species, it can be affected by various factors such as: 
• age: the microflora of live young suckling mammal is different from that of the 
adult 
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• diet: to some extent this will be responsible for the changes seen with age, but 
even among adults the composition of the diet can affect the composition of 
the gut microflora 
• environment: the conditions under which farm animals are reared differ from 
the  natural  conditions  under  which  their  wild  counterparts  develop.  The 
physiological  responses  to  the  artificial  nature  of  the  domestic/farm 
environment may  affect the gut microflora 
• stress: the unnatural conditions of farm rearing produce stresses which induce 
hormonal changes which can, in their turn, affect the mucous secretion and the 
flora composition of the gut. 
• medication: the use of antibiotics and other chemical antibacterial compounds 
either  as  growth  promoters  or  as  therapeutic  agents  can  change  the  gut 
microflora in such a way to allow the growth of pathogens.
Probiotic  preparations  can  contain  either  only  one  strain  of  microorganism  (e.g. 
Lactobacillus reuteri in GAIA feed) or different strains (e.g. Protexin which contains 
L.acidophilus,  L.  rhamnosus,  L.  plantarum.  L.  delbrueckii subsp.  bulgaricus,  S.  
thermophilus, Enterococcus faecium, Bifidobacterium bifidum, Candida pintolopesii  
and Aspergillus oryzae). This latter type of preparation can be justified by the claim 
that it works in a broad spectrum and can be expected to be active in different species 
of  host  animal  and  against  different  conditions,  such as  microbial  infections  and 
antibiotic-relieved growth depression. The most important probiotic microorganisms 
used for  farm animals  are listed in table 6.  The main  targets of animal  probiotic 
preparations  are  chicken,  pigs  and cattle,  but  the  efficacy  of  probiotics  has  been 
demonstrated also in pets, horses and other farm animals (Fuller, 1999).
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Table 6. Microrganisms used in probiotics for farm animals
Lactobacillus acidophilus                                                          Bifidobacterium pseudolongum       
Lactobacillus rhamnosus                                                            Bifidobacterium brevis              
Lactobacillus casei subsp. casei                                                 Bifidobacterium bifidum 
Lactobacillus reuteri                                                                  Bacillus subtilis                            
Lactobacillus plantarum                                                            Bacillus cereus                                   
Lactobacillus fermentum                                                            Bacillus toyoi                              
Lactobacillus delbrueckii subsp. bulgaricus                              Bacillus natto                   
Lactobacillus brevis                                                                    Bacillus mesentericus                  
Lactobacillus helveticus                                                             Bacillus licheniformis             
Lactococcus lactis                                                                      Clostridium butyricum
Streptococcus salivarius subsp. thermophilus                            Pediococcus pentosaceus
Streptococcus lactis                                                                    Saccharomyces cerevisiae 
Enterococcus faecium                                                                Candida pintolopesii
Enterococcus faecalis                                                                 Aspergillus oryzae
Many authors suggest the importance of the choice of the right strain and the dose on 
the results of the probiotic administration in animal, but it seems important also to 
take into consideration the age of the animal, his health, the different composition of 
the probiotic preparation, the conditions of management  of the animals  and other 
environmental factors. Fuller (1999) remarked that “if the right probiotic is given at 
the right time in the right dose, it will have a significant effect on the animal’s health 
and/or growth which will be reflected as a significant improvement in the farmer’s 
bank balance”.
Modern rearing methods which include unnatural rearing conditions and diets induce 
stress and can cause changes in the composition of the microflora which compromise 
the animals' resistance to infection. The aim of the probiotic approach is to repair the 
deficiencies  in  the  microflora  and  restore  the  animals'  resistance  to  diseases.
Such a treatment does not introduce any external chemicals into the animal's internal 
60
environment and does not run the risk of contaminating the carcass and introducing 
hazardous chemicals into the food chain. 
Probiotics are now replacing the chemical growth promoters for farm animals and 
claims have also been made for their ability to increase resistance to diseases. The 
benefits claimed for probiotics in farm animals are as follows: 
• Increased growth rate
• Improved digestion
• Provision of essential nutrients
• Greater resistance to infectious diseases
• Improved feed conversion
• Better absorption of nutrient
• Increased egg production
• Increased egg quality
• Improved meat quality and less contamination
• Improved milk yield
• Improved milk quality
• Reduced morbidity or mortality on animals
It  has been shown that the gut microflora is involved in the  protection against a 
variety  of  pathogens  including  Escherichia  coli,  Salmonella,  Campylobacter and 
Clostridium.
Consequently the probiotic approach may be effective in the prevention and therapy 
of these infections.
The selection of the organisms studied has been largely empirical but is has been 
established that obligate and facultative anaerobes are required. Mead concluded that 
the most active organisms in protecting chicks were the lactobacilli (L. acidophilus,  
Lactobacillus  fermentum,  Lactobacillus  salivarius)  and  certain  gram-positive 
anaerobic cocci (Mead et al., 1987). The mixtures tested ranged from 10-50 different 
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strains.  The method of administration was also examined;  oral  dosing proved the 
best but not commercially applicable. Instead, the spraying of the eggs and injection 
into the air sac gave encouraging results.
The use of probiotics as farm animal feed supplements
The use of probiotics as farm animal feed supplements  started in the 1970s. They 
were originally incorporated into feed to enhance the animal's growth and to improve 
its  health  with  an  increased  resistance  to  diseases.  The  effect  of  probiotics  was 
thought to be on the gastrointestinal tract and could affect the  incidence of diarrhoea 
and other gut infections. However, recent studies in several countries have shown that 
the effects  may  be more  general.  According to  the results  obtained,  some of  the 
bacteria  used  in  probiotics  (lactobacilli)  are  capable  of  stimulating  the  immune 
system. This opens up a whole new area of potential application for probiotics in 
which it will be possible to influence disease situations in sites remote from the gut, 
and  also  prevent  intestinal  disease.  There  are  two  ways  in  which  the  probiotic 
microorganisms  in  the  gut  can  stimulate  the  immune  system:  they  can  migrate 
through the gut wall  as viable cells and multiply to a limited extent,  alternatively 
antigens released by the dead organisms can be absorbed and stimulate the immune 
system directly.  A  third  way  could  be  represented  by  the  indirect  action  of  the 
lactobacilli through an effect on the other components of the gut flora.The product of 
this change will induce the immune response. 
Animal trials 
A typical example  of animal trial is done in Spain by Tortuero et al. (1995). They 
compared  two  probiotic  preparations  containing  a)  Enteroccus  faecium and 
Lactobacillus  casei and  b)  the  two  yoghurt  starter  organisms,  Streptococcus 
salivarius subsp.  thermophilus and  L.  delbrueckii subsp.  bulgaricus.  In  the  first 
experiment the preparation containing  E.faecium and  L. casei increased the weight 
gain during the experimental period up to 21 days of age. The yoghurt-starter cultures 
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also gave a positive response but only between 12 and 21 days of age. However, 
when the preparation containing  E. faecium and  L. casei was retested, it  failed to 
improve the weight gain. The second test was carried out with pigs from split litters, 
whereas the first experiment was carried out with piglets distributed randomly in the 
two treatments.  At the moment it is difficult to assess the significance of this and 
undoubtedly  there  were  other  factors  which  varied  between  the  two  trials.
This result confirms that under the right conditions a significant growth response can 
be obtained. But it also clearly shows the kind of confusion existing in this type of 
experimentation  in  which  attempts  to  repeat  a  positive  result  often  fail  and it  is 
impossible to explain such a failure since it is difficult to ensure that all the relevant 
factors other than the supplementation are constant. There was a larger decrease in 
the  coliform  count  from  log10  8.10  down  to  6.85  in  the  group,  showing  an 
improvement  in  the  growth  rate.  This  group  also  showed  an  increase  in  the 
concentration of interleukin Z (from 3.74 ng/g down to 7.43 ng.g). Neither of these 
differences were statistically significant. However, they do agree with other studies 
showing  affects  on  the  coliform  count  and  the  immune  status.
An extensive and well conducted trial on poultry was published in 1996 (Nahashon et 
al.  1996).  It  considered  a  wide  range  of  features  including  growth  rate,  feed 
conversion and egg production. The feed supplement employed was a Lactobacillus 
strain but no further information regarding the identification of the species was given. 
The trial looked at the effects occurring during the pullet phase (7-19 weeks) and 
during  the  egg-laying  phase  (20-59  weeks).  During  the  pullet  phase,  the  feed 
consumption and the weight gain increased as a result of feeding the  Lactobacillus 
supplement,  but  there  was no weight  gain for  the layers.  However,  there  was an 
increased daily feed consumption and an increased egg size. 
The quality of the eggs was not affected. In the past, several studies claimed positive 
effects on egg production but they were not statistically significant. An interesting 
new approach to probiotic administration to chickens has appeared recently. Embrex, 
in the States, developed a device for inoculating eggs with vaccine. In collaboration 
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with Probiotics  International  Ltd,  UK, trials were carried out  with the multistrain 
probiotic, Protexin. Eggs at 18 days incubation were inoculated with Protexin into the 
airsac or amnion. This procedure had no effect on hatchability; in fact, the injected 
eggs had a slightly increased hatchability and accelerated hatch date. The results so 
far available are only very preliminary, but the mean figures from the two trials show 
that there is an increase in body weight at 2 weeks of up to 8.7% depending on the 
dose and the rate of inoculation. 
The work on probiotics for cattle has increased in recent years. In calves, studies have 
been carried out using Saccharomyces cerevisiae, Aspergillus oryzae, various species 
of  Lactobacillus and  Enterococcus faecium.  In the past  ten years,  positive effects 
(although  not  always  significant)  on  feed  intake,  weight  gain,  earlier  weaning, 
reduced scouring decreased faecal coliform count and a lower demand for antibiotic 
treatment  have been found. It  is  interesting to note that benefits  don’t have to be 
always measurable in terms of increased growth rate or feed efficiency; as in the case 
of a study by Seymour et al. (1995), the effect may be demonstrated by monitoring 
the days of fever experienced by the animal and the number of antibiotic treatments 
required to maintain it in good health. In adult cattle the studies have used mainly the 
fungal  probiotics.  With  this   preparation for  beef  cattle,  recent  experiments  have 
shown improvements in feed efficiency and dry matter intake. The analysis of all the 
published data on this subject  indicates  that  the average increase in daily gain of 
cattle fed yeast culture was 7.3%. The corresponding figure for feed efficiency was 
6.0% (Huber, 1990). Numerous studies have been done with lactating cattle. Over 
several  years the average increase in milk yield of cows treated with  Aspergillus 
oryzae has  been  of  2.5%.  Increases  in  milk  yield  have  also  been  obtained  by 
supplementation  with  yeast.  Both  types  of  supplementation  have  induced  higher 
butterfat concentrations in milk. 
Campylobacter jejuni
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Campylobacter jejuni is a pathogenic bacteria recognised as the most frequent cause 
of gastrointestinal disease in  industrialised and developing countries. The most 
common route of infection is by ingestion of contaminated food, milk or water, 
with poultry being a particularly common source of contamination, as C. jejuni is 
a commensal of the gastrointestinal tract of many species of birds. Therefore, the 
consumption of poultry meat contaminated by Campylobacter is a significant risk 
factor /which can cause infection .
 The use of antibiotics in feed to prevent colonization of  Campylobacter has been 
prohibited  in  Western  Europe  so  researches  should  be  carried  out  to  identify 
alternative strategies  to  contrast  the infection from this  bacterium in animals  .  In 
addition, the common trend to prescribe antibiotics has favored the emergence of 
antibiotic-resistant  pathogen  strains  often  in  association  with  the  disruption  of 
protective flora and raising the risk of pathogen infections. As a consequence, there is 
an increasing interest in the development of adjunctive or alternative therapies based 
on  bacterial replacement through the  use of  probiotics derived from the natural 
intestinal flora. Probiotic bacteria are useful in the management of gastrointestinal 
infections  in  both  human  and  animals  (Salminen  et  al.,  1999).  The  possible 
mechanisms underlying these inhibitory effects include competition for nutrient and 
adhesion sites, toxin inactivation, secretion of antimicrobial substances, and immune 
stimulation, but their respective roles remain unclear  (Fooks et al., 1999). 
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Chapter 5.   In vitro selection of probiotic strains
Although progress in probiotic research has been achieved over the past few years, 
not all  of the available probiotic bacteria which are on the market  have adequate 
scientific documentation (Sanders and Huis in’t Veld, 1999). If nutritional and health 
benefits are to be derived from products containing probiotic bacteria, it should be 
desirable to understand the underlying mechanisms , and to use the strains that have 
proved to be the most promising. The probiotic concept will only gain acceptance if 
these  underlying  mechanisms  are  elucidated.  Consequently,  it  is  necessary  to 
establish rational criteria for the screening and selection of candidate microorganisms 
and also to evaluate the efficacy of the selected strains or the food products in well-
controlled human clinical trials. 
Since there was no international consensus on the methodology to assess efficiency 
and safety of probiotics, the Food and Agriculture Organization (FAO) and the World 
Health Organization (WHO) have compiled and evaluated the scientific evidence on 
functional  and  safety  aspects  of  probiotics  and  generated  “Guidelines  for  the 
Evaluation of Probiotics in Food” during the joint workshop group held in Canada, in 
May 2002 (Fao and WHO, 2002). FAO and WHO and the countries they represented 
requested  guidelines  and  recommendations  for  the  criteria  and  methodologies 
required to identify and define probiotics and establish the minimum requirements 
needed to accurately substantiate health claims. Although the FAO and WHO reports 
focused  on  foods,  many  of  the  recommendations,  including  the  definition  of 
probiotics, were approved at the Meeting of the International Scientific Association 
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for Probiotics and Prebiotics in May 2002. A scheme outlining the guidelines for the 
evaluation of probiotics is shown in Fig.8 below. 
Fig. 8. FAO and WHO guidelines for probiotics in food
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These guidelines address the following points:
• Strain identification
 The first consideration is to identify and characterize the organism at the genus and 
species-level. A combination of phenotypic and genetic tests should be used. Once 
the strain has been identified, a scientifically recognized name must be employed and 
the strains must be deposited in an internationally recognized culture collection. 
• In vitro tests to screen potential probiotics and assessment of efficacy
In vitro tests of candidate probiotic strains, some of them summarized in Tab. 7, are 
thought  to  provide  some  insight  for  a  more  appropriate  choice  for  in  vivo 
functionality. 
Tab 7. Main in vitro tests currently used for the study of probiotic strains (Modified 
from report FAO, 2002)  
Resistance to gastric acidity
Bile acid resistance
Adherence to mucus and or epithelial cells and cell lines of humans and/or animals
Antimicrobial activity against potentially pathogenic bacteria
Ability to reduce pathogen adhesion to surfaces
Among  the  several  criteria  used  for  the  selection  of  probiotic  strains,  the  most 
commonly employed is the survival in the stressful gastro intestinal tract conditions 
(low pH and high bile salts concentrations), the ability to transitory colonize the GIT, 
which is  related with the adhesion  to  mucus  and/or  intestinal  epithelium and the 
antimicrobial activity through the production of antimicrobial molecules or the ability 
to inhibit/displace the adhesion of pathogens. Several in vitro and in vivo tests are 
employed  for  the  screening  of  these  characteristics,  although  there  is  a  lack  of 
standardised or unified methodology for the assessment of probiotic functionality. 
The transit of probiotics included in foods through different sections on the GIT takes 
variable time and it  is  submitted to different  stressful  conditions.  In human,  after 
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mastication, the first barrier that bacteria must overcome is the low pH value of the 
stomach with values ranging from 1 to 3 and mean exposure time of 90 minutes. In 
the  duodenum  the  pH  value  rises  to  6-6.5,  but  bile  salts  are  poured  from  the 
gallbladder and  reach concentrations ranging from 1. to 2% during the first hour of 
digestion which decrease afterwards to 0.3% w/v or lower (Lee and Salminen, 2009). 
The residence period in the small intestine until 50% emptied varies between 2.5 and 
3 hours and the transit through the colon could take up to 40 hours. In this location 
pH values are close to neutral (from 5.5 to 7) and the physiological concentration of 
bile salts is lower. 
In animal the pH values and bile salts concentrations are different. For the screening 
of putative probiotic bacteria researchers simulate the GIT conditons in vitro, testing 
several pH values and bile concentrations for variables times in order to determine 
the survival of the strain under test. 
In the complex GIT ecosystem probiotics have developed mechanisms to survive in 
competition with other  microorganisms.  Essentially,  the antagonism is  exerted by 
competition for nutrients and for physical location, but also through the production of 
antimicrobial substances: the ability of probiotics to produce antimicrobials is one 
mechanism to  inhibit,  exclude  or  compete  with  adherent  enteropathogens  for  the 
ecological niche. The inhibition ability is strain and culture condition-dependent and 
several  molecules  and  mechanisms  are  involved  in  the  interrelationship  between 
probiotics and pathogens. 
Even  if  LAB  strains  have  a  long  history  of  safe  consumption  in  traditionally 
fermented products and several species have been awarded a GRAS status by the 
American Food and Drug Association or a qualified presumption of safety (QPS) 
consideration by the European Food Safety Authority (EFSA), some characteristics 
must  be  carefully  studied  to  ensure  the  safety  of  the  novel  lactobacilli  and 
bifidobacteria strains. 
• Safety 
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As  efficacy  is  inextricably  linked  to  safety,  any  claims  of  health  benefits  for  a 
probiotic require substantiation by scientific evidence. The employment of “history of 
safe use” as a criterion for the safety of food organisms is an arbitrary classification. 
Lactic acid bacteria and yeasts intrinsic to the production of traditional foods have 
been accepted  as  safe  without  any real  scientific  criteria,  partly  because  they are 
normal  commensal  flora,  and  partly  because  they  have  been  consumed  through 
centuries  presumably  without  adverse  effect.  The  shift  from  dairy  foods  to 
complementary  or  prescribed  medicines  with  therapeutic  claims  has  elevated 
probiotics to a class that was once the exclusive field of pharmaceuticals.  How to 
assess the safety of new probiotic products needs to be re-evaluated in these altered 
circumstances. Regulators must judge whether a probiotic is a food, a supplement or 
a clinical therapy and develop enforceable safety standards accordingly. If probiotics 
are  intended  for  therapeutic  use  they  must  be  evaluated  for  quality,  safety,  and 
efficacy in the same way as any other therapeutics-with documented and verifiable 
characterization of the active ingredient, dose, efficacy, safety, and adverse effects 
(Lee and Salminen, 2009). For the Evaluation of Probiotic in Food, the FAO and 
WHO workshop in the meeting held in Canada (FAO and WHO, 2002) advised to 
characterise  probiotic  strains  at  least  with  the  following  tests:  determination  of 
antibiotic resistance profile,  assessment of metabolic activities,  assessment  of side 
effects during human studies and postmarket epidemiological surveillance of adverse 
incidents in consumers.
In addition, if the strain under evaluation belongs to a species known to produce a 
mammalian  toxin  or  to  have  haemolytic  potential,  it  must  be  tested  for  these 
characteristics.
The EFSA has proposed a scheme based on the concept  of  QPS,  defined as  “an 
assumption  based  on  reasonable  evidence”  which  has  allowed  the  application  of 
certain restrictions (EFSA, 2005). The scheme aims at achieving a consistent generic 
safety assessment of microorganisms through the food chain without compromising 
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safety standards. Individual evaluations would be limited to aspects particular to the 
organism, such as acquired antibiotic resistance determinants in LAB. 
Bernardeau  and  collaborators  (Bernardeau  et  al.,  2008)  consider  this  generic 
approach  to  the   safety  assessment  of  microorganisms   not  relevant  to  the 
Lactobacillus genus and have proposed modifications. They claim that LAB are not a 
homogeneous group as some species are pathogens, and that the rarely pathogenic 
Lactobacillus genus should undergo its own limited safety assessment.  The genus 
should be awarded the status of Long Standing Presumption of Safety based on its 
long history of safe use in fermented foods. Individual species could then be assessed 
for safety based on one, two, or a full suite of tests, depending on the intended use. 
The first safety test would be to demonstrate an absence of antibiotic resistance and 
the ability for transference. The second, a high dose tolerance test in animals, would 
be  required  if  the  organism  was  not  resistant  to  antibiotics  and  was  a  known 
lactobacillus  for  which  a  new  application  was  being  proposed.  A  full  safety 
assessment would be required if the body of knowledge was insufficient. 
Selection of probiotic strains for use in food and animal feed 
Food companies worldwide are seeking ways to incorporate probiotics into a much 
broader  range  of  foods  and  beverages.  However,  incorporating  live  probiotic 
microorganisms  into  foods  and  keeping  them  alive  throughout  shelf  life  is  a 
significant challenge for food technologists. 
For  a  successful  delivery  in  foods,  probiotics  must  survive  food  processing  and 
storage  during  maturation  and  shelf-life.  To  incorporate  probiotics  into  foods 
companies have to take into account several parameters. The critical points to address 
when incorporating probiotics into foods (Lee and Salminen, 2009) include:
o The selection of a compatible probiotic strain/food type combination
o The  use  of  food-processing  conditions  that  are  compatible  with  probiotic 
survival
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o If fermentation is required, ensuring that the food matrix will support probiotic 
growth
o The  selection  of  the  product  formulation,  packaging  and  environmental 
conditions  to  ensure  adequate  probiotic  survival  over  the  product’s  supply 
chain and during shelf storage.
o Ensuring that addition of the probiotic does not adversely impact on the taste 
and texture of the product.
Acid stress
The growth of LAB is marked by the generation of lactic acid as end product of 
fermentation and this accumulates in the extracellular environment. This implies that 
LAB often confront with acid stress and acid is an important environmental stress 
present in LAB during the fermentation of foods and beverages. It must be  noted that 
lactic acid is a weak organic acid that it does not charge at low pH and can easily pass 
the cell membrane in the protonated form. The marked production of organic acid 
from these bacteria creates a hostile environment for many other organisms. Many 
methods of food preservation by fermentation are based on this characteristic. These 
bacteria can also face an acidic environment in the stomach after consumption, and 
the development of probiotics revived the interest for studies about LAB survival in 
the digestive tract. The cariogenicity of oral LAB such as streptococci and lactobacilli 
is directly linked to their acidogenicity (i.e. the ability to produce acid at low pH) and 
acidurance (i.e. the capacity of functioning at low pH). With the only exception of 
some species of the genera  Lactobacillus,  Leuconostoc and  Oenococcus,  LAB are 
neutrophiles (i.e., optimal pH for growth between 5 and 9). Not much is known about 
the effects of acid stress on bacterial physiology. It is well established, however, that 
acids can passively diffuse through the cell membrane and after access the cytoplasm 
and  rapidly  dissociate  into  protons  and  charged  derivatives  to  which  the  cell 
membrane is impermeable. The intracellular accumulation of protons may have the 
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effect of lowering  the intracellular pH and thus affect the transmembrane ΔpH which 
contributes  to  the  proton  motive  force   used  as  an  energy  source  in  numerous 
transmembrane  transport  processes.  The activity  of  acid-sensitive enzymes is  also 
reduced  and proteins and DNA are damaged by the internal acidification. There is 
also a detrimental effect of the accumulation in the cytoplasm of the anionic moiety 
on  cellular  physiology  possibly  through  a  chelating  interaction  with  essential 
elements. 
In LAB, acid tolerance rises in at least two distinct physiological states:
1. during logarithmic growth an adaptative response can be induced by incubation 
at a non-lethal acidic pH
2. after reaching the stationary phase, acid tolerance increases as a result of the 
induction of a general stress response
The latter response is usually independent of the external pH. It is not known whether 
these responses are independent or may overlap. The growth in biofilms may be a 
third state which improves the acid tolerance, but it has been only demonstrated for 
S. mutans (Li et al., 2001; Zhu et al., 2001). 
Bile salts stress
Bile is a complex digestive secretion which helps  the dispersion and absorption of 
fats. Bile acids (also often called bile salts) are the major constituents of bile and 
derive from cholic acid (CA) which is itself synthesized from cholesterol. In the liver 
some  bile acids are conjugated to glycine or taurine.  
The  bile  acids  undergo  extensive  chemical  modifications  (deconjugation, 
dehydroxylation, dehydrogenation and deglucuronidation) in the colon almost solely 
as a result of microbial activity. The possible toxic effects of bile acids for bacterial 
cells is still to be fully understood; however, as they act as detergent and dissemble 
biological  membranes,  bile  acids  are  surface  active,  amphipatic  molecules  with 
potent antimicrobial activity. Gram-positive bacteria do not have an outer membrane 
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which can constitute the first permeability barrier, so they are  often more sensitive to 
the  toxic  agents  in  their  environment  than  Gram-negative  bacteria.  Both  Gram-
negative and Gram-positive bacteria develop specific mechanisms to resist the toxic 
action of bile and manage to live in a bile-rich environment such as the digestive 
tract.  The resistance to bile stress has been mostly examined in two categories of 
bacteria: the enteric pathogens, which can survive in the digestive tract, and the food-
associated LAB or bifidobacteria considered as potential probiotics and often selected 
to resist to the digestive stress (Van de Gutche et al, 2002).
Bile  acids  can  be  metabolized  by  some  microorganisms  of  the  intestinal  flora 
including some lactic acid bacteria and it is believed that this ability can contribute to 
the protection against bile. In lactobacilli, the  bile salt hydrolases (BSH) deconjugate 
bile acids, hydrolysing the amino acid glycine or taurine from the steroid core. This 
hydrolysis modifies the properties of bile and remarkably reduces its solubility at low 
pH and its detergent activity. Some studies have reported an active uptake of CA, 
dependent on the pH and the presence of glucose in several species of lactobacilli. 
This activity, not related to BSH, results in an intracellular accumulation of CA. Mot 
much is known about the role of this system in lactobacilli and its relation to CA or 
bile tolerance. 
Choice of a right combination between probiotic organism and food
When incorporating a probiotic into food the first step is to identify the compatibility 
between the attributes of the selected strains and the food production steps and food 
matrix.  The  difference  in  the  technological  characteristics  of  different  probiotic 
species  and  strains  requires  a  special  care  to  be  taken  in  selecting  the  most 
appropriate  strain  for  a  particular  application.  This  may  involve  a  compromise 
between the desired health attributes and the technological capabilities of particular 
strains for particular food applications. When developing new products some research 
may be required to ensure that the selected strain is able to survive well in the food, 
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provided the appropriate technological properties and that the added probiotic does 
not adversely affect the taste, the texture and the smell of the food or beverage. The 
metabolism of  the  probiotic  organism is  an  important  consideration  in  fermented 
probiotic foods, not only for  the  growth and survival of the probiobic, but also for 
food  quality.  For  example,  heterofermentative  lactobacilli  that  produce  CO2 as  a 
metabolic  end product are not suitable where gas formation adversely impacts on 
food quality.
Physiology of the probiotic   
An important  factor  in  probiotic  survival  is  the  physiology of  the  bacteria  when 
prepared, and the physiological state of the bacteria in the product itself: if the food 
product is dry, i.e. a powdered infant formula, the probiotic will also be dried and in a 
quiescent  state  during storage.  However,  when included in  a  wet  product  (like  a 
yogurt), the bacteria will be in a vegetative state and potentially metabolically active. 
Bacteria  are  able  to  respond  to  stressful  environments  through  the  induction  of 
various stress tolerance mechanisms. The induction of stress proteins by exposure of 
the cells to sublethal  stresses such as heat,  cold,  starvation, low pH, and osmotic 
stress  can  condition  probiotics  to  better  tolerate  environmental  stresses  in  food 
production, storage, and gastrointestinal transit.
Technological characteristics of the probiotic:
Temperature
One of  the  functional  aspects  for  the  characterisation  of  novel  putative  probiotic 
strain for  use in  food is  temperature  (see fig.  9).  Temperature  is  a  critical  factor 
influencing  probiotic  survival  during  manufacture  and  storage:  the  lower  the 
temperature the stabler the probiotic viability in the food product . During processing, 
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temperatures above 45-50°C will be detrimental to the probiotic survival. The higher 
the temperature, the shorter the period of exposure necessary to severely decrease the 
numbers of viable bacteria, ranging from hours or minutes at 45-55°C to second at 
higher  temperatures.  Elevated  temperatures  also  have  a  detrimental  effect  on  the 
stability during the shipping and storageof the product. 
Protein denaturation is  the greatest  effect  induced by high temperature;  however, 
studies have identified membranes and nucleic acids  as cellular sites of heat injury. 
The heat stress also affects the transmembrane proton gradient, resulting in a decrease 
of the intracellular pH.
During the exposure of cells  to heat shock, the responses take place through   the 
increased synthesis of a group of evolutionary conserved heat shock proteins which 
promote  the  correct  folding  of  nascent  polypeptides,  the  assembly  of  protein 
complexes, the degradation and translocation of proteins. Heat stress in lactobacilli 
has  been  studied  by  analyzing  its  effect  on  growth,  heat  tolerance  and  protein 
synthesis.  The genetic differences among species,  the physiology of the cells and 
other  environmental  factors  (growth medium,  pH,  water  activity,  salt  content  and 
preservatives) affect the resistance of lactobacilli to heat stress.
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Fig. 9 Procedure for the characterisation of novel strain with putative probiotic status.
Starvation stress
Bacteria spend most of their time in stationary phase. The growth arrest and the onset 
of the  stationary phase can be caused by numerous stress conditions like cold, heat, 
osmotic, oxidative or acid stress, or starvation. Nutrient starvation is one of the most 
frequent stresses and the bacterial growth itself contributes to the  nutrient exhaustion 
and the subsequent starvation for one or several compounds. Furthermore,  extreme 
environmental  stress  conditions  may  determine  a  deprivation  of  one  or  several 
components,  apart from their direct effects on the cells constituents.  For example, 
extreme acidic conditions can reduce the activity of some transporters and diminish 
the availability of essential substrates thus provoking indirectly starvation or energy 
depletion,  regardless  of  the  extracellular  amount  of  the  substrate  (Konings  et  al. 
1997). These conditions of energy or essential elements depletion could be dangerous 
for  long-term cell  viability.  However  many  bacteria  seem to  be  well  adapted  to 
survive long-term starvation  and some  can  enter  a  stress-resistant  spore-forming 
process. Others, including LAB, do not show this capacity and have developed other 
strategies. In these bacteria, nutrient starvation leading to growth arrest is generally 
linked to  the modification of cell morphology, like cell division at the beginning of 
the stationary phase which leads to a reduction of cell size, as it  has been described 
for many non-spore forming bacteria and also for some enterococci and lactococci. 
LAB are a heterogeneous group of bacteria which grow in very different media, and 
therefore do not face identical starvation conditions. That is why, diverse starvation 
surviving mechanisms developed by different LAB may be observed.
Water activity
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For  quiescent,  dried,  probiotic  bacteria  water  activity  is  a  crucial  determinant  of 
survival  in  food  products  during  storage.  As  moisture  levels  and  water  activity 
increase the survival of probiotics substantially decreases. Probiotics can survive well 
over long shelf lives (12 months or more) at room temperatures in dried products as 
long as the low moisture levels in the products can be maintained. In general, the 
lower  the  water  activity, the  better  the  bacterial  survival.  There  is  a  substantial 
interaction between water activity and temperature in relation to their impact on the 
survival  of  quiescent  probiotics.  As  the  storage  temperature  is  increased  the 
detrimental impact of moisture is magnified. Although the precise mechanisms of cell 
death remain  unclear,  osmotic  stress  appears  to play a  role,  with the presence  of 
smaller molecules resulting in a poorer bacterial survival.
Osmotic stress 
Active  metabolism  takes  place  if  the  intracellular  conditions  remain  relatively 
constant  in relation to the  ionic composition, pH, and metabolite levels. Moreover, 
the maintenance of a constant positive turgor is generally considered as the driving 
force for the cell expansion. The bacterial  cytoplasmic membrane is permeable to 
water but forms an effective barrier for most solutes, consequently a change in the 
osmolality of the environment could rapidly compromise essential cell functions, and 
bacteria  would  have  to  adapt  to  such  a  change  in  their  environment  in  order  to 
survive. Usually, they can do so by accumulating compatible solutes (by uptake or 
synthesis) under hyperosmotic conditions, and releasing (or degrading) them under 
hypoosmotic conditions. Apart from their effect on the osmotic balance, compatible 
solutes may also stabilize enzymes and thereby provide protection not only against 
osmotic stress but also against high temperature, freeze-thawing and drying (Poolman 
et al. 1998). 
Viability in probiotic products
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In order to have a positive effect on health, probiotics in food should remain viable 
during  the  storage  and  the  gastrointestinal  transit.  Different  minimum  levels  of 
probiotics in probiotic products have been reported; however these levels are likely to 
depend  on  the  specific  strain  used.  Dose-response  studies  are  needed  in  the 
assessment of probiotic strains, to determine the effective level of bacteria in one 
given product.
Antibiotic resistance
About  50  years  ago,  antibiotics  were  introduced  for  the  treatment  of  microbial 
diseases. Since then, the greatest threat to the use of antimicrobial agents for therapy 
of  bacterial  infections  has  been  the  development  of  antimicrobial  resistance  in 
pathogenic bacteria. The magnitude of the problem is significantly increased by the 
possibility  of  bacteria  to  transfer  resistance  determinants  horizontally  and  by  the 
increase in  the  use  (over-use  and  misuse)  of  antibiotics,  which  has  created  an 
enormous selective pressure towards resistant bacteria. 
Between men and animals antibiotic resistant bacteria are mainly trasmitted via the 
food chain. In particular the animanl indigenous microflora and the human GIT came 
into contact throug fermented dairy products and fermented meat which haven’t been 
heat treated before consumtion. Although most food-associated lactic acid bacteria 
have  acquired  the  GRAS  status,  the  potential  health  risk,  due  to  the  transfer  of 
antibiotic  resistance  genes  from LAB reservoir  strains  to  bacteria  in  the  resident 
microflora of the human gastrointestinal tract and hence to the pathogenic bacteria, 
has not been fully addressed. Fermented milk products use lactic starter cultures, and 
these  bacteria  enter  our  intestines  in  large  numbers;  here  they  interact  with  the 
intestinal microflora. The commercial introduction of probiotics containing antibiotic 
resistance strains may also have negative consequences, for example, when resistance 
is transferred to intestinal pathogens. 
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The  evolution  and  enrichment  of  antibiotic  resistant  bacteria  have  been  recently 
reported  in  studies  about  the  application  of  antibiotics  in  human  and  veterinary 
medicine (Levy,  1997; WHO, 1997),  agriculture (Falkiner,  1998) and aquaculture 
(Reilly and Kaferstein, 1997); the phenomenon is regularly observed when a new 
antibiotic  is  introduced (Levy,  1997).  Two factors  determine  the  development  of 
antibiotic resistance in bacteria: the presence of resistance genes and the selective 
pressure by the use of antibiotics (Levy, 1992). Before discussing these two factors,it 
is  necessary  to  make a  distinction  between intrinsic  and acquired resistance.  The 
resistance  to  a  given  antibiotic  can  be  intrinsic  to  a  bacterial  species  or  genus 
(inherent or natural resistance) and it results in the ability of the organism to thrive in 
the  presence  of  an  antimicrobial  agent  due  to  an  inherent  characteristic  of  the 
organism. The intrinsic resistance is not horizontally transferable, and poses no risk 
in  non-pathogenic  bacteria.  On the contrary,  the  acquired  resistance  is  present  in 
some strains within a species usually susceptible to the antibiotic under consideration, 
and  might  be  horizontally  spread  among  bacteria.  The  acquired  resistance  to 
antimicrobial  agents  can  arise  either  from mutations  in  the  bacterial  genome  or 
through the acquisition of additional genes coding for a resistance mechanism. These 
genetic changes alter the defensive functions of the bacteria by changing the target of 
the  drug,  by  changing  the  membrane  permeability,  by  enzymatic  inactivation  of 
antibiotic  (e.g.  by  β-lactamases,  aminoglycoside  acetyl-,  nucleotidyl-  and 
phosphoryl-transferases),  by  active  transport  of  antibiotics  (e.g.  by  membrane 
inserted  ATP-dependent  efflux  systems),  by  modification  of  the  target  (e.g. 
methylation  of  23S  rRNA,  mutation  of  aminoacid  sequence  of  topoisomerase) 
(Davies, 1997), or by routing metabolic pathways around the disrupted point (Poole, 
2002).
The selective pressure imposed by the use of antimicrobial agents plays a key role in 
the  emergence  of  resistant  bacteria.  Whenever  a  mixed  bacterial  population  is 
exposed to antimicrobial agents, it is likely that there will be bacteria that are resistant 
to the respective drugs at  the concentration applied.  Under selective pressure,  the 
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numbers of these will increase and some may pass their resistance genes to other 
members of the population (Aarestrup, 1999). A single antibiotic may not only be 
selected for resistance to that particular drug. It can also include resistance to other 
structurally  related  compounds  of  the  same  class.  When  antibiotics  of  different 
classes share the same target site, and this target site is modified by the product of a 
resistance  gene,  cross-resistance  between  structurally  unrelated  antibiotics  is 
observed.  In  addition,  a  number  of  plasmids  have  been  identified  which  carry 
multiple  resistance  genes,  resulting in  co-transfer.  The risk of  potential  spread of 
resistance genes from probiotics to pathogenic bacteria is therefore higher if the gene 
is carried on a mobile genetic element (like a plasmid or a thansposon). On the other 
hand, it is important that a probiotic co-administered with an oral antibiotic therapy is 
resistant to particular antibiotics. 
Regulation
Various regolatory bodies have addressed the safety issues concerning the use of the 
LAB organisms in animal nutrition in different countries. The presence of acquired 
antibiotic resistance factors is considered highly undesirable in Europe but of lesser 
relevance  in  the  USA.  In  the  United  States  of  America,  the  Food  and  Drug 
Administration (FDA) classifies certain microorganisms as GRAS. An organism or a 
product  with  a  GRAS  status  is  exempt  from  the  statutory  premarket  approval 
requirements (Mathur and Singh, 2005). An organism can either be included in the 
GRAS list or have the status of history of safe use. However, the European view 
point is more restrictive since the Scientific Committee on Animal Nutrition (SCAN), 
(one of the main scientific committees in the food and feed area), has put forward the 
proposal that any listing should be qualified, provided that certain specifications are 
met.  This  may  simply  be  a  requirement  to  demonstrate  the  absence  of  acquired 
resistance  factors,  as  in  the  case  of  many  live  organisms  currently  used  in 
manufacturing dairy products or added to them. The development of a system that 
would  allow  a  qualified  presumption  of  safety  (QPS)  has  been  strognly 
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recommended. In a QPS system the safety assessment of food LAB could be limited 
to the presence of transmissible antibiotic resistance markers as other tests are not 
relevant for lactic bacteria. The Opinion of SCAN on the criteria for assessing the 
safety  of  microorganisms  resistant  to  antibiotics  of  human clinical  and veterinary 
importance  was  adopted  on  3  July  2001  and  later  revised  on  18  April  2002 
(EuropeanCommission,  2002). According to SCAN all  bacterial products intended 
for  use  as  feed  additives  must be  examined  to  establish  the  susceptibility  of  the 
component strain(s) to a relevant range of antibiotics. Such tests must be made in a 
consistent manner using internationally recognized and standardised methods.
The determination of the minimum inhibitory concentration (MIC) of the antibiotic 
has been suggested along with breakpoints categorizing bacterial species as resistant. 
It  has  been  mentioned  that  determination  of  MIC  is  not  necessary  for  species 
designated as inherently resistant to the antibiotic. The general lack of  relavant datat 
hinders the proposal of breakpoints for lactic acid bacteria. For some genera of lactic 
acid  bacteria,  such  as  Lactobacillus,  there  are  no  generally  accepted  standard 
procedures for MIC determination and information on MIC ranges is rather limited. 
The breakpoints suggested by SCAN (see table 8) may be seen as a practical response 
to  introduce  consistency  in  the  separation  of  strains  with  acquired  transferable 
resistance  form susceptible  strains.  According to  the SCAN, every  time  the MIC 
value is  at or above the given breakpoints further investigation should be carried out. 
Table 8.   The Microbiological  breakpoints used by SCAN categorising bacterial 
species as resistant (mg/l)
  
 Antibiotic                          E.faecium     E.faecalis     Pediococcus     Lactobacillus sp.     Bacillus                     
Ampicillin                                    8                   8                     3                            2                     2
Streptomycin                            1024              1024                 32                          16                   64
Kanamycin/neomycin               1024              1024                32                          32                   64
Gentamycin                                500               500                   4                            1                     8
Chloramphenicol                        16                 16                   16                           16                  16
Tetracycline                                16                 16                   16                          16                   16
Erythromycin                               4                   4                     4                            4                     4
Quinupristin/dalfopristin             4                   R                     4                            4                     4
Vancomycin                                 8                   8                     R                           4                     4
Trimethoprim                               8                   8                    16                          32                     8
Cipro/enrofloxacin                       4                   2                    16                           4                      1
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Linezolid                                      4                   4                     4                            4                      4
Rifampin                                      4                   4                     8                           32                     4           
R = Certain species are inherently resistant, and for these species MIC determination is not necessary
In 2005, a new decision of FEEDAP Panel of the EFSA updated anew the criteria 
used  for  the  assessment  of  bacteria  for  resistance  to  antibiotics  of  human  and 
veterinary  importance  (EFSA,  2005).  The  aim  of  this  decision  was  to  provide 
guidance for developing studies to show the potential of each bacteria strain to bear 
resistance  and  to  transfer  it. The  basis  of  such  evaluation  started  with  the 
determination  in  vitro of  the  antibacterial  activity  (MIC) for  a  relevant  range of 
antibiotics of human and veterinary importance (table 9). The detection of the MIC 
above  the  breakpoint  levels  in  one  or  more  antimicrobials  required  further 
investigations to make the distinction between acquired and intrinsic resistance; the 
microbiological breakpoints categorizing bacteria as resistant are expressed in table 
aa. According to the principle of FEEDAP, when a bacterial strain proves resistant to 
a  specific  antibiotic,  while  others  species  are   normally  susceptible  to  the  same 
antibiotic, the applicant should evaluate the reason for such resistance. If an acquired 
resistance may be transferred or if  known exogenous resistance genes are present, 
the probiotic strain is not considered suitable for use as feed additive (Anadon et al., 
2006).
In  addition,  the  determination  of  antibiotic  resistance  among  LAB is  affected by 
problems regarding the use of media and MIC breakpoints for the genera or species; 
MIC breakpoint values have been shown to be species specific and consequently they 
vary between species of the same genera (Danielsen and Wind, 2003).
Studiyng the antibiotic resistance of 40 starter cultures and 5 probiotic cultures at the 
genetic level, Hummel and collaborators in 2007 (Hummel et al.,  2007) identified 
factors likely to hinder the implementation of the safety evaluation scheme proposed 
in EFSA’s QPS system and concluded that there were no approved standard MICs at 
which an organism may be considered resistant or susceptible to an antibiotic, except 
for Enterococcus species.
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From the evaluation of the current scientific data, it has been concluded that there is 
not  a  precise  standard  to  enforce  to  assess  the  resistance  of  probiotic  strains   to 
antibiotics; further studies are needed. 
Table  9.  FEEDAP microbiological  breakpoints  categorizing  bacteria  as  resistant 
(mg/l).  Strains  with  MICs  higher  than  the  breakpoints  below  are  considered  as 
resistant. 
  
 Antibiotic               Lactobacillus                Lactobacillus           Lactobacillus          Entero-         Pediococcus
                                       obligate                 heterofermetative           plantarum          coccus sp
                              homofermentative    
Ampicillin                         4                                       4                               4                       8                         4 
Vancomycin                      4                                       n.r.                           n.r.                    8                       n.r.
Gentamycin                       8                                        8                              64                   512                       4
Kanamycin                      16                                      16                              64                  1024                      4
Streptomycin                   16                                      16                              64                  1024                      4             
Neomycin                        16                                      16                              32                  1024                      8
Erythromycin                    4                                        4                               4                      4                         4
Clindamycin                     4                                         4                               4                      4                         4
Quinupristin + 
Dalfopristin                      4                                         4                               4                      4                          4  
Tetracycline                      8                                         8                             32                    16                         4
Chloramphenicol              4                                         4                               8                      8                         4
Trimethoprim                   8                                         8                               8                      8                          8
Linezolid                          4                                         4                               4                      4                          4
  
 Antibiotic               Leuconostoc               Lactococcus               Streptococcus             Bacillus spp.           Other Gram-
                                                                             lactis                        thermophilus                                             positive
Ampicillin                        4                                     4                                      4                          n.r.                           2 
Vancomycin                     n.r.                                  4                                      4                           4                             4
Gentamycin                      4                                     8                                      8                           4                              4
Kanamycin                        8                                    8                                      8                           8                              8
Streptomycin                     8                                   16                                    16                          8                              8
Neomycin                          8                                    8                                      8                           8                              8
Erythromycin                    4                                    4                                      4                            4                             4
Clindamycin                     4                                    4                                       4                            4                             4
Quinupristin + 
Dalfopristin                       4                                    4                                      4                            4                              4
Tetracycline                      4                                    4                                      4                             8                              4
Chloramphenicol              4                                    8                                       8                            8                              4
Trimethoprim                    8                                   n.r.                                   n.r.                          8                              8
Linezolid                           4                                    4                                       4                            4                              4
Strains with MICs higher than the breakpoints below are considered as resistant. 
n.r., not required. including L. salivarius.
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Aim of the dissertation 
Lactic acid bacteria and bifidobacteria are the best candidates for use as protective 
and probiotic cultures, because they have been used since the beginning of history as 
starter cultures and they are present in almost all fermented foods like vegetables, 
meat products and dairy products; in addiction, they are part of the natural microflora 
of both farm animals and humans and they have a long history of consumption and 
safe use.
“Protective culture” are bacteria especially selected and developed for their ability to 
control the growth of pathogenic and/or spoilage microorganisms in fermented food. 
Their inhibition toward pathogens is due to the direct competition for nutrients and to 
the production of antimicrobial substances. Protective cultures are also useful in food 
product,  in  particular  in  the  extension  or  mantainance  of  shelf  life  by  avoiding 
microbial  organoleptic  degradation,  but  also in the reduction of  supply chain and 
distribution costs, in the replacement of chemical preservatives by a natural and safe 
solution and they are used alone or in conjunction with starter cultures to contribute 
in formation of texture, colour and flavour of food product. Beneficial bacteria in the 
food process chain can have a protective role, such as protecting food product/process 
from the infection or contamination respectively and a probiotic role, conferring a 
beneficial effect upon the host, either on a farm animal through animal feed, or on the 
final consumer, through the food product. 
The  aim  of  this  research  is  to  select  probiotic  bacteria  strains  able  to  inhibit 
pathogenic bacteria either at the level of food products or at the level of farm animals, 
that  can  survive  the  passage  of  the  gastrointestinal  tract  and  food  processing 
conditions and that can be incorporated in the development of prevention strategies 
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for foodborne pathogenic microorganisms throughout the food chain. The beneficial 
effect of the protective and probiotic cultures can take place at any level of the food 
process chain, from the animals to the food product.
The criteria adopted for the selection of candidate protective and probiotic cultures 
are in accordance with the relevant international literature and with the guidelines for 
evaluation  of  probiotics  in  food  suggested  by  the  Joint  FAO/WHO  Expert 
Consultation  Report  (FAO  and  WHO,  2002),  especially  concerning  the  in  vitro 
functional  characterization  (resistance  to  gastric  activity,  bile  acids,  antimicrobial 
activity)  and  safety  assessment  (haemolytic  activity  and  antibiotic  resistance)  of 
potential  probiotics  strains. A  deeper  knowledge  of  the  mechanisms  of  stress 
resistance should enable to understand better the bases of the adaptive responses and 
cross protection, and to  optimise their exploitation in order to prepare LAB to be 
employed in industrial processes and to be administered to farm animals.
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   PART II 
MATERIALS AND METHODS
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Chapter 1.   Antimicrobial activity 
The  research  described  in  this  thesis  is  framed  within  VI  FP  European  Project 
PathogenCombact  (www.pathogencombat.com).  The first  part  of  the investigation 
was carried out on 60 strains of Lactic Acid Bacteria and bifidobacteria provided by 
DANISCO, a partner of the PathogenCombat Project, and by the BUSCoB collection 
(Bologna University Scardovi Collection of Bacteria) of the Microbiology area of the 
Department of Agroenvironmental Science and Technology (University of Bologna, 
Italy) to assay their antimicrobial activity against Campylobacter jejuni. 
• C. jejuni CIP 70.2 (Type strain)
• C jejuni LMG 8842 from the Belgian Co-ordinated Collections 
                     of Micro-organisms (BCCM™) 
• C. jejuni 221/05 wild strain from poultry
The antimicrobial activity was tested in vitro by using the spot agar test, based on the 
observation of the inhibition of pathogen’s growth using live cells and the neutralised 
free-culture supernatants of strains tested, following the procedure of Schillinger and 
Lucke (1989). The strains which showed to inhibit the growth of pathogen, were then 
submitted to the well diffusion assay, performed as described by Casla et al. (1996). 
Tab. 10.   Bacterial strains used 
 
  Strain                                                            Species                                                              Source                        
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PCA 236                                                   Lactobacillus sp.                                                 Kasseri cheese
PCA 259                                                   L. plantarum                                                       Xynotyri cheese
PCA 263                                                   Lactobacillus sp.                                                 Xynotyri cheese
PCA 275                                                   Lactobacillus sp.                                                 Feta cheese
PCA 293                                                   L. plantarum                                                       Feta cheese
PCD 71                                                     Lactobacillus sp.                                                 Unknown (Danisco) 
PCD 101                                                   L. pentosus                                                          Unknown (Danisco)
PCD 119                                                   Leuc. mesenteroides                                            Unknown (Danisco)
PCD 215                                                   P.  pentosaceus                                                   Unknown (Danisco)
PCD 240                                                   P. pentosaceus                                                    Unknown (Danisco)
PCK 18                                                     Leuconostoc sp.                                                  Maasai milk (Kenya)
PCK 37                                                     Unidentified                                                       Maasai milk (Kenya)
PCK 38                                                     Unidentified                                                       Maasai milk (Kenya)
PCK 73                                                     Unidentified                                                       Coffee fermentation (Ethiopia)
PCA 227                                                   Lactobacillus sp.                                                 Unknown
PCA 144                                                   L. fermentum                                                       Kasseri cheese
PCA 244                                                   L. reuteri                                                             Adult intestine
PCA 306                                                   L. plantarum                                                       Feta cheese
PCA 314                                                   L. plantarum                                                       Feta cheese
PCD 227                                                   L. plantarum                                                       Unknown (Danisco)
PCD 241                                                   L. plantarum                                                       Unknown (Danisco)
PCD 103                                                   Unidentified                                                       Unknown (Danisco)
PCK 40                                                     Lactobacillus  sp.                                                Maasai-milk (Kenya)
PCK 46                                                     Unidentified                                                       Maasai-milk (Kenya)
PCK 49                                                     Unidentified                                                       Maasai-milk (Kenya)
PCK 66                                                     Lactobacillus sp.                                                 Coffee fermentation (Ethiopia)  
PCK 74                                                     Leuconostoc sp.                                                   Coffee fermentation (Ethiopia)
PCK 161                                                   Unidentified                                                        Unknown
PCK 88                                                     Lactobacillus sp.                                                 Coffee fermentation  
(Tanzania)
PCK 103                                                   Lactobacillus sp.                                                  Salgam (Turkey)
PCS 18                                                      Unidentified                                                        Cheese
PCS 20                                                      Unidentified                                                        Cheese
PCS 25                                                      Unidentified                                                        Cheese
PCB 12                                                      Bifidobacterium sp.                                             Chicken
PCB 14                                                      Bifidobacterium sp.                                             Chicken
PCB 26                                                      Bifidobacterium sp.                                             Rumen
PCB 50                                                      Bifidobacterium sp.                                             Mouse
PCB 51                                                      Bifidobacterium sp.                                             Mouse
PCB 54                                                      Bifidobacterium sp.                                             Rat
PCB 70                                                      Bifidobacterium sp.                                             Rabbit
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PCB 71                                                      Bifidobacterium sp.                                             Rabbit
PCB 76                                                      Bifidobacterium sp.                                             Rabbit
PCB 107                                                    Bifidobacterium sp.                                             Calf
PCB 110                                                    Bifidobacterium sp.                                             Calf
PCB 111                                                    Bifidobacterium sp.                                             Calf
PCB 133                                                    Bifidobacterium sp.                                             New-born
PCB 134                                                    Bifidobacterium sp.                                             New-born
PCB 139                                                    Bifidobacterium sp.                                             New-born
PCB 142                                                    Bifidobacterium sp.                                             New-born
PCB 148                                                    Bifidobacterium sp.                                             New-born
PCB 150                                                    Bifidobacterium  sp.                                            New-born
PCB 157                                                    Bifidobacterium sp.                                             New-born
PCB 158                                                    Bifidobacterium sp.                                             New-born
PCB 191                                                    Bifidobacterium  sp.                                            Piglets
PCD 232B                                                 B. longum                                                            Unknown (Danisco)
PCD 359B                                                 B.thermophilum                                                   Unknown (Danisco)
PCD 733B                                                 B.longum                                                             Unknown (Danisco)
PCD 735B                                                 Unidentified                                                        Unknown (Danisco)
PCD 880B                                                 B. adolescentis                                                     Unknown 
PCD 889B                                                 B. longum                                                            Unknown (Danisco)
The strains,  stored as frozen culture, were cultivated in agar plates,  examined for 
colony morphology and subjected to  microscopic observation. Only one colony from 
agar plate was sub-cultivated in appropriate broth medium, then streaked again  on 
agar plates and, again, only one colony was taken out and cultivated in broth medium, 
in order to ensure the  purity  of the strain. 
Cultivation of strains
The “stock culture” of the LAB strains were kept in skim milk at -80°C. At first, two 
subcultures  were  made  from  the  stock  culture  to  obtain  a  fresh,  exponentially 
growing cell culture. Bifidobacteria were cultured in TPY (Tryptone, Peptone, Yeast, 
see table 11) broth (Scardovi, 1986; Modesto et al., 2003) at 37°C for 24-48 hours in 
anaerobic  conditions  generated  by  using  Anaerocult  A  (Merck,  Darmstadt, 
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Germany), were  cultivated  in  MRS  (DeMan-Rogosa  Sharpe)  broth  (Merck, 
Darmstadt,  Germany)  at  30°C  or  37°C  depending  on  the  species;  in  anaerobic 
conditions as described above for 18-24 hours. 
Tab. 11. Composition of TPY broth 
 
  TPY                                                                  g/l                        
Tryptone                                                            10.0 g                                 
Pepton                                                                 5.0 g                      
Glucose                                                              15.0 g                          
Yeast extract                                                       2.5 g                               
K2HPO4                                                                    1.5 g                       
MgCl2.6H2O                                                        0.5 g                           
Cistein-HCl                                                         0.5 g                                  
Tween 80                                                             0.5 g                              
pH                                                                        6.5                                  
The  strains  of  Campylobacter were  grown  on  Nutrient  agar  (Oxoid,  Ltd., 
Basingstoke,  Hampshire,  England)  containing  5%  sheep  blood  at  42  °C  under 
microaerophilic  atmosphere  (5%  O2,  10%  CO2,  85%  N2)  generated  by  using 
CampyGen Atmosphere Generation System (Oxoid, Ltd., Basingstoke, Hampshire, 
England) in anaerobic jars for 24-48 hours. Thereafter, one typical colony of each 
strain  of  Campylobacter was  transferred  into  NB  (Nutrient  broth)  (Oxoid,  Ltd., 
Basingstoke,  Hampshire,  England) supplemented with 5 % of Laked Horse Blood 
(Oxoid,  Ltd.,  Basingstoke,  Hampshire,  England),  kept  under  microaerophilic 
conditions for 48 hours at 42 °C and then used for the experiment.
Agar Spot Test using living cells
Preparation of the Campylobacter strains 
Campylobacter strains were grown until the broth culture achieves or exceeds the 
turbidity of the 0.5 McFarland standard (usually 24-48 hours). The turbidity of the 
actively growing culture was adjusted with sterile broth to obtain a turbidity optically 
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comparable  to  that  of  the  0.5  McFarland  standard.  This  results  in  a  suspension 
containing approximately 1 x 107 cfu/ml (Kuana et al., 2008; Andrews, 2001). To 
perform this step properly adequate light is needed to visually compare the inoculum 
tube  and  the  McFarland  standard  against  a  card  with  a  white  background  and 
contrasting black lines.  
Work procedure
TPY agar or MRS agar (depending on the strain used) was poured in petri dishes until 
they solified. Then, 10  µl of LAB or bifidobacteria growth were spotted onto fresh 
lawns of the appropriate agar (TPY agar or MRS agar) and after 30 minutes, plates 
were incubated in anaerobic conditions for 24 hours at 37°C. 
Subsequently, the plates were overlaid with 10 ml of NB (Nutrient Broth) (Oxoid) 
additionated  with  0,7%  agar  to  obtain  a  “Soft”  agar,  containing  100  µl  of  the 
Campylobacter cell suspension as described in previous section. Then, petri dishes 
were  left  to  dry  and  incubated  anaerobically  at  37°C.  After  24-48  hours  were 
observed the inhibition zones. Each assay was performed in duplicate and 5  µl of 
acetic acid (1 M) was used as a positive control and sterile MRS or TPY broth at pH 
6.5 were used as a negative control. 
The Spot Agar test was performed also by using cell-free culture supernatants.
Agar Spot Test using cell-free culture supernatants
Preparation of cell-free culture supernatants
LAB and bifidobacteria strains grown overnight in 9 ml of appropriate media were 
harvested by centrifugation at 15.000  g at 4°C for 15 minutes, twice. Pellets were 
removed and supernatants were adjusted to pH 6.5 with 10 N NaOH (to exclude the 
effect  of  organic  acids)  to  obtain  the  “NCSs”  (Neutralised  cell-free  culture 
supernatants).
94
Work procedure
As in the spot agar test using living cells, a TPY agar or MRS agar (depending on the 
strain used) was put in petri dishes and left to solify. 10 µl of LAB cell-free culture 
supernatants  prepared  as  described  above  were  spotted  onto  fresh  lawns  of  the 
appropriate  agar  (TPY agar  or  MRS agar)  and after  30  minutes,  the  plates  were 
incubated in anaerobic conditions for 24-48 hours at 37°C. 
Subsequently, the plates were overlaid with 10 ml of nutrient broth 0.7% of agar, 
containing 100 µl of the Campylobacter cell suspension. The petri were incubated for 
24 hours at 37°C in anaerobic conditions and the inhibition zones were observed. The 
experiment was duplicated. 5 µl of acetic acid  (1 M) was used as a positive control 
and sterile MRS or TPY broth at pH 6.5 were used as a negative control.
Well Diffusion Assay
In the well diffusion assay, an actively growing broth culture of Campylobacter strain 
was adjusted with sterile broth to obtain a suspension of about 1 x 107 cfu/ml. Then, 
500  µl of this cells suspension was added to 20 ml of Nutrient Agar (1,5 % agar) 
(Oxoid,  Ltd.,  Basingstoke,  Hampshire,  England),  poured  into  petri  dishes,  and 
allowed to solidify at room temperature. Wells (5 mm in diameter) were made on the 
solidified agar with a sterile pasteur or sterile metal cylinder, and were filled with 
50 µl  of  NCSs  from  each  strain  tested.  After  48  hours  of  incubation  in 
microaerophilic conditions at 42°C, the inhibition zones were observed. Each assay 
was performed in duplicate, and also in this case 5 µl of acetic acid  (1 M) was used 
as a positive control, sterile broth as a negative control.
 
This test was performed on PCA 227, PCA 236, PCA 263, PCA 275, PCK 73, PCK 
18, PCK 103, PCD 733 B, PCD 103, PCB 133 and PCS 20 strains, as they had shown 
an antagonistic activity towards C jejuni in the previous spot agar test.
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Chapter 2.   Screening for survival in gastrointestinal tract and food 
processing conditions 
The screening for survival in the gastrointestinal tract (low pH and presence of bile 
salts) and tolerance towards stress conditions prevailing in the food processing (heat 
treatment,  osmotic stress and starvation) was performed on the 11 strains selected 
from previous antimicrobial activity tests. 
Enumeration of viable cells
Viable cells were enumerated by plating diluted samples (peptonized water or saline 
solution) on MRS or TPY agar. Cultures were diluted 1:10 (1 part culture to 9 ml 
peptonized  water  or  saline  solution).  Cultures  were  incubated  for  18-24  hours 
(depending on strains) in anaerobic jars at  37°C to determine the population. The 
bacterial growth was expressed in colony forming units per milliliter (cfu/ml) and the 
survival percentage (% ± sd) of strains to different treatments was then calculated. 
Buffers, reagents and media:
Man Rogosa Sharpe (MRS) broth medium was used to cultivate isolated lactic acid 
bacteria,  as  well  as  MRS  agar  (Merck,  Darmstadt,  Germany).  TPY  (Tryptone, 
Peptone,  Yeast  extract)  medium  was  used  for  bifidobacteria  and  prepared  in 
according to the indication of Scardovi (1986). The following buffers were used:
PBS buffer: K2HPO4 1.41 g/l; KH2PO4 0.26 g/l and sodium chloride 8.0 g/l. Peptone 
water:  Peptone  10.0  g/l;  sodium  chloride  5.0  g/l;  disodium  hydrogen  phosphate 
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dodecahydrate  9.0  g/l;  potassium  dihydrogen  phosphate  1.5  g/l  (pH  7.2).  PBS 
(Phosphate Buffered Saline, Dulbecco A) buffer was obtained from Oxoid (Oxoid, 
Ltd., Basingstoke, Hampshire, England); peptone water was obtained from Merck; 
saline tablets were obtained from Oxoid. Solutions were prepared in 100 ml volume 
and autoclaved at 121 °C for 20 min and stored at room temperature until used.
Resistance to low pH
Berrada et  al.  (1991) reported the time from the entrance to the release from the 
human  stomach  to  be  90  min.  Thus,  the  strains  selected  to  be  used  as  probiotic 
bacteria should be able to tolerate acid for at least 90 min.
Growth, harvesting of cells and work protocol for the evaluation of the effect of pH 
on survival:
Lactobacilli and enterococci from stock culture at -80°C were once subcultured in 10 
ml  of  MRS  broth  for  18  hours  at  37  °C  depending  on  species,  in  anaerobic 
conditions. The final growth was obtained after another subculture in 10 ml of MRS 
broth for 18 hours at 37°C. The bifidobacteria were subcultured twice in 10 ml of 
TPY broth for 24-48 hours at 37°C in anaerobic conditions. 
Effect of pH on survival was determined following the procedure of Huang et al. 
(2007).
For  all  strains,  the  initial  population  was  adjusted  with  sterile  saline  solution  to 
approximately 109 cfu/ml. Then, 1 ml was taken as reference value (T0): the number 
of  viable  cells  was  determined  by  serial  10-fold  dilution  in  peptone  water  1  ml 
aliquots were inoculated evenly on MRS or TPY agar. The plates were incubated 
anaerobically at 37°C for 24-48 hours and the colony forming units estimated. The 
verification of the identity of the colonies was carried out through observation at 
microscope. The remaining 9 ml were centrifuged at 12.000 rpm for 10 minutes at 
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20°C and the supernatants were removed under aseptic conditions. 9 ml of sterile 
PBS buffer at pH 7.2 were added to pellets and the tubes were vortexed to obtain a 
full resuspension. Then, another centrifugation was carried out at 12.000 rpm for 10 
minutes at 20°C and the supernatants were removed again. Finally, 9 ml of sterile 
PBS buffer at pH 2.5 were added and the tube vortexed again. Then, the tubes were 
incubated at 37°C, and after 30 minutes, 1,2 and 3 hours, 1 ml was taken and diluted 
serially in peptone water or saline solution (in case of Bifidobacteria), and finally 
plated with MRS or TPY agar. The plates were incubated for 24-48 hours at 37°C, in 
anaerobic atmosphere, for cfu determination. Sterile double distilled water (pH 6.4) 
served as a control. Each experiment was repeated four times.
Resistance to bile salts 
In humans, after a meal, the bile salt concentration sharply increases in the duodenum 
up  to  about  15  mmol/L  and  then  progressively  decreases  to  5  mmol/L.  In  the 
jejunum,  the  bile  salt  concentration  is  about  10  mmol/L,  and,  in  the  ileum,  the 
concentration falls below 4 mmol/L because of active ileal absorption.
Growth, harvesting of cells and work protocol for the bile tolerance test:
The bile salt solutions were prepared using Oxgall (Ox-Bile LP0055, Oxoid) powder. 
The powder was rehydrated by preparing 10 g dry powder base in 90 ml distilled 
water. From this solution, final concentrations of 0,5, 1, 2 and 4% w/v were prepared 
in PBS buffer and pH was adjusted to 8.0 with NaOH 1 M. Oxgall solutions were 
sterilized through a 0.22  µm filter and fresh prepared just before use.  PBS buffer, 
peptone water and media were prepared as previously described.
From stock culture at -80 °C the 11 strains previously selected were subcultured in 10 
ml of MRS or TPY broth for 18-24 hours depending on species at 37°C in anaerobic 
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conditions. The final growth was obtained after another subculture in 10 ml of MRS 
or TPY broth for 18-24 hours depending on species at 37 °C. 
The resistance to bile salt was assayed following the procedure of Huang and others 
(2007): for all strains, the initial population was adjusted with sterile saline solution 
to approximately 109 cfu/ml and one millilitre of culture was taken out from each 
tube immediately as reference value (T0). For the remaining 9 ml,  the cells were 
centrifuged at 12.000 rpm for 10 minutes at 20°C. The supernatants were discarded, 
and the cell pellets were washed once with PBS buffer pH 7.2 and resuspend in it. 
The  cells  were  centrifuged  again  at  12.000 rpm for  10  minutes  at  20°C and the 
supernatants were removed. Nine milliliter of sterile PBS buffer at pH 8 containing 1 
or 2% (w/v) Oxgall were added to the pellets and the tube vortexed again for full 
resuspension.  The  number  of  surviving  cells  was  determined  after  the  anaerobic 
incubation at 37°C at timed intervals (0,5, 1, 2 and 4 hours) by plating them on MRS 
or TPY agar medium after serial dilution in peptone water (for LAB and enterococci) 
or saline solution (for Bifidobacteria). Sterile double distilled water without oxgall 
(pH 6.4) was used as a control. CFUs were counted after 24-48 hours, depending on 
species.  The  verification  of  the  identity  of  the  colonies  was  performed  through 
observation at microscope. Each experiment was repeated four times.
Heat stress 
Lactic acid bacteria are extensively used in the dairy industry, consequently they have 
to face the various harsh conditions imposed by industrial processes. One of the  most 
recurrent conditions could be the exposure to high temperature. 
Lactic acid bacteria are used  as starters for manufacture of cheese and  some kinds of 
cheeses are traditionally fermented at a naturally decreasing temperature from about 
55°C (cooking temperature of the curds) to 30 °C or below. 
Growth, harvesting of cells and work protocol for resistance to heat stress: 
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The strains were grown in 10 ml of MRS or TPY broth twice from stock cultures 
until a final population of about  109 cfu/ml was obtained. Then, one milliliter was 
taken  as  reference  value.  The  remaining  part  of  the  broth  grown  cultures  were 
harvested (12.000 rpm for 10 minutes at 20°C) two times and resuspended in 10 ml 
of  sterile  PBS (pH 7.2).  The last  PBS was preheated  at  the required temperature 
(50°C and 55°C).  Then, the cultures were transferred to water baths maintained at 50 
and 55°C for 15, 30 and 60 minutes. At the end of the time samples were chilled on 
ice  for  10  minutes,  diluted  and  plated  on  MRS  or  TPY  agar  and  incubated 
anaerobically at 37°C for 24-48 hours, in relation to the different species.  Finally, 
CFUs were counted. Tests were performed four times.
Osmotic stress 
In their various applications in the food and feed industry, lactic acid bacteria can be 
exposed to osmotic stress when important quantities of salt or sugar are added to the 
product.
Growth, harvesting of cells and work protocol for resistance to heat stress: 
From frozen stock cultures, the strains were subcultured twice in 10 ml MRS or TPY 
broth. After 18-24 hours of incubation in anaerobic atmosphere at 37 °C (to afford 
about 109 cells per milliliter), 1 ml was pipetted out and immediately 10-fold diluted 
in peptone water  to estimate  the CFUs. The rest  of  the culture  was harvested by 
centrifugation  at 12.000 rpm for 10 min at 16oC and the supernatants were removed; 
sterile PBS buffer at pH 7.2 was used for washing and suspending the cells. Then, the 
cells were harvested again at the same conditions and the pellets were resuspended in 
PBS buffer  at  pH 7.2,  containing   6  % NaCl,  vortexed and incubated  under  the 
previously described conditions. After 0, 30 and 60 minutes one milliliter was taken 
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out and serially diluted in peptone water (0.9% NaCl for bifidobacteria) and then 
plated in MRS or TPY agar. The plates were incubated for 24-48 h, depending on 
species, at 37oC, for CFUs determination. Experiments were repeated three times.
Starvation stress 
Nutrient starvation is one of the most frequent stresses for bacteria. Bacterial growth 
itself contributes to the  nutrient exhaustion and the subsequent starvation for one or 
several compounds. 
Growth, harvesting of cells and work protocol for resistance to  starvation stress:
The  stock cultures of the LAB strains were kept in skim milk at -80°C. First, two 
subcultures  were  made  in  10  ml  of  MRS  or  TPY  broth  to  obtain  a  fresh, 
exponentially  growing  cell  cultures;  the  culture  conditions  were  the  same  of  the 
precedent protocols.
In order to standardize the assay, the initial population was approximately 109 cfu/ml. 
From this solution 1 milliliter was taken as reference value. The rest was centrifuged 
(12.000 rpm, 10 min, 15oC), the supernatants discharged and the pellets were washed 
with sterile PBS buffer (pH 7.2), twice. The suspensions were then incubated at 37°C 
in anaerobic  conditions and after  6,  12 and 24 hours,  1  milliliter  was  taken out, 
serially diluted in sterile peptone or saline water for the determination of the CFUs, 
plated in the appropriate agar medium (MRS or TPY) and incubated for 24-48 hours 
at 37°C anaerobically. Experiments were repeated three times.
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Chapter 3.   Hemolytic activity
In  the  selection  of  strain  for  its  putative  probiotic  characteristics  its  security   is 
essential. The hemolysis is a common virulence factor among pathogens, it serves 
mainly to make iron available to the microbes and causes anaemia and oedema to the 
host.
In the ordinary laboratory practice the hemolytic activity of a specific strains is tested 
by streaking it on agar plates additioned with a sheep or human blood and the areas 
adjacent to the colony to be tested are put under observation. When Alpha hemolysis 
(α-hemolysis) is present the colony is surrounded by a zone of intact but discolored 
erythrocytes that have a green or brownish-green color. This appearance is generally 
due to the action of  peroxide produced by the bacteria.  This  is  sometimes called 
“partial hemolysis”. 
Beta  hemolysis  ((β-hemolysis),  sometimes  called  “complete  hemolysis”,  is  a 
complete  lysis  of  red cells  in  the media  around and under  the colonies:  the area 
appears lightened and transparent. In the clear zone few or no intact erythrocytes are 
found. This reaction is best seen when the organism is growing under reduced oxygen 
concentration (the peroxide production is thereby decreased). β hemolysis is caused 
by one or more erythrocyte-lysing enzymes (hemolysins). If an organism does not 
induce  hemolysis,  it  is  said  to  display  gamma  hemolysis  (γ-hemolysis),  the  agar 
under  and  around  the  colony  remains  unchanged  (this  is  also  called  “non-
hemolytic”).
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Work protocol for the assay of hemolytic activity
In the procedure for hemolytic activity of putative probiotic bacteria, the strains were 
once  subcultured  in  MRS  or  TPY  broth  and  incubated  18-24  hours  at  37°C  in 
anaerobic conditions. Then, fresh bacterial cell cultures were streaked on Columbia 
agar plates, containing 5 % of sheep blood. The plates were then incubated for 24 
hours at 37 °C in anaerobic jars. As suggested by Maragkoudakis and collaborators 
(Maragkoudakis et al., 2009), the strains that produced green-hued zones around the 
colonies  (α-hemolysis)  or  did  not  produce  any  effect  on  the  blood  plates  (γ-
hemolysis) were considered non hemolytic. The strains showing blood lysis zones 
around the colonies were classified as hemolytic (β-hemolysis).  Experiments were 
performed in triplicate.
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Chapter 4.   Identification of strains
The  identification was performed on the 11 strains that have shown antimicrobial 
activity against the tested pathogens with phenotypic methods (for the strains PCA 
227, PCA 236, PCA 263, PCA 275, PCK 73, PCK 18, PCK 103, PCD 103, PCS 20) 
and molecular methods (for the above listed strains plus PCB133 and PCD 733B).
Phenotypic identification 
Sugar fermentation reactions were performed using API 50 CH test strip and 50 CHL 
medium (bioMérieux, Marcy l'Etoile, France) which represent a standardized system 
for the identification of bacteria.  API 50 CH strip consist of 50 microtubes used to 
study the fermentation  of  substrates  belonging to  the carbohydrate  family  and its 
derivatives (heterosides, polyalcohols, uronic acids). During incubation, fermentation 
is revealed by a colour change in the tube, caused by the anaerobic production of acid 
and detected by the pH indicator present in the medium. The first tube, which does 
not  contain  any  active  ingredient,  is  used  as  a  negative  control.  API  20  STREP 
system was used to perform a phenotypic identification of the strain belonging to the 
genus  Enterococcus.  It  is  a  standardized  systems   for  the identification  that  uses 
enzymatic tests and a specific database.  The strains are obtained according to the 
manufacturer’s  instructions and performed in duplicates.  Profiles were determined 
with APILAB PLUS software program version 4.0. The tests are performed on PCA 
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227, PCA 236, PCA 263, PCA 275, PCK 73, PCK 18, PCK 103, PCD 103 and PCS 
20 strains. 
Molecular identification
From stock cultures (-80 °C),  the strains were cultured in MRS or TPY broth in 
anaerobic conditions, 37 °C. After 18-24 hours (depending on the species), the strains 
were streaked into plates containing appropriate agar medium, and let grow cultivated 
left to grown in anaerobic conditions at 37 °C. The colonies formed on the media are 
picked with a sterile toothpick, and suspended in 50  µl  of TE (10 mM Tris-HCl, 
1mM EDTA; pH 8). The DNA extraction was conducted with the methodology of 
Matsuki  et al. (2003). The bacterial suspension was heated at 95°C for 10 minutes, 
and 1  µl of the supernatant was subjected to PCR. All the TE suspension samples 
were stored at -20 °C.
Molecular identification at the species level of the two Bifidobacterium strains
Preliminary  biochemical  texts  (fosfochetolase  tests,  sugar  fermentation,  PAGE 
pattern  of  soluble  protein)  and  microscopic  observations  previously  performed 
allowed to assign the two strains (PCB 133 and PCD 733B) to the Bifidobacterium 
longum species.  In this work, the assignment  of the two strains to the  B. longum 
species was confirmed via PCR methods as described below.
Species-specific primers designed by Matsuki et al. (1999) are used (primer BiLON-
1 and primer BiLON-2). PCR was carried out in a total volume of 25 µl of reaction 
mixture containing 10 mM of Tris-HCl (pH 8.3), 50 mM of KCl, 2.5 mM of MgCl2 
(Applied Biosystems, Foster City, Ca), 200  µM each dNTP (Fermentas  GmbH, St. 
Leon-Rot,  Germany) 25  µM of  BiLON-1 (5’-TTCCAGTTGATCGCATGGTC-3’) 
(EurofinsMWG Synthesis GmbH, Ebersberg, Germany) and 25 µM of BiLON-2 (5’-
GGGAAGCCGTATCTCTACGA-3’)  (Eurofins, MWG),  0.45  U  of  Taq  DNA 
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polymerase (Fermentas) and 1 µl of template DNA. The PCR amplification program 
consisted of one cycle of 94 °C for 5 minutes, then 35 cycles of 94 °C for 20 seconds, 
55 °C for 20 seconds, and 72 °C for 30 seconds, and finally one cycle of 72 °C for 5 
minutes.  Amplifications  were  carried  out  with  a  DNA  thermocycler  ((Biometra, 
Göttingen,  Germany).  The  amplification  products  were  then  separated  by 
electrophoresis in 1.5% (w/v) agarose gel and ethidium bromide (0.5 µg/ml) staining 
was performed to observe the presence of bands under UV transillumination  (Bio-
Rad) and photographed (Nikon, Tokyo, Japan). A positive control was performed by 
using DNA from a B. longum type strain from our collection and the negative control 
wqas performed by using water instead of DNA. 
Molecular identification of the Lactobacillus spp. strains
The results of the API systems support that the PCA 236, PCA 263, PCA 275, PCS 
20 and PCK 73 strains belong to the same species  L. plantarum.  To perform the 
molecular  identification of these strains,  a  PCR with species-specific  primers was 
done.
For species  specific amplification of  Lb. Plantarum,  the primer  pair  Lplan-vreg1-
F/Lpla-vreg1-R (Eurofins MWG) designed by Klocke et al. (2006), were used. PCR 
reactions were performed in a 25 μl mixture volume containing: 1x GeneAmp PCR 
Buffer  II  without  MgCl2 (Applied Biosystems),  2.5  mM MgCl2,  100 ng of  DNA 
template, 250 nM each primer, 0.25 mM (each) dNTP (Fermentas GmbH) and 0.625 
U/μl AmpliTaq Gold DNA Polymerase (Applied Biosystems). PCR reactions were 
carried  out  in  a  TGradient Thermocycler (Biometra)  according  to  the  following 
amplification profile: a first cycle of incubation of 3 min at 95° C, then 30 cycles of 
amplification, including 30 sec at 94° C, 1 min at 57° C, and 90 sec at 72° C and a 
final  cycle  of  3  min  at  72°  C. Eight  μl  portions  of  the  PCR  products  were 
electrophoresed  in  a  1.5% agarose  gel  and  were  subsequently  visualized  by  UV 
illumination after ethidium bromide (EtBr) staining. The ladders used are GeneRuler 
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100 bp DNA Ladder Plus or GeneRuler 1 kb DNA Ladder Plus (Fermentas). Agarose 
gel  pictures  were  taken  shooting  with  a  digital  camera  CoolPix  5400  (Nikon 
Corporation,  Tokyo,  Japan)  equipped with special  filters  for  EtBr  and a  compact 
camera hood (MicroBiotech, Bologna, Italy). Pictures were finally normalised with 
Nikon Editor Software 6.2 (Nikon).
Molecular identification of the Enterococcus durans strain
  
The  results  of  the  API  systems  support  that  the  PCD 103  belong  to  the  species 
Enterococcus durans. Identification was confirmed via PCR. The extraction of DNA 
from strain PCD 103 was carried out as previously described. The primers used were 
those  designed  by  Knijff  et  al.  (2001),  precisely:  DuHiF  (5’-
TTATGTCCCAGTATTGAAAAATCAA-3’)  and  DuR  (5’-
TGAATCATATTGGTATGCAGTCCG-3’), both purchased from MWG. PCR was 
performed in 20  µl  reaction mixture  containing 2  µl  10 x PCR Buffer  (Polymed, 
Florence, Italy), 1.25  µmol/l  of each primer, 300  µmol/l  of each dNTP, 6 mmol/l 
MgCl2, 0.5 U of Taq DNA polymerase (Fermentas) and 2  µl of DNA, extracted as 
previously  described.  The  amplification  was  carried  out  in  a  thermal  cycler, 
programmed as follows: an initial denaturation step of 94 °C for 5 min, 30 cycles of 
94 °C for 45 sec, 57 °C for 45 sec and 72 °C for 45 sec, followed by a final extension 
at 72 °C for 7 minutes. The amplification products were electrophoresed at 80 V on a 
1.5% (wt./vol.) agarose gel stained with ethidium bromide and photographed.  
  
Molecular identification of the Lactobacillus pentosus strain
For  species-specific  amplification  of  Lactobacillus  pentosus,  the  primers  pair 
16S/Lpe (EurofinsMWG) designed by Berthier and Ehlrich (1998) were used. PCR 
reactions were performed in a 25 μl mixture volume containing: 1x GeneAmp PCR 
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Buffer  II  without  MgCl2 (Applied  Biosystems),  2.5  mM  MgCl2,100  ng  of  DNA 
template, 300 nM each primer, 0.25 mM (each) dNTP (Fermentas)  and 0.625 U/μl 
AmpliTaq Gold DNA Polymerase (Applied Biosystems). PCR reactions were carried 
out in a  TGradient Thermocycler (Biometra, Göttingen, Germany) according to the 
following amplification profile: a first cycle of incubation of 5 min at 95° C, then 30 
cycles of amplification, including 1 min at 94° C, 1 min at 53° C, and 1 min at 72° C 
and a final cycle of 3 min at 72° C. Eight μl portions of the PCR products were 
electrophoresed in a 1.5% agarose gel and were visualized by UV illumination after 
ethidium bromide staining. 
Molecular identification of the Leuconostoc mesenteroides strain
For  species  specific  amplification  of  Leuconostoc mesenteroides,  the primers  pair 
Lmes-F/Lmes-R  (Eurofins  MWG) designed by Lee  et  al.  (2000)  were used.  PCR 
reactions  were  performed  in  a  25  μl  mixture  volume  containing  GeneAmp PCR 
Buffer  II  without  MgCl2 (Applied Biosystems),  2.5  mM MgCl2,  200 ng of  DNA 
template,  500 nM each primer,  0.2  mM (each)  dNTP (Fermentas) and 1.25 U/μl 
AmpliTaq Gold DNA Polymerase (Applied Biosystems).  PCR reactions were carried 
out in a Veriti 96 well Fast Thermal Cycler (Applied Biosystems) according to the 
following amplification profile: a first cycle of incubation of 5 min at 95° C, then 30 
cycles of amplification, including 1 min at 95° C, 1 min at 60° C, 2 min at 72° C and 
a  final  cycle  of  10  min  at  72°  C.  Eight  μl  portions  of  the  PCR  products  were 
electrophoresed in agarose gel and visualized by UV illumination.
Molecular identification of  the Lactobacillus delbrueckii strain
For  species  specific  amplification  of  Lactobacillus  delbrueckii,  the  primers  pair 
Ldelb-F/Ldelb-R (Eurofins MWG) designed by Byun  et al. (2004) were used. PCR 
reactions  were  performed  in  a  25  μl  mixture  volume  containing  1  x  HotStarTaq 
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Master Mix (Qiagen GmbH, Hilden, Germany) including 1.5 mM MgCl2 and 0.2 mM 
(each) dNTP, 50 ng of DNA template and 100 nM of each primer.  PCR reactions 
were  carried  out  in  a  Veriti  96  well  Fast  Thermal  Cycler  (Applied  Biosystems) 
according to the following amplification profile: a first cycle of incubation of 15 min 
at 95° C, then 40 cycles of amplification, including 15 sec at 95° C, 1 min at 62° C, 
and a final cycle of 3 min at 72° C. Eight μl portions of the PCR products were 
electrophoresed in a 1.5% agarose gel and were visualized by UV illumination after 
ethidium bromide staining. 
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Chapter 5.   Antibiotic resistance profiles
Bacterial strains
All bacterial strains from genus Lactobacillus (strains PCA 227, PCA 236, PCA 263, 
PCA 275, and PCK 73)  and Leuconostoc (PCK 18) were grown in MRS broth for 18 
h  on  37°C  under  aerobic  conditions  and  all  bacterial  strains  from  genus 
Bifidobacteria (strains PCB 133 and PCD 733 B) were grown in TPY broth at 37 °C 
under anaerobic conditions. After 18 hours of incubation, 1 milliliter of the culture 
was taken out and transferred in 9 ml of fresh MRS or TPY broth, put in jars in 
anaerobic conditions at 37 °C for 18 hours.  
  
Antibiotic solutions
The antibiotic resistance was assessed by cultivating bacterial strains in presence of 
antibiotics.  The  antibiotics  used  were:  Tetracycline,  Trimethoprim,  Cefuroxime, 
Kanamycin, Chloramphenicol, Vancomycin, Ampycillin, Streptomycin (all from St. 
Louis,  Mo.,  USA)  and  Erythromycin  (from  Fluka,  Buchs  SG,  Switzerland).  All 
antibiotic solutions were diluted in distilled water or DMSO or water with Ethanol 
(see table 12) to prepare stock solution and then additionally diluted with water to 
final concentration of 2, 4, 8, 16, 32, 64, 128 and 256 μg/ml for antibiotic resistance 
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assay. All these dilutions were sterilized by microfiltration with 0,22  µm pore size 
filter (Millipore, Carrigtwohill, Ireland) before use. 
Table 12.  Solvents used for the antibiotic stock solutions. 
  
Antibiotic                                            Solvent used
 
Tetracycline                                         distilled water
Trimethoprim                                       DMSO
Cefuroxime                                          distilled water
Kanamycin                                          distilled water
Chloramphenicol                                 distilled water with ethanol
Vancomycin                                        distilled water
Ampycillin                                           distilled water
Streptomycin                                       distilled water
Erythromycin                                       distilled water with ethanol
Antibiotic resistance assay
The assay was performed in 96 well plates by making serial dilution of antibiotics of 
concentration raging from 256 μg per ml to 2 μg per ml. In each well we added 20 μl 
of appropriate dilution of antibiotic, 160 μl of fresh MRS or TPY broth and 20 μl of 
overnight bacterial suspension previously diluted 1:9 in fresh MRS or TPY broth to 
obtain 106 CFU per ml. The number of tested bacteria was additionally determined by 
measuring the optical  density (OD) at  620nm and through the  use of  a standard 
McFarland  standards.  The  positive  control  in  assay  was  a  mixture  of  bacterial 
suspension (20 μl), broth (160 μl) and water or DMSO or water with ethanol (20 μl) 
without addition of antibiotic solution,  and the negative control  was a mixture of 
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bacterial  suspension  in  water.  Two additional  controls  were  included;  mixture  of 
water, broth and antibiotic solution and broth only. The plates were then incubated 
for  24 hours in anaerobic conditions at  37 °C in order  to determine the minimal 
inhibitory concentration. Minimal inhibitory concentration (MIC) is defined as the 
lowest concentration of antibiotic giving a complete inhibition of visible growth in 
comparison to an antibiotic free control well and was measured by reading optical 
density at 620 nm. The MIC50 and the MIC90 were defined as the MIC that inhibited 
50% and 90% of the tested microorganisms, respectively. 
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Chapter 1.   Antimicrobial activity of LAB and bifidobacteria against 
Campylobacter strains
According to the results obtained with spot agar test with cell cultures, a high number 
of  strains  (15  strains  out  of  the  60  tested)  have  shown  an  antimicrobial  activity 
against the 3 strains of C. jejuni. Table 13 summarizes these results. 
The  strains  which  gave  the  best  results  were  mainly  belonging  to  the  genera 
Lactobacillus (PCA 236, PCA 259, PCA 275, PCA 293, PCA 227, PCA 306) and 
Bifidobacterium (PCB 107, PCB 110, PCB 111, PCB 148, PCD 232B, PCD 359B, 
PCD 889B). Only the strains PCK 40 and PCB 71 have shown no activity with any of 
the three Campylobacter strains. 
Considering that in the described spot agar test the antagonistic activities could be 
due to the production of organic acids from the bacteria, in order to assay whether 
this activity could be due to the formation of non-acidic products,  spot  agar tests 
using  neutralised  cell-free  culture  supernatants  (NCSs)  were  performed.  All  the 
strains which had evidenced inhibition with at least one of the Campylobacter strains 
were  employed  in  this  experiments. When  NCSs  were  spotted,  the  number  of 
antagonistic  strains  against  pathogens  decreased  dramatically,  and  only  11  strain 
showed an antimicrobial activity against at least one of the strain (listed  in table 14). 
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Table 13.   Inhibitory activity of cell cultures of strains, as determined with the agar 
spot test of Schillinger and Lücke (1989).
                                                                                   Inhibitory activity*
                        Campylob.        Campylob.         Campylob.                                                            Campylob.        Campylob.         Campylob.
                                  jejuni                jejuni                   jejuni                                                                   jejuni                 jejuni                   jejuni    
  Strain            CIP 70.2       LMG 8842       221/05                        Strain            CIP 70.2       LMG 8842       221/05 
PCA 236          +                   +                     +                              PCK 103                   -                  +                    +    
PCA 259          +                   +                     +                              PCS 18                       -                  -                    +
PCA 263         +                    -                     +                                PCS 20                      -                  +                    +
PCA 275         +                   +                     +                                PCS 25                      -                  -                    +
PCA 293          +                   +                     +                               PCB 12                      -                  -                    +
PCD 71            -                   -                     +                                PCB 14                      -                  -                    +
PCD 101         -                   -                    +                                  PCB 26                      -                  +                    +
PCD 119          -                   -                    +                                 PCB 50                     +                  -                    +
PCD 215         -                  -                    +                                   PCB 51                      -                  -                    +
PCD 240         -                  -                    +                                   PCB 54                     +                  +                    -
PCK 18           +                  +                    +                                   PCB 70                   +                  -                    -
PCK 37           -                  +                    +                                    PCB 71                   -                  -                    -
PCK 38          +                 -                    -                                       PCB 76                   +                  -                    -
PCK 73          +                  -                    +                                    PCB 107                  +                 +                    +
PCA 227        +                  +                    +                                    PCB 110                 +                  +                    +
PCA 144        +                  -                    -                                     PCB 111                 +                  +                    +
PCA 244        -                  +                   -                                     PCB 133                  +                  +                    -
PCA 306        +                  +                    +                                   PCB 134                 +                  -                    +
PCA 314       -                  -                    +                                     PCB 139                  +                  -                    -
PCD 227        -                  -                    +                                    PCB 142                  +                  +                    -
PCD 241        -                  -                    +                                    PCB 148                  +                  +                    +
PCD 103     -                  -                    +                                       PCB 150                  +                  -                    - 
PCK 40      -                  -                    -                                         PCB 157                  +                  -                    -
PCK 46       +                  -                    +                                       PCB 158                 +                  -                    -
PCK 49       +                 -                    -                                        PCB 191                  +                  -                    -
PCK 66       +                  -                    -                                       PCD 232B               +                  +                    +
PCK 74       +                  -                    +                                      PCD 359B               +                  +                    +
PCK 161    +                  +                   +                                        PCD 733B               -                  +                    +
PCK 88      -                  -                    +                                         PCD 735B              -                  +                    -
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PCD 889B     +                  +                    +                                    PCD 880B             +                 +                    -
                                                                                                                                           
*+, clear inhibition zone ≥ 1 mm;  -, no inhibition zone.
Table 14.   Inhibitory spectrum of the pH neutralized cell-free supernatants of the 
LAB strains,  as  determined with the agar spot  test  of  Schillinger  and F K Lücke 
(1989).
                                                                             Inhibitory activity*
                        Campylob.        Campylob.         Campylob.                                                            Campylob.        Campylob.         Campylob.
                                  jejuni                jejuni                   jejuni                                                                   jejuni                 jejuni                   jejuni    
  Strain            CIP 70.2       LMG 8842       221/05                        Strain            CIP 70.2       LMG 8842       221/05 
PCA 227          -                   -                     +                              PCD 103                 -                  -                    +    
PCA 236          -                   -                     +                              PCK 18                   -                  -                    +
PCA 263         -                    -                     +                                PCK 73                +                  -                    +
PCA 275         -                   -                     +                                PCK 103                -                  +                    -
PCS 20          -                   -                     +                               PCB 133                  +                  -                    -
PCD 733B      -                  -                     +            
*+, clear inhibition zone ≥ 1.0 mm; -, no inhibition zone.
These 11 strains were then submitted to well diffusion assay test,  whose results are 
shows in table 15. 
Table 15.  Inhibitory activity of pH neutralized cell-free supernatants of the strains 
tested determined with the well diffusion assay
                                                                             Inhibitory activity*
                        Campylob.        Campylob.         Campylob.                                                            Campylob.        Campylob.         Campylob.
                                  jejuni                jejuni                   jejuni                                                                   jejuni                 jejuni                   jejuni    
  Strain            CIP 70.2       LMG 8842       221/05                        Strain            CIP 70.2       LMG 8842       221/05 
PCA 227          -                   +                     -                              PCD 103                   -                  +                    -   
PCA 236          -                   +                     -                              PCK 18                     -                  -                    +
PCA 263         -                    +                    +                              PCK 73                     +                  -                    +
PCA 275         -                   +                     +                              PCK 103                    -                +                    +
PCS 20          -                   +                     +                                PCB 133                    -                   +                    +
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PCD 733B      -                  -                     +            
*+, clear inhibition zone ≥ 1.0 mm; -, no inhibition zone.
The results performed with the spot agar assay and with the well diffusion assays by 
using  NCSs  are  not  always  in  agreement;  however,  they  clearly  show  that  the 
antimicrobial activity depends on the indicator strain used and that the well diffusion 
assay is more sensible in the indication of the antimicrobial activity with respect to 
the spot agar assay. By using the well diffusion assay, 7 starins showed inhibitory 
activity against at least two of the three Campylobacter strains used.
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Chapter  2.  Screening for survival in gastrointestinal tract and food 
processing conditions 
The gastrointestinal tract is the major location to affect the viability of LAB cells. 
The  in vitro criteria used in this study for the selection of candidate probiotics are 
defined  in  the  guidelines  of  FAO/WHO  committee  (Joint  FAO/WHO  Working 
Report, 2002). The  in vitro screening of the survival of LAB in simulated GI tract 
conditions  may  have  value  in  predicting  the  actual  in  vivo survival  of  a  strain. 
According to Havennar and Husis (1992), the stabilities of LAB cells obtained from 
either in vivo or in vitro study are similar. Moreover, the type of the in vivo studies as 
well as the experimental parameters (i.e. mode of administration) can be designed 
most  effectively by the outcome of the above  in vitro test  results.  The tests were 
performed on the 11 strains which had shown marked antimicrobial activity against 
Campylobacter strains (i.e. those described in Table 13).
Resistance to pH
For acid tolerance study, PBS or human (or animal) gastric liquid could be used. In 
this study, the viable LAB counts of each strain were determined after 0, 30, 60, 120 
and 180 minutes of incubation in PBS buffer (pH 2.5). 
For  statistical  analysis,  all  plate  count  data  were  converted  to  log  cfu  ml-1 (% 
Survival). Survival rates of the strains varied during incubation (Table 16, 17 and fig. 
10). 
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Results from Table 1 and 2 show that after 1 hour almost all strains have lost their 
viability. Only PCS 20 (7.89 log cfu ml-1; 12.62% survival) and PCA 263 (6.04 log 
cfu ml-1; 0.09% survival) strains retain their viability after 60 minutes of exposure.  
Table 16.   Survivala of strains tested at pH 2.5, value expressed as log cfu ml-1 at 
each sampling time  
  Strain            Viable counts of strains as log cfu ml-1 (SD)
                           0 min                     30 min                    60 min                    120 min                    180 min
PCA 227          9.08±0.82                 6.78±1.50                5.17±1,29                4.60±2.94                  0,70±0.58
PCA 236          9.45±1.00                 7.70±0.96                5.1781.83                0.40±0.50                  0.40±0.50
PCA 263          9.08±1.73                 6.48±0.96                6.04±1.26                6.00±1.83                  5.59±1.29
PCA 275          8.84±1.29                 6.08±2.99                3.43±2.45                3.37±3.10                  0.88±0.50
PCK 73            8.68±1.50                 4.56±1.29                1.10±0.50                0.88±0.50                  0.70±0.58
PCK 18           8.63±1.71                 6.78±3.10                 1.00±0.82                0.88±0.96                  0.70±0.58   
PCK 103         8.47±2.22                  8.47±1.71                 4.34±1.71               2.93±1.41                  1.00±0.82
PCD 103         8.96±1.26                  7.50±0.96                 1.10±0.50                1.00±0.00                 0.88±0.50
PCS 20            8.79±2.16                8.69±1.29                  7.89±0.82                5.55±4.65                  5.39±2.38
PCB 133         8.43±2.36                  4.37±2.65                 3.35±2.75                1.10±0.50                  0.88±0.50
PCD 733B      9.90±4.11                  3.08±1.29                 2.95±1.41                1.00±0.00                  1.00±0.82
a Each value in the table represents the mean value ± standard deviation (SD) from four trials.
Table 17.   Survival of strain tested at pH 2.5, value expressed in % Survival. 
  Strain                                                                   Survival %
                           0 min                     30 min                    60 min                    120 min                    180 min
PCA 227               100%                      0.51%                       0.01%                      0.00%                        0.00%
PCA 236               100%                      1.77%                        0.01%                     0.00%                        0.00%     
PCA 263               100%                      0.25%                        0.09%                      0.08%                       0.03%    
PCA 275               100%                      0.17%                         0.00%                     0.00%                      0.00%
PCK 73                 100%                      0.01%                         0.00%                     0.00%                      0.00%
PCK 18                 100%                      1.42%                        0.00%                       0.00%                       0.00%
PCK 103               100%                      98.48%                       0.01%                      0.00%                        0.00%
PCD 103               100%                      3.44%                         0.00%                      0.00%                      0.00%
120
PCS 20                 100%                       81.15%                       12.62%                    0.06%                       0.04%  
PCB 133               100%                      0.01%                         0.00%                      0.00%                      0.00%
PCD 733B             100%                       0.00%                         0.00%                     0.00%                      0.00%
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Fig 10.  Resistance to pH 2.5
PCK 103 strain shows optimal resistance after 30 minutes (8.47 log cfu ml-1; 98.48% 
survival), but its viability rapidly decreases after this time. After 3 hours of exposure 
to pH 2.5, viable counts were determined only for PCS 20 (5.39 log cfu ml-1; 0.04% 
survival) and PCA 263 (5.59log cfu ml-1; 0.03%  survival).
Resistance to bile salts
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The bile in human and animal intestine is also an important factor which affects the 
microrganism viability. Although the composition of human bile juice is not exactly 
the same as that of the oxgall solution, most studies use oxgall as one substitute for 
human and animal bile because of their similarity (Brashears et al., 2003). 
Table 18.  Effecta of Ox-gall 1% and 2% (w/v) on the growth of the 11 strains tested. 
Results are expressed as log cfu ml-1 (SD)
  Strain                                    Ox-gall 1%                                                     Ox-gall 2%
                            0 min              60 min              240 min                    0 min              60 min              240 min            
PCA 227           8.66±1.71          8.59±0.96           8.59±2.08               8.64±1.29         8.61±0.58          8.60±1.73
PCA 236          8.99±1.71           8.95±1.89           8.94±0.82               8.89±0.96        8.81±1.26          8.81±1.63      
PCA 263          8.42±1.00           8.36±0.82           8.32±0.96               8.43±0.96         8.40±0.96         8.35±0.96  
PCA 275          8.65±0.82           8.53±0.82           8.60±0.82               8.69±0.58         8.39±0.96         8.55±1.26
PCK 73            8.20±0.96           8.00±0.82           7.80±0.96               8.13±0.96         8.12±1.29         7.80±0.50
PCK 18           8.37±0.96            8.25±0.82            8.13±0.50              8.48±1.26         8.04±0.96         8.40±0.82   
PCK 103         8.88±0.96            8.68±0.96            8.25±0.50              9.12±0.50         8.69±1.00         8.14±0.96  
PCD 103         8.45±0.82            8.38±0.96            8.28±0.82              8.56±1.29         8.35±0.96          8.28±0.82 
PCS 20           8.79±0.50            8.76±1.29            8.75±1.71              9.08±0.96          8.96±1.26         8.79±1.00
PCB 133         8.72±0.82            8.62±0.50            7.99±0.96              8.90±1.71          8.63±0.50          8.30±1.71 
PCD 733B      8.01±2.87            7.58±0.96             6.51±0.50             8.14±0.58          7.22±1.50         6.44±0.50
a Each value in the table represents the mean value ± standard deviation (SD) from four trials.
Table 19. Survival  of  strains tested after  exposure to  Ox-gall  1% and 2%, value 
expressed in % Survival. 
  Strain                                        Ox-gall 1%                                                     Ox-gall 2%                             
                             0 min              60 min              240 min                    0 min              60 min              240 min
PCA 227           100%                 85.85%                85.02%                100%                    91.62%             90.71%
PCA 236          100%                  90.33%                89.57%                100%                    83.28%             83.32%      
PCA 263          100%                  86.79%                78.30%                100%                    94.39%             83.18%  
PCA 275          100%                  75.56%                88.89%                100%                    51.03%             72.68%
PCK 73            100%                 64.43%                 40.03%                100%                    96.85%             47.31%
PCK 18           100%                   75.08%                57.37%                100%                    36.40%             82.50%   
PCK 103         100%                    62.62%               23.28%                100%                    37.09%            10.52%  
PCD 103         100%                   86.61%                67.86%                100%                    60.96%             52.05% 
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PCS 20           100%                    92.37                  90.36%                 100%                   77.04%               51.36%
PCB 133         100%                   78.77%                18.40%                100%                    52.65%              24.61% 
PCD 733B      100%                   36.92%                 3.18%                  100%                    12.18%              2.00%
Probiotic strains were also examined for their ability to survive after exposure of 1% 
and 2% (w/v) oxgall solutions. CFUs were determined at time 0 and after 1 and 4 
hours. Results were summarised in table 18, 19 and figures 11 and 12.
At Ox-gall concentration of 1% (w/v) more than 50% of the initial population survive 
after  1 hour of  exposure,  except  for  PCD 733B (7.58±0.96 log cfu ml-1;  36.92% 
survival).  At the same concentration of bile salt  (1%), but after 4 hours, 7 of the 
eleven strains retain their viability of more than 50% of the initial population: PCA 
227 (8.59±2.08 log cfu ml-1;  85.85% survival),  PCA 236 (8.94±0.82 log cfu ml-1; 
89.57% survival),  PCA 263 (8.32±0.96 log cfu ml-1;  78.30% survival),  PCA 275 
(8.53±0.82 log cfu ml-1; 88.89% survival), PCK 18 (8.13±0.50 log cfu ml-1; 57.37% 
survival), PCD 103 (8.28±0.82 log cfu ml-1; 67.86% survival) and PCS 20 (8.75±1.71 
log  cfu  ml-1;  90.36%  survival).  Only  PCD  733B  strain  shows  lower  resistance 
(6.51±0.50 log cfu ml-1; 3.18% survival). This strains also rapidly lost its viability 
after 1 hour of exposure at 2% Ox-gall (7.22±1.50 log cfu ml-1; 12.18% survival). The 
other  strains  retain their  viability  even after  4 hour  at  2% Ox-gall,  but  PCB 133 
(8.30±1.71 log cfu ml-1; 24.61% survival) shows moderate resistance as well as PCK 
103 (8.14±0.96 log cfu ml-1;  10.52% survival)  strain.  Most  strains  show to resist 
better in 1% solution of bile salt than in the more concentrated one (PCA 236, PCA 
273, PCK 103, PCD 103, PCS 20, PCB 133 and PCD 733B), but other strains show 
an opposite behaviour (PCA 263, PCK 73), probably due to intrinsic characteristics 
of the strain.
PCA 275 strain shows susceptibility to Ox-gall 1% (8.59±0.58 log cfu ml-1; 75.56% 
survival) and 2% (8.39±0.96 log cfu ml-1;  51.03% survival) concentrations after 1 
hour of exposure, but this susceptibility decreases after 4 hours at both concentrations 
of the bile salts (8.53±0.82 log cfu ml-1; 88.89% survival with Ox-gall 1% treatment 
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and  8.55±1.26  log  cfu  ml-1;  72.68%  survival  with  Ox-gall  2%  treatment).  This 
behaviour is  probably the consequence of an adaptation of the strain to stress,  as 
already evidenced in the literature by Anukam and Koyama (2007). Similar results 
are found for PCK 18 strain.
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Resistance to temperature
Thermophilic  and thermotolerant  organisms have an advantage since they survive 
higher  temperature  during  processing  and  storage.  They  have  a  better  chance  of 
remaining viable during the process required for prolonged storage and they lead to a 
distinctly more effective product. In addition, thermophilic LAB are well-known for 
their biotechnological importance in the food industry.
In this work, the eleven strains were tested for their capacity to resist to 50 °C and 55 
°C. Table 20 and 21 and figures 13 and 14 shows the effect of the heat treatment on 
the strains tested. 
Table 20.  Effecta of temperature (50°C and 55°C) on the growth of the 11 strain 
tested. Results are expressed as log cfu ml-1 (SD)
  Strain                                           50°C                                                                               55°C
                           0 min          15 min          30 min          60 min           0 min          15 min          30 min          60 min 
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PCA 227        8.51±0.82    8.49±2.87      8.46±0.96    8.46±1.29     8.51±2.65    8.46±1.29    8.46±1.83     8.45±1.83
PCA 236        9.18±1.83    9.16±1.41      9.14±0.82    9.08±0.96     9.11±0.58     9.04±1.26    9.03±1.26    9.03±0.82      
PCA 263        8.30±2.63    8.27±0.82      8.25±0.82    8.07±1.26     8.34±0.82     8.26±1.26    8.21±1.41    8.08±0.96  
PCA 275        8.81±1.29    8.74±1.29      8.72±1.29    8.71±0.58     8.83±0.58     8.77±1.73    8.70±0.96    8.69±4.35
PCK 73          8.72±1.41    8.63±0.82      8.60±1.71    8.59±1.71     8.70±1.83     8.59±0.96     8.59±1.26    8.59±1.89
PCK 18          8.36±0.82    8.34±0.50       8.07±2.50     8.02±0.50  8.31±1.50      8.27±1.41     8.01±2.06   8.00±0.82
PCK 103       8.47±0.96     8.43±1.29        8.41±2.65    8.15±2.63    8.48±0.96      8.41±2.16      8.29±1.50    8.09±3.11
PCD 103       8.74±1.29    8.61±1.41      8.60±4.99    8.53±1.71     8.74±1.29     8.60±1.73     8.60±0.96    8.51±1.83
PCS 20          9.10±0.96    9.08±0.96      9.07±1.29    8.17±0.50     9.07±0.96     9.03±1.41     9.02±1.89    8.11±1.89
PCB 133        8.22±0.96    8.08±2.16      8.04±1.89    7.74±1.50     8.22±1.26     8.08±1.29     8.00±2.22   7.76±0.82
PCD 733B     8.72±1.29    8.71±0.82      8.71±1.41    8.70±1.50     8.72±2.16     8.70±1.71     8.69±3.56    8.67±0.58
a Each value in the table represents the mean value ± standard deviation (SD) from four trials.
Table 21. Survival of strains tested after heat treatment (50 °C and 55 °C), value 
expressed in % Survival. 
  Strain                                                   50°C                                                                          55°C                             
                              0 min          15 min          30 min          60 min           0 min          15 min          30 min         60 min
PCA 227           100%            95.43%         88.93%         88.39%            100%          90.08%         89.30%        87.29%
PCA 236          100%             94.70%         92.05%         79.64%            100%          85.80%         83.85%        83.27%
PCA 263          100%             93.88%         89.39%         58.05%            100%          83.53%         74.19%        55.18%
PCA 275          100%             85.70%         80.89%         80.57%            100%          87.68%         74.57%        73.53%
PCK 73            100%             81.99%         76.77%         74.38%            100%          78.72%         78.82%        78.52%
PCK 18            100%             96.15%         52.09%         46.15%            100%          91.78%         50.67%         48.59%
PCK 103         100%             89.84%          85.81%          47.94%           100%         84.70%         65.10%        40.86%
PCD 103         100%             73.70%         71.66%         62.28%            100%         73.37.%         72.77%        59.14%
PCS 20            100%              94.50%        93.12%         11.59%            100%          92.51%         90.58%        10.92%
PCB 133         100%              73.44%         66.62%         33.23%            100%          73.14%         60.24%       34.60%
PCD 733B      100%              96.87%         96.49%         94.83%            100%          95.00%         94.29%        89.05%
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Fig. 13.  Resistance of the strains tested to 50 °C
0 h
15'
30'
60'
PCA
227
PCA
236
PCA
263
PCA
275
PCK
73
PCK
18
PCK
103
PCD
733B
PCD
103
PCB
133
PCS
20
0,00
10,00
20,00
30,00
40,00
50,00
60,00
70,00
80,00
90,00
100,00
Survival %
Minutes
Strains
Resistance to 55 °C
PCA 227
PCA 236
PCA 263
PCA 275
PCK 73
PCK 18
PCK 103
PCD 733B
PCD 103
PCB 133
PCS 20
Fig. 14.  Resistance to 55 °C
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Tables 18 and 19 show that all strains are relatively resistants to both 50 °C and 55 
°C heat treatments, even after 1 hour of exposure. Only PCS 20 was sensitive after 60 
minutes at 50 °C (8.17±0.50 log cfu ml-1; 11.59% survival) and 55 °C (8.11±1.89 log 
cfu  ml-1;  10.92% survival).  PCB 133 strains  shown moderate  tolerance  to  50  °C 
(7.74±1.50 log cfu ml-1; 33.23% survival)  and 55 °C (7.76±0.82 log cfu ml-1; 34.60% 
survival) after 1 hour of heat stress,  as well as PCK 103 (8.15±2.63 log cfu ml-1; 
47.94% survival at 50° and 8.09±3.11 log cfu ml-1; 40.86% survival at 55 °C). In 
general, all strains show a  better tolerance to the lower temperature heat treatment 
(50 °C) than  to the higher one (55 °C).
Resistance to osmotic stress
In the different applications in the food and feed industry, lactic acid bacteria and 
bifidobacteria can be exposed to osmotic stress when important quantities of salt or 
sugar are added to the product.  The effects  of osmotic  stress  caused by high salt 
concentration on the viability of the selected strains is studied. Table 23 and figure 15 
illustrate the percentage of survival of strains after 30 minutes and 60 minutes of 
exposure to NaCl 6% solution. 
Table 22.  Survivala of strains after exposure to NaCl 6% 
  Strain            Viable counts of strains as log cfu ml-1 (SD)
                                                                                             Time
                                     0 min                                               30 min                                                     60 min                    
PCA 227                   8.83±1.00                                         8.81±0.58                                              8.79±0.58                
PCA 236                   8.90±1.73                                         8.89±0.58                                              8.83±1.00                
PCA 263                   8.41±3.21                                         8.21±1.53                                              7.76±0.58                
PCA 275                   8.75±0.58                                         8.72±1.53                                              8.68±0.58                
PCK 73                     8.15±2.65                                         8.00±1.15                                              7.99±1.00                
PCK 18                     8.35±3.21                                         8.35±1.00                                              8.32±2.65                
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PCK 103                   8.93±0.58                                         8.90±1.53                                              8.79±2.08               
PCD 103                  8.71±2.65                                          8.49±2.65                                              8.63±2.52                
PCS 20                     9.53±1.53                                          9.43±1.15                                              9.27±1.53                
PCB 133                   8.45±1.00                                         8.40±1.00                                               8.34±1.00                
PCD 733B                8.79±0.58                                         8.77±1.53                                               8.73±1.53                
a Each value in the table represents the mean value ± standard deviation (SD) from three trials.
After 60 minute exposure, all the strains are relatively resistants: except for PCA 263 
strain (7.76±0.58 log cfu ml-1; 22.43% survival), all the strains retain their viability of 
more than 50% of the initial population, showing an optimal capacity to resist  stress.
Table 23. Survival (%) of strains tested after a NaCl 6% treatment. 
  Strain                                                                      Survival %
                                  0 min                                          30 min                                                        60 min                    
PCA 227               100%                                               94.12%                                                       91.67%                      
PCA 236               100%                                               97.08%                                                       85.00%                     
PCA 263               100%                                               62.84%                                                       22.43%                       
PCA 275               100%                                               94.61%                                                       86.83%                     
PCK 73                 100%                                               70.66%                                                       69.01%                     
PCK 18                 100%                                               98.96%                                                        91.86%                       
PCK 103               100%                                              93.77%                                                        71.60%                      
PCD 103               100%                                              83.30%                                                         67.84%                      
PCS 20                 100%                                               78.64%                                                        55.02%                    
PCB 133               100%                                               90.00%                                                        78.57%                      
PCD 733B             100%                                              96.74%                                                         87.50%                     
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The best  results are done by PCA 227 (8.79±0.58 log cfu ml-1;  91.67% survival), 
PCK 18 (8.32±2.65 log cfu ml-1; 91.86% survival), PCA 236 (8.83±1.00 log cfu ml-1; 
85.00% survival), PCA 275 (8.68±0.58 log cfu ml-1; 86.83% survival) and PCD 733B 
(8.73±1.53  log  cfu  ml-1;  87.50% survival).  For  all  strains,  the  viable  cell  counts 
decrease as the time of exposure to the solution NaCl 6% increases.
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Fig. 15.  Resistance to NaCl 6%. 
Resistance to starvation stress
Stationary phase due to nutrient limitation corresponds to the usual conditions that 
microorganisms  encounter  in  their  natural  environment,  but  also  in  particular 
condition, like the industrial  transformation.  In this study, the eleven strains were 
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tested for  their  survival  after  6,  12 and 24 hours of  starvation stress.  Results  are 
summarized in table 24 and 25. 
Table 24.   Survivala of strains tested after exposition to starvation stress 
  Strain            Viable counts of strains as log cfu ml-1 (SD)
                                                                                             Time (hours)
                                     0 hours                           6 hours                               12 hours                              24 hours 
PCA 227                   8.85±1.53                           8.44±1.53                           8.40±0.58                                     8.08±1.00 
PCA 236                   8.80±0.58                          8.78±0.58                           8.78±2.65                                      8.74±1.15 
PCA 263                   9.24±0.58                          8.43±1.00                           8.20±1.00                                     7.75±1.00 
PCA 275                   8.92±1.00                          8.81±0.58                            8.81±0.58                                     8.64±1.00 
PCK 73                     9.33±1.15                          9.26±1.53                           9.12±1.00                                      9.10±2.00 
PCK 18                     8.62±2.52                          8.60±2.08                           8.47±1.53                                      8.26±1.15 
PCK 103                   9.20±0.58                          9.17±1.15                           9.12±2.52                                     9.11±1.53 
PCD 103                  8.54±1.00                            8.51±1.53                          8.51±3.46                                    8.50±2.08 
PCS 20                     9.29±2.08                            9.07±2.65                          9.21±2.08                                    9.24±3.79 
PCB 133                   8.39±1.15                            8.30±1.00                         8.19±1.15                                     8.10±1.15 
PCD 733B                9.08±1.00                            8.56±1.53                         8.46±1.00                                    8.44±0.58 
a Each value in the table represents the mean value ± standard deviation (SD) from three trials.
Table 25.   Survival (%) of strains after starvation stress. 
  Strain                                                                      Survival %
                                  0 hours                           6 hours                               12 hours                              24 hours 
PCA 227               100%                                      39.15%                              35.85%                               16.98% 
PCA 236               100%                                      95.79%                               94.74%                               87.37% 
PCA 263               100%                                      15.40%                               9.16%                                   3.21% 
PCA 275               100%                                      77.91%                                77.51%                              53.01% 
PCK 73                 100%                                      84.29%                                61.12%                              59.25% 
PCK 18                 100%                                      94.99%                                69.71%                              43.72% 
131
PCK 103               100%                                      92.68%                                82.64%                              81.17% 
PCD 103               100%                                      94.61%                                94.51                                 92.00% 
PCS 20                 100%                                       60.41%                                83.11%                             88.40% 
PCB 133               100%                                       81.08%                                63.51%                             51.35% 
PCD 733B             100%                                       30.56%                               24.17%                             23.06% 
The most resistant strain is PCD 103, showing 92% of survival even after 24 hour of 
stress  (8.50±2.08 log cfu ml-1).  PCA 236, PCK 103 and PCS 20 strains show an 
optimal resistance: their survival after the maximum time of stress are more than 80% 
of the initial population. After 24 hours, PCA 275 (8.64±1.00 log cfu ml-1; 53.01% 
survival), PCK 73 (9.10±2.00 log cfu ml-1; 59.25% survival), PCK 18 (8.26±1.15 log 
cfu ml-1; 43.72% survival), PCB 133 (8.10±1.15 log cfu ml-1; 51.35% survival) shows 
good resistance, while PCA 227 (8.08±1.00 log cfu ml-1; 16.98% survival) and PCD 
733B (8.44±0.58 log cfu ml-1; 23.06% survival) have moderate capacity to resist, only 
PCA 263 (8.43±1.00 log cfu ml-1; 15.40% survival) is already sensitive  after 6 hours 
of treatment: its survival percentage after 24 hours is very low (3.21%).
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Fig. 16.  Resistance to starvation stress.
Chapter 3.   Hemolytic activity
The absence of hemolytic activity is essential for the selection of strains possessing 
putative probiotic characteristics.  None of the tested strains exhibited β-hemolytic 
activities after 24 hours. Fig. 17 and 18 shows some results.
Fig. 17. PCA 275 strain in Columbia agar blood.. after 24 hours of incubation.
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Fig. 18. PCS 20 strain (left) in Columbia agar blood after 24 hours of incubation.
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Chapter 4.   Identification of strains
Phenotypic identification
The biochemical identification of the 9 LAB which had shown interesting inhibitory 
activity towards  Campylobacter spp. was performed with an API 50 CHL kit  and 
API20 STREP. The identification results given by APILAB Plus software version 4.0 
database are shown in Table 26:
 
Table 26.   Identification of strains             
                                               
Strain                         Identification system                            Strain                     %ID (percentage of identification)
PCA 227                         API 50 CHL                          Lactobacillus pentosus                                              99.9% 
PCA 236                         API 50 CHL                          Lactobacillus plantarum                                            99.3%
PCA 263                         API 50 CHL                          Lactobacillus plantarum                                            99.9%
PCA 275                         API 50 CHL                          Lactobacillus plantarum                                            91.1%
PCK 73                           API 50 CHL                          Lactobacillus plantarum                                            99.9%
PCK 18                           API 50 CHL                          Leuconostoc mesenteroides                                        85.5%
PCK 103                         API 50 CHL                          Lactobacillus delbrueckii ssp delbrueckii                  95.2%          
PCD 103                         API 20 STREP                      Enterococcus durans                                                   91.9%
PCS 20                            API 50 CHL                         Lactobacillus plantarum                                             98.3% 
For all strains, identification levels from good to excellent were obtained. 
Molecular identification
To confirm biochemical identifications, species-specific PCR was performed on the 
DNA of all strains, as described in the section Matherial and methods.  PCA 236, 
PCA 263, PCA 275, PCS 20 and PCK 73 strains were identified as  Lactobacillus 
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plantarum. The DNA of Lactobacillus plantarum DSMZ 20174 strain was used as a 
positive control (Fig. 19). 
PCD 103 strain was identified as Enterococcus durans as shows in Fig 20. Positive 
control  used  was  DSMZ  20633  strain.  Regarding  PCB  133  and  PCD  733B, 
biochemical  and phenotypic characterization previously performed had allowed to 
identify them as  Bifidobacterium longum strains. The identification was confirmed 
via species-specific PCR (Fig. 21). In  the negative controls of all  PCR analyses, 
sterile water was used in substitution of DNA.
PCA  227  strain  was  identified  as  Lactobacillus  pentosus (Fig.  22),  PCK  18  as 
Leuconostoc mesenteroides (fig. 23) and PCK 103 as Lactobacillus delbrueckii (fig. 
24). 
Fig.19. PCR  electrophoretogram of  Lactobacillus  plantarum  strains.  75  bp  PCR 
products  obtained  for  7  Lactobacillus  species  and  1  Leuconostoc species  with 
Lactobacillus plantarum specific primers. Lane 1, PCA227; lane 2, PCA236; lane 3, 
PCA263; lane 4, PCA275; lane 5, PCS20; lane 6, PCK18; lane 7, PCK73; lane 8, 
PCK103; lane 9, negative control (PCR performed with primers pair Lplan-vreg1-
F/Lpla-vreg1-R and E. coli).
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Fig.20.  PCR electrophoretogram of E. durans strain. Lane 3, positive control; lane 4, 
negative control; lane 5 and 6, PCD 103. 
Fig.21. Bifidobacterium longum. 831 bp PCR products obtained for Bifidobacterium 
species with  B. longum  specific primers. Lane M, GeneRuler 100 bp DNA Ladder 
Plus; lane 1, PCB133 [200 ng]; lane 2, PCD733 [200 ng]; lane 3, PCB133 [100ng]; 
lane 4, PCD733 [100ng]; lane 5, negative control (PCR performed with primers pair 
BiLON-1/BiLON-2 and E. coli).
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Figure 22. Lactobacillus pentosus 250 bp PCR products obtained for 7 Lactobacillus 
species  and  1  Leuconostoc species  with  Lb.  pentosus specific  primers.  Lane  1, 
PCA227; lane 2, PCA236; lane 3, PCA263; lane 4, PCA275; lane 5, GeneRuler 1 kb 
DNA Ladder Plus; lane 6, GeneRuler 100 bp DNA Ladder Plus; lane 7, PCK18; lane 
8,  PCK73;  lane  9,  PCK103;  lane  10,  PCS20;  lane  11,  negative  control  (PCR 
performed with primers pair Lpen-F/16S and E. coli).
Figure  23.   Leuconostoc  mesenteroides.  1150  bp  PCR  products  obtained  for  7 
Lactobacillus  species and 1  Leuconostoc species  with  Leu. mesenteroides  specific 
primers.  Lane  1,  GeneRuler  1  kb  DNA  Ladder  Plus;  lane  2,  PCA227;  lane  3, 
PCA236; lane 4, PCA263; lane 5, PCA275; lane 6, PCK18; lane 7, PCK73; lane 8, 
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PCK103; lane 9, PCS20; lane 10, negative control (PCR performed with primers pair 
Lmes-F/Lmes-R and E. coli).
Figure 24.   Lactobacillus delbrueckii (Tilsala). 500 bp PCR products obtained for 7 
Lactobacillus  species  and  1  Leuconostoc species  with  Lb.  dulbrueckii specific 
primers.  Lane  1,  GeneRuler  1  kb  DNA  Ladder  Plus;  lane  2,  PCA227;  lane  3, 
PCA236; lane 4, PCA263; lane 5, PCA275; lane 6, PCK103; lane 7, PCK73; lane 8, 
PCK18; lane 9, PCS20; lane 10, negative control (PCR performed with primers pair 
Delb-F/Delb-R and E. coli).
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Chapter 5.   Antibiotic resistance
The  determination  of  the  antibiotic  resistance  of  bifidobacteria  and  LAB  is  an 
important  issue,  considering  that  these  probiotics  are  often  co-administered  with 
antibiotics.  On the other  hand,  probiotics  can represent  a potential  source for  the 
spread of antibiotic genes. All strains tested showed resistance to the antibiotic tested: 
ampycillin,  vancomycin,  trimethoprim,  streptomycin,  kanamycin,  cefuroxime, 
chloramphenicol,  erythromycin   and  tetracycline.  Further  studies  are  needed  to 
confirm these results.
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Discussion
The  beneficial  bacterial  effects  of  probiotics  on  human  and  animal  health  have 
increasingly been highlighted during the past years. According to FAO and WHO 
guidelines (FAO/WHO, 2002), prospective probiotics must fulfill certain criteria and 
should be selected through a defined process. The selection criteria for LAB to be 
used  as  ‘probiotics’  include  the  ability  to  inhibit  the  growth  of  pathogens,  to 
withstand transit through the GI tract, and to survive after food processing conditions. 
In this context, the aim of the present study was to apply established in vitro tests to 
evaluate the probiotic potential of selected LAB and bifidobacteria strains. 
Among  the  60  strains  (mainly  Lactobacillus,  Pediococcus,  Leuconostoc and 
Bifidobacterium spp.) investigated for their antimicrobial activity by using spot agar 
test  with  cell  cultures,  a  relatively  high  number  of  them managed  to  inhibit  the 
growth  of  Campylobacter jejuni strains,  an  emergent  Gram  negative  pathogen 
causing human enteritis frequently associated with raw or uncooked poultry products: 
60% of the tested strains was able to contrast the growth of C. jejuni strain CIP 70.2; 
43.3% of C. jejuni strain LMG 8842 and 68.3% of C. jejuni 221/05 strain. These high 
percentages  might  result  from  the  production  of  organic  acids  from  strain 
metabolism, which inhibit growth by pH reduction of the medium. In fact, when spot 
agar test was performer with neutralized supernatants, only 11 strains showed a weak 
inhibition zone, the majority of which belonging to the genus Lactobacillus. The well 
diffusion assay test performed with neutralized supernatants confirmed that in some 
strains,  in  particular  PCA 263,  PCA 275,  PCK 103 (Lactobacillus spp.),  PCS 20 
(unidentified strain isolated from cheese), PCK 73 (unidentified strain isolated from 
coffee fermentation), PCD 733B and PCK 173 (Bifidobacterium spp.), the inhibitory 
activity may not result only from acidification.  The putative presence of non-acidic 
inhibitory compounds need to be further investigated. A very interesting result is the 
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higher percentage of inhibition against C. jejuni 221/05, the wild strain isolated from 
chicken GI tract. 
Further investigation  were  aimed  at  evaluating  if  the  11  strains  showing  higher 
antimicrobial  activity  against  Campylobacter spp.  were  able  to  survive  passage 
through the gastrointestinal tract. The first barrier is represented by the low pH in the 
stomach (pH of about 2.5). Since food ingestion can take up to 3 hours, the survival 
rates  of  the  strain  was  also  examined  in  artificial  gastric  juice  (pH  2.5)  after 
incubation for up to 3 hours. Two strains, PCS 20 and PCK 103 showed to have 
strong resistance after 30 minutes, but they lost  their viability after this time. The 
other strains showed lower resistance .  The ability of potentially probiotic strains to 
survive in acidic conditions has been investigated in a number of studies, which have 
shown great variation between strains and species. Hood and Zottola (1988) showed 
that no cells of a Lactobacillus acidophilus culture were recovered following 45 min 
exposure to pH 2·0, while at pH 4·0 the number of cells was not significantly reduced 
after  2 h.  Similar  trends  have  been  shown  for  the  survival  of  Lactobacillus 
rhamnosus GG in human gastric juice at pH values ranging from 1·0 to 7·0 (Goldin 
et al.  1992).  In  general,  Bifidobacterium cultures  are  less  acid  tolerant  than 
Lactobacillus cultures  and  this  can  be  seen  in  their  reduced  tolerance  to  human 
gastric juice (Dunne et al. 1999). Furthermore, the choice of the food carrier such as 
dairy products may enhance microbial survival in gastric juice, most likely due to a 
buffering or protective effect. This effect may be due to the buffering capacity of the 
food product.  The addition of milk or milk proteins to the gastric juice or  media 
simulating gastric juice significantly increases the pH and enhances survival of some 
Lactobacillus and  Bifidobacterium species  (Charteris  et al.  1998). Lactobacilli  are 
mainly  acid  tolerant  or  aciduric,  particularly  when  isolated  from  the  harsh 
environment of the GIT (McLauchlan et al. 1998). This approach has been used in 
the screening of human faecal Bifidobacterium and has yielded strains which are both 
acid and bile tolerant (Chung et al. 1999): these stressed cultures have a higher ability 
to survive in the presence of bile and acid compared with other bacteria. So, even if 
144
our  strain  are  less  resistants  to  low pH, they  could be used  as  probiotic  cultures 
because  they  might  show  a  higher  resistance  with  crossed  stresses. Bile-salt 
resistance is the next major challenge for the microorganisms which are expected to 
survive in the GIT. Although the intestinal bile acid concentration in human is about 
0.3/0.5% (w/v), in this study the tolerance of the bacteria was tested in two different 
concentrations of 1% and 2% (w/v) of bile salts respectively, since there is limited 
information about the concentration of bile acid in animal intestine (Kim et al., 2007). 
With  the  exception  of  PCD  733B,  PCB  133  and  PCK  103,  all  strains  showed 
tolerance ranging from good to excellent, with a survival percentage reaching 90.71% 
after 4 hours of 2% bile salts treatment for PCA 227 strain. It is interesting to note 
that the two strains of Bifidobacteria showed a lower tolerance to stress.  After an 
initial  decrease,  some  strains  increased  slightly  their  survival  percentage  at  the 
maximum time of exposure; this might have been due to the adjustment of the strains 
to  the  stress  situation.  However,  remarkable differences  between  strains  are  also 
described in the literature (Berrada et al., 1991; Pochart et al., 1992). 
A major challenge associated with the application of probiotic cultures in functional 
foods and in animal feed is the retention of viability during industrial processing. The 
control of the resistance of probiotic bacteria to temperature stress may also have 
potential practical benefits in the industrial fermentation processes in which bacteria 
with enhanced thermotolerance are required. In this study, we assayed the ability of 
selected strains to survive after heat treatment with 2 temperatures (50 °C and 55 °C) 
at different time of exposure. At 50 °C, only PCS 20 and PCB 133 strains showed 
low/moderate resistance after the longer exposure time (60 min). At 55 °C, these two 
strains,  as  well  as  the   PCK 103  strain,  showed  a  reduced  heat  resistance.  The 
majority of strains retained their viability even at 55 °C and after 60 min, showing a 
survival percentage ranging from 40% to 89%.
Among  the  many  ways  used  to  preserve  food  products,  the  increased  osmotic 
pressure, i.e. the lowering of water activity (aw), is one of the most widely used. The 
desiccation or the addition of high amounts of osmotically active compounds such as 
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salts or sugars lowers the water activity of the food. Therefore, the investigation of 
the  resistance  of  putative  probiotic  strains  against  osmotic  stress  is  of  crucial 
importance in selecting new probiotics for the application in foods and animal feed. 
In this study, the strains were submitted to 6% NaCl for 30 and 60 minutes, and the 
results showed the optimal  resistance of 10 out  of the 11 strains,  with a survival 
percentage higher than 55% after  60 minutes of  exposure.  Only PCA 263 strains 
showed  low  resistance  (22.43%  after  60  min),  probably  due  to  the  intrinsic 
characteristics of the strain. 
As  to  starvation  stress,  the  strains  showed  variable  behaviour.  After  6  hours  the 
majority of them showed strong resistance,  and the same result  was obtained also 
after 12 hours. After 24 hours, the most resistant strains were PCA 236, PCK 103, 
PCD 103 and PCS 20 (survival percentage of more than 80%), but also the remaining 
strains showed resistance even if only moderate.  Only PCA 263 strain showed no 
resistance at all. 
The strains tested were also safe, as shown by the absence of the β-hemolytic activity 
in all the 11 selected strains. 
The results from phenotypic identification carried out by using API systems were 
confirmed by molecular techniques, which showed that the majority of strains belong 
to the same species Lactobacillus plantarum (PCA 236, PCA 263, PCA 275, PCK 73 
and PCS 20 strains), while PCB 133 and PCD 733B strains belong to the species 
Bifidobacterium longum. PCA 227 strain was identified as  Lactobacillus pentosus, 
and PCK 18 as  Leuconostoc mesenteroides.  PCK 103 as  Lactobacillus delbrueckii 
and PCD 103 as Enterococcus durans.
As  to  antibiotic  resistance,  all  strains  showed  MIC  ≥256  μg/ml  towards  all  the 
antibiotics  assayed  (Tetracycline,  Trimethoprim,  Cefuroxime,  Kanamycin, 
Chloramphenicol, Vancomycin, Ampycillin, Streptomycin and Erythromycin), thus 
evidencing a  high  resistance  of  all  the  strains.  Several  studies  are  present  in  the 
literature regarding the antibiotic resistance of L. plantarum (West and Warner, 1985; 
Florez et al. 2006; Engervam et al. 2009); these works evidence that MIC values for 
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several antibiotics, among which those tested in this research, vary widely between 
strains.  A high percentage  of  L.  plantarum strains  described in  the  literature  are 
resistant  to  tetracycline,  erythromycin,  and  cloramphenichol  and  most  of  the 
antibiotic resistance strains of  L. plantarum harboured plasmid-encoded resistance 
genes (Egervan et al. 2009). Therefore, when present in the food chain and in the 
intestinal tract of animals and humans, these bacteria may function as reservoir of 
antibiotic  resistance  genes  than  can  be  transferred  to  pathogenic  bacteria.  The 
determination of the transferability of the antibiotic resistance carried by the strains 
characterized in this work is therefore essential to assay the safety of the strains. 
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Conclusion
The in vitro criteria used in this study for the selection of candidate probiotics have 
been chosen from the selection guidelines provided by the FAO/WHO committee. 
The eleven putative probiotic bacteria strains (identified by both phenotypical and 
molecular methods as 5 L. plantarum strains, a  L. pentosus strains, a  L. delbrueckii 
strain,  an  Enterococcus  durans strain,  a  Leuconostoc  mesenteroides strain  and  2 
Bifidobacterium longum strains) are able to inhibit the growth of C. jejuni strain and 
are  resistant  to  the  stresses  in  the  GI  tract,  with  the  exception  of  low pH.  Low 
resistance  to  acidic  pH can  be  overcome  by  the  choice  of  a  food  carrier  or  by 
protection  via  microencapsulation  that  may  enhance  microbial  survival  in  gastric 
juice.  The  strains  survive  well  in  food  processing  conditions  (heat,  osmotic  and 
starvation stress) and have shown no β-hemolytic activity. The antibiotic resistance 
of these strains needs further characterization. However, we can conclude that the 
selected strains, in particular PCA 236, PCA 275, PCD 103, PCB 133 strains could 
be  selected  as  probiotics  to  be  used  in  industry,  but  also  in  nutraceutical  form, 
provided they are protected from the action of low pH. 
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The Pathogen Combat Project
The research described in this thesis is framed within EU 6th Framework Programme 
(www.pathogencombat.com) PathogenCombat. It is an integrated project that  began 
on  1st of April 2005 and will run until April 2010. PathogenCombat consists of 44 
partners in Europe and Australia: 24  are research institutions and organisations, 17 
are SMEs and 3  are industrial partners. Food safety is of fundamental importance to 
the European consumer, the food industry and the economy. The impact on trade and 
competitiveness is substantial.  Despite the significant  investment in the field ,  the 
incidence of food derived diseases is increasing in the EU. PathogenCombat aims at 
dealing  with  this  pan-European  problem  through  a  holistic,  multidisciplinary 
approach towards threats from new/emerging pathogens in the entire food chain. A 
number  of  advanced  platforms  will  be  developed  to  investigate  the  survival  and 
virulence expression of pathogens in feed and food and on contact surfaces in the 
food chain including the intestinal tract of farm animals. The platforms, several of 
which are used for the first  time in food safety studies,  include bioimaging,  laser 
tweezers,  phage  display/convergent  evolution,  functional  mammalian  cell  models, 
functional  genomics  and  microarrays.  New/emerging  foodborne  bacteria,  yeast, 
filamentous fungi and viruses are targeted  for milk and dairy products, ruminants, 
poultry  and pigs  and  their  meat  products.  The  overall  and specific  objectives  of 
PathogenCombat can briefly be described as follows: 
• The production of safe food with no or acceptably low levels of pathogens. 
• The determination  of  factors  in  the  food chain,  which  enable  the  viability, 
persistence and virulence of pathogens.
•  The detection and prediction of the occurrence and virulence of pathogens in 
the  food  chain  with  molecular  biology  based  culture  independent  techniques  and 
microarrays. 
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• The  determination  of  host-pathogen  interaction  with  functional  cell  model 
replacing the use of experimental animals.
• The prevention of pathogen transmission along the food chain through new 
processing  technologies  and  systems,  protective  cultures  and new information  on 
host-pathogen interaction.
• The application of PathogenCombat deliverables. in the food chain/SMEs. 
• The control of pathogens  throughout the food chain with new mathematical 
models.
• The development of  a Food Safety Management System, which incorporates 
the deliverables of PathogenCombat.
• The creation of  a Small and medium Enterprises (SME) Network including 
dissemination  of  knowledge,  dissemination  of  results  and  training  of  SMEs  and 
consumer awareness of food safety.
In particular, inside the PathogenCombat, the aim of WorkPackage 10 is to find lactic 
acid bacteria  and bifidobacteria  strains able  to inhibit,  either  at  the level  of  farm 
animals or at the level of food products, the pathogens studied in PathogenCombat. 
Specifically,  to  obtain  a  selection  of  well  characterized  protective  and  probiotic 
cultures  of  lactic  acid  bacteria  and  bifidobacteria  strains,  which  display  a  clear 
inhibition of the pathogenic bacteria and mycotoxin producing moulds considered in 
the project and which can survive the passage of the gastrointestinal tract and food 
processing  conditions  and  environments.  Strains  with  this  potential  can  then  be 
considered as protective and probiotic cultures to be incorporated in the development 
of  prevention  strategies  for  foodborne  pathogenic  microorganisms  throughout  the 
food chain.
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